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This thesis demonstrates many of factors that influence the effects of nicotine on 
anxiety. In the social interaction test, nicotine induced both anxiolytic and anxiogenic 
effects in singly housed animals that were dose-dependent, low doses having anxiolytic 
and high doses anxiogenic effects. However, in group-housed rats only anxiolytic 
effects were detected but at a more limited dose range. In singly housed animals, the 
effect of a low dose of nicotine (0.1 mg/kg; s. c. ) was time-dependent with an anxiogenic 
effect observed after 5 min, an anxiolytic effect after 30 min and another anxiogenic 
effect after 60 min. After 7 days of nicotine treatment with this low dose, tolerance 
developed to the initial anxiogenic and the anxiolytic effect. The dorsal hippocampus 
and dorsal raphe nucleus (DRN) were identified as brain regions mediating these effects. 
After 7 days of nicotine treatment an anxiogenic withdrawal response was observed at 
72h after termination of treatment and was reversed by nicotine injected subcutaneously 
or into the DRN. Animals trained to self-administer nicotine (0.45 mg/kg/day) for 4 
weeks showed an anxiogenic effect as did rats receiving the same dose by intravenous 
injection, subcutaneous injection or continuous infusion by osmotic minipump. None of 
these animals showed a withdrawal response at 24 or 72h following termination of 
treatment. 
In the elevated plus-maze, acute administration of nicotine had only anxiogenic effects, 
but the time-course of these effects were influenced by the housing conditions, with an 
.ý 
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anxiogenic effect at 5 and 30 min in group housed rats, but 30 and 60 min in isolated 
rats. In isolated rats, 5 min after injection nicotine was ineffective but after 7 days of 
treatment (0.1 mg/kg/day) a significant anxiolytic effect emerged to which the rats 
became tolerant to after 14 days. An anxiogenic withdrawal response was observed at 
24h after termination of nicotine treatment and was reversed by intra-hippocampal 
nicotine. 
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Anxiety can be defined as an emotional state that produces an unpleasant feeling of 
apprehension, which is normally accompanied by somatic symptoms and signs, 
including palpitations, hyperventilation, pallor, dry mouth, sweating, postural tremor, 
fatigue and tics (Millet et al., 1998). Anxiety and fear are very similar phenomena, but 
they can be distinguished from each other in that fear is related to a real threat, whereas 
anxiety is a response that occurs to the anticipation of danger (Bremner et al., 1996). 
Anxiety is a very common human experience and many people suffer from attacks 
daily, due to problems at work or social interaction. However, for 5-10% of the 
population, the anxiety is extreme and they feel the need to seek psychiatric help. The 
psychiatric diagnosis of an anxiety disorder is not a simple one, but there is broad 
agreement about major categories (American Psychiatric Association, DSM-IV, 1994; 
World Health Organization, ICD-10,1993). In adults, anxiety disorders are divided 
into two subsections: anxiety states and phobic disorders (see Table 1.1). The 
treatment of these disorders is very complex as they are not equally drug-responsive 
and indeed different treatments are effective in treating the different types of anxiety. 
For example, Generalised anxiety disorder (GAD), the most common of the anxiety 
disorders, is treated most effectively with the benzodiazepines and 5-HT1A receptor 
16 
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agonists, whereas panic disorder responds better to antidepressant treatment. These 
differences in the treatment for anxiety disorders raise the question as to whether there 
are distinct neurobiological substrates that underlie the different types of anxiety. 




Generalised Anxiety Disorder Characterised by 6 months of anxious 
mood or worried preoccupations 
Panic Disorder Characterised by random unpredictable 
attacks of panic caused by a fear of 
dying for example 
Obsessive-compulsive Disorder Characterised by recurrent obsessions 
(thoughts, ideas, images, impulses) and 
compulsions (hand washing which 
serves to reduce anxiety) 
Post-traumatic Stress Disorder Characterised by re-experiencing a 
traumatic event accompanied with 
anxiety- and depressive-like 
experiences 
Phobic States 
Social Phobia Characterised by the persistent fear of 
situations in which the individual is 
exposed to the scrutiny of others 
Simple Phobia Characterised by intense anxiety when 
exposed to some specific phobic 
stimulus, and persistent fear of this 
stimulus between episodes of exposure 
Agoraphobia Characterised by an attack of anxiety or 
panic in a variety of public places 
17 
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1.2 Drug Treatment of Anxiety 
The benzodiazepines (e. g. diazepam [Valium] and chlordiazepoxide [Librium]) are a 
class of compounds that have commonly used in the treatment of anxiety disorders 
(File, 1990a; Lader, 1989). Benzodiazepines have a rapid onset of action and have a 
maximal effect within 2 weeks (Ashton, 1994). They have been most extensively used 
for the treatment of GAD (Argyropoulos et al., 2000; Ninan, 1999). Andresch et al. 
(1991) have shown alprazolam, a high potency benzodiazepine, to be effective in the 
treatment of panic disorder. However, another study showed that there was no 
significant difference on symptoms between the use of alprazolam and behavioural 
therapy (Klosko et al., 1990). The treatment of choice for specific phobic disorders is 
behavioural therapy but it has been suggested that the benzodiazepines may have an 
additive effect (Wardle, 1990). Benzodiazepines replaced barbiturates in the 1960s as 
they were thought to have fewer side effects, but over the last few years the unwanted 
side effects on the benzodiazepines have become apparent. Benzodiazepines have a 
number of adverse side-effects including psychomotor depression (Weingartner et al., 
1993), cognitive impairment (Sellal et al., 1992; Lister, 1985) and long-term use may 
result in dependence (Rickels et al., 1988). There is now considerable evidence 
suggesting that with daily use, tolerance develops to the pharmacological effects of 
benzodiazepines, most noticeably to their sedative and anticonvulsant effects but also 
to their anxiolytic effects (Higgitt et al., 1988; Lucki et al., 1986). Withdrawal from 
these drugs also results in a syndrome that is often characterised in humans by 
symptoms such as insomnia, weight loss, increased anxiety, tremors and seizures 
(Tyrer, 1988; Ladewig, 1984; Pertusson and Lader, 1981). These unwanted side 
18 
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effects have led to the search for novel compounds that are effective in treating anxiety, 
but do not have these side effects. 
The serotonergic system has been implicated in the neurochemistry of anxiety for a 
long time and compounds selective for the 5-HT1A receptors, such as buspirone, 
gepirone and ipsapirone, have been shown to have clinical efficacy in the treatment of 
GAD, without the apparent unwanted side effects of the benzodiazepines (Pecknold, 
1997). However, in contrast to the immediate effects of the benzodiazepines, the onset 
of action of buspirone does not occur for two weeks and in some patients can take 3-6 
weeks to take effect (Sussman, 1987). Also, patients who have responded well to 
benzodiazepines in the past appear to not respond so well to buspirone (Sussman, 
1987). There is also evidence that 5-HT2 receptor antagonists, such as ritanserin, have 
anxiolytic effects in humans (Katz, 1993; Bersani et al., 1991; Hensman et al., 1991; 
Bressa et al., 1987). 
More recent studies have shown that many anxiety disorders can be treated with 
antidepressants. The selective serotonin re-uptake inhibitors (e. g. velafaxine and 
fluoxetine) have been shown to be effective in the treatment of most anxiety disorders 
(Argyropoulos et al., 2000; Schatzberg, 2000). The tricyclic antidepressants (TCAs), 
such as imipramine and clomipramine, have been shown to be therapeutic most 
noticeably in the treatment of panic disorder (Barlow et al., 2000). However, they are 
also effective in the treatment of GAD, obsessive compulsive disorder and like the 
benzodiazepines they have an additive effect to behavioural therapy in the treatment of 
19 
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specific phobias (Argyropoulos et al., 2000). Monoamineoxidase inhibitors, such as 
phenelzine, have been shown to be as effective as the TCAs in the treatment of panic 
disorder but there use is restricted due to the side-effects in long-term use 
(Argyropoulos et al., 2000). 
1.3 Animal Tests of Anxiety 
Animal models of anxiety form the backbone of preclinical research and they 
endeavour to represent some aspect of the aetiology, symptomatology or treatment of 
anxiety disorders (Menard and Treit, 1999). There is a very wide range of animal tests 
of anxiety, which can be divided in to two main types, conditioned, and unconditioned 
behaviours, see Table 1.2. Models of conditioned behaviour involves animals' 
conditioned responses to stressful and often painful stimuli (e. g. exposure to electric 
footshock), whilst in unconditioned tests involve animals' spontaneous or natural 
reactions to stress stimuli that do not explicitly involve pain or discomfort (e. g. 
exposure to a novel test chamber). 
20 
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Table 1.2 Some commonly used animal models of anxiety. Modified from Olivier et al., 
2000. 
Conditioned Responses Unconditioned Responses 
Conflict tests - Geller-Seifter conflict Social interaction 
Vogel punished drinking 
Fear potentiated startle Elevated plus-maze 
Shock-probe avoidance Light-dark exploration. 
Conditioned taste aversion Ultrasonic vocalisation 
The models of conditioned behaviour that are most commonly used are the Geller- 
Seifter conflict test (Geller and Seifter, 1960) and the Vogel water-lick conflict test 
(Vogel et al, 1971). In the Geller-Seifter conflict test, lever pressing following a 
distinct stimulus (e. g. light) results in the presentation of food and a punishment (e. g. 
electric shock). Thus, the animal is faced with the choice between reward and 
punishment, which will result in a suppressed response. A variety of anxiolytic drugs 
produce an attenuation of the behavioural suppression, which is considered an indicator 
for anxiolytic activity in this model (Corbin et al., 2000; Giusti et al., 1993). The 
Vogel conflict model is a variation of this procedure but is more advantageous as it 
eliminates the prolonged training that the Geller-Seifter test needs (Vogel et al., 1971). 
In this test, rats are given shocks while drinking and administration of drugs that have 
been shown to be anxiolytic in humans attenuates this suppressed behaviour. 
Disadvantages of these tests are that it is difficult to know whether the anxiolytic effect 
is a true effect of the drug (e. g benzodiazepines) or to some other aspect of the drug's 
pharmacological effect, such as facilitation of their motivation for food, sedation and/or 
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reduced pain sensitivity. In addition, it is difficult to observe the anxiogenic effect of a 
drug because the punishment induced anxiety is at such a high level. 
The second types of anxiety test are the unconditioned or ethologically based tests and 
these can be divided into tests that are based on social or exploratory behaviour. In 
contrast to the conditioned tests, the fear seen in these tests is not conditioned but 
produced by rats being in a novel environment. Three of the most widely used of the 
unconditioned tests are, the social interaction test (a test of social behaviour; Figure 
1.1), the elevated plus-maze test (a-test of exploratory behaviour; Figure 1.2) and the 
light-dark exploration test. The social interaction test of anxiety has been validated 
extensively using both behavioural and physiological measures (File and Hyde, 1978). 
In this test, the dependent variable is the time spent in social interaction by pairs of 
male rats, see Figure 1.1. A decrease in social interaction, without a concomitant 
decrease in locomotor activity, is defined as a specific anxiogenic effect and an 
increase in social interaction, without an increase in locomotor activity, is defined as an 
anxiolytic effect. The anxiety generated by this test can be manipulated by changing 
the light level in the test arena and/or the rats' familiarity with the arena. Social 
interaction is maximal when the animals are tested in an arena with which they are 
familiar and in which the light level is low. If the illuminance is increased, or if the 
arena is unfamiliar, the time spent in social interaction decreases, and is lowest when 
the rats are tested in an unfamiliar brightly lit arena. For a more detailed account of 
this test, see File (1997a). The social interaction test has proved sensitive to a wide 
range of anxiolytic drugs, such as the benzodiazepines, the barbiturates, ethanol, 
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selective serotonin re-uptake inhibitor, paroxetine, and the neurokininl receptor 
antagonist, CGP 49823 (File, 1997b; Lightowler et al., 1994; Barnes et al., 1990; File, 
1980; File et al., 1976). It is also possible using this test to detect anxiogenic effects of 
drugs, such as ß-carbolines, pentylenetetrazole, picrotoxin, phencyclidine, caffeine, 
yohimbine and amphetamine (Buczek et al., 1998; Bhattacharya et a1., 1997; Sams- 
Dodd, 1995; Johnston and File, 1988; File et al., 1986; Pellow and File, 1986; Guy and 
Gardner, 1985; File and Lister, 1984) and of neuropeptides such as ACTH and CRF 
(Sajdyk et al., 1999; Dunn and File, 1987; Niesink and van Ree, 1984; File and Clarke, 
1980; File and Vellucci, 1978). The anxiogenic state that is induced by withdrawal 
from chronic treatment of benzodiazepines, ethanol, and caffeine can also be detected 
using this test (Andrews et al., 1997; Bhattacharya et al., 1997; File et al., 1992,1991a, 
b; Andrews and File, 1992; Costall et al., 1990a, b; File et al., 1989). The test is also 
sensitive to an environmental stressors, such as the disturbance from building work 
(File, 1994) and to non-pharmacological methods such as a5 min exposure to the 
odour of a cat (Zangrossi and File, 1992). 
The elevated plus-maze apparatus is raised 50cm off the floor and consists of two open 
arms and two arms enclosed by walls. Rats normally avoid the two open arms and 
restrict their activity to the closed arms. An anxiolytic effect is indicated by an 
increase in the proportion of activity that is seen on the open arms (i. e. an increase in 
the percentage time spent on the open arms, and the number of entries on to the open 
arms), and an anxiogenic effect by a decrease in the portion of activity on the open 
arms. The number of times an animal enters in to the closed arms is the measure of 
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non-specific locomotor activity. For a more detailed account, see File (1992) and 
Pellow et al. (1985). Like the social interaction test, this test has proved sensitive to 
both anxiolytic (Hale et al., 1990; Johnston and File, 1989a) and anxiogenic (Cruz et 
al., 1994; Lapin, 1993; Johnston and File, 1989b; Baldwin et al., 1989) drugs. The 
anxiogenic state that is induced by withdrawal from chronic treatment of 
benzodiazepines and ethanol can also be detected using this test (File et al., 1991b, 
1987a). 
In the light-dark exploration test the number of transitions made by mice between a 
light and a dark compartment is used as the measure of anxiety (Crawley et al., 1994; 
Crawley, 1981). The mice are faced in this test with a conflict between the desire to 
explore a novel area and their aversion to bright light. An increase in transitions, 
without an increase in locomotor activity, is taken to indicate an anxiolytic effect. 
Mice are placed on the brightly lit side of a two-compartment chamber, and the number 
of transitions between the light and dark sides, as well as the time spent on the two 
sides are recorded. This test has also proved sensitive to both anxiolytic (Hascoet et al., 
2000; Okuyama et al., 1999; Artaiz et al, 1998; Chaouloff et al, 1997; Bourin et al., 
1996; Shimada et al., 1995; Barnes et al., 1992; Onaivi and Martin, 1989; Costall et al., 
1989a, b, 1988) and anxiogenic (El Yacoubi et al., 2000; Shimada et al., 1995; de 
Angelis, 1992; Onaivi and Martin, 1989; Costall et al., 1989a, b) drugs. The 
anxiogenic state that is induced by withdrawal from chronic treatment of 
benzodiazepines, ethanol cocaine and nicotine can also be detected using this test 
(Costall et al., 1990a, b, c) 
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Figure 1.1 The social interaction test arena showing a pair of male 
hooded Lister rats 














There is increasing evidence to suggest that different animal tests of anxiety measure 
different types of anxiety (Flaherty et al., 1998; Ramos et al., 1997; Belzung and Le 
Pape, 1994; File, 1992). Factor analysis studies have shown the factor loadings for the 
social interaction, elevated plus-maze and Vogel punished drinking tests all load on 
different factors f (Fernandes and File, 1996; File, 1992), thus suggesting that the 
anxiety generated in these tests is different. There is also evidence to suggest that the 
anxiety induced on re-exposure to the plus-maze (Trial 2) is different from that in 
animals that are naive to the plus-maze (Trial 1; Rodgers et al., 1997; File, 1992). 
Evidence to support this is that benzodiazepines are anxiolytic on Trial 1 but 
ineffective on Trial 2 (Rodgers and Shepherd, 1993; Rodgers et al., 1992; File, 1990b). 
This has led to the speculation that Trial 2 of the maze may be a model of phobia (File 
and Zangrossi, 1993). 
1.4 Brain regions and neurotransmitters that are involved in anxiety 
There are a number of brain structures that have been implicated in mediating anxiety. 
These include the raphe nuclei, median (MRN) and dorsal (DRN), the periaqueductal 
gray (PAG), and limbic structures, such as the dorsal hippocampus, lateral septum and 
the central and basolateral nuclei of the amygdala (for review see Menard and Treit, 
1999). Accumulating evidence from lesioning studies and central drug administration 
has shown that different brain regions and neurotransmitters control behaviour in 
different animal tests of anxiety (Menard and Treit, 1999,1996; Treit and Menard, 
1997). There is a great deal of evidence suggesting that benzodiazepine agonists 
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administered into different brain regions produce reasonably consistent anxiolytic 
effects in a variety of animal tests. However, evidence regarding the effects of 5-HT1A 
receptor agonists, 5-HT2 compounds and 5-HT3 receptor antagonists is somewhat less 
consistent, both anatomically and behaviourally. 
1.4.1 The GABAergic system 
Gamma-aminobutyric acid (GABA) is the major inhibitory transmitter in the brain and thus 
suppresses neuronal firing thereby inhibiting and regulating other neurotransmitters (Ninan, 
1999). GABAergic neurones have been shown to be present in all areas of the central 
nervous system (CNS), in various densities, and it is estimated that they account for one third 
of all neurotransmission in the CNS (Shephard, 1987). To date there are three known 
GABA-receptors, the GABAA, GABAB and GABAc receptors (Sigel and Buhr, 1997). 
GABAB receptors are G protein-coupled receptors and upon agonist binding they mediate 
hyperpolarization of post-synaptic membranes and inhibition of neurotransmitter release from 
presynaptic terminals (Marshall et al, 1999). They have been implicated in numerous 
neuronal processes (Couve et al., 2000). However, GABAA receptors are the most 
characterised of the GABA receptors and are members of the ligand-gated ion channel 
superfamily (Johnston, 1996). They are pentameric structures that surround a central core 
through which Cl' ions pass (Olsen and Tobin, 1990). The receptor is composed of 5 sub- 
units (a, ß, y, S and p) and several different forms of these subunits have been identified, with 
different combinations of these subunits conferring marked differences in pharmacology 
(Mihic et al., 1995; Olsen and Tobin, 1990). When GABA or a GABAA agonist binds to the 
receptor the chloride channel opens and allows the intracellular flow of Cl" ions. This influx 
inhibits the activity of the neurone to conduct impulses by becoming hyperpolarised. There 
are binding sites on the GABAA receptor for other modulatory agents, including the 
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benzodiazepines, barbiturates, ethanol, steroids and some general anaesthetics (Johnston, 
1996). 
Benzodiazepine receptors are widely distributed throughout the CNS and are 
particularly abundant in limbic structures such as the hippocampus, septum and 
amygdala (Niehoff and Kuhar, 1983; Young and Kuhar, 1980). They are situated on 
the GABAA receptor and the benzodiazepines influence the potency of GABA by 
allosterically modulating the receptor. The benzodiazepine binding site is thought to 
be situated on the a subunit and the presence of the y subunit is required of 
benzodiazepine potentiation of the GABA response (Wu et al., 1994; Olsen and Tobin, 
1990). Unlike the barbiturates, which prolong the mean channel opening time of 
GABAA receptor, the benzodiazepines increase the frequency of single channel 
openings (Study and Barker, 1981). Benzodiazepines are unable to open the channel in 
the absence of GABA. 
The full importance of the benzodiazepine binding site was that its activation could 
result in both anxiolytic and anxiogenic effects. Thus, benzodiazepine agonists (e. g. 
diazepam, chlordiazepbxide) cause an increase in GABA transmission eliciting an 
anxiolytic effect (Smith and Olsen, 1995; Zorumski and Isenberg, 1991), whilst 
benzodiazepine inverse agonists (e. g. FG 7142) cause a decrease in transmission and 
elicit an anxiogenic effect (Biggio et al., 1987; Stephens et al., 1984; Thiebot et al., 
1984). There is a third class of compounds acting at the benzodiazepine receptor, the 




pharmacological effects on their own but they antagonise the effects of the benzodiazepine 
agonists and inverse agonists (Haefely, 1983). A recent study has shown that the a2 subunit 
of the GABAA receptor may be involved in the anxiety, as mice with this subunit knocked 
out showed no response to diazepam where as wild-type mice elicited an increase in both the 
time spent and the number of entries in the open arms (Low et al., 2000). The al subunit has 
been shown to mediate the sedative, amnesic and anticonvulsant actions of diazepam 
(McKernan et al., 2000; Rudolph et al., 1999). 
Direct administration of benzodiazepines into midbrain (DRN and MRN) and limbic 
structures, has robust anxiolytic effects in tests of both conditioned and unconditioned 
anxiety (Gonzalez et al., 1998,1996; Gonzalez and File, 1997; Pesold and Treit, 1996,1995, 
1994; Plaznik et al., 1994; Stefanski et al., 1993; Hodges et al., 1987; Scheel-Kruger and 
Petersen, 1982; Shibata et al., 1982; Thiebot et al., 1980). Many of these anxiolytic effects 
were reversed by administration of the benzodiazepine antagonist flumazenil (Gonzalez and 
File, 1997). Agonist stimulation of the benzodiazepine receptor system does not uniformly 
modify anxiety. For example, administration of midazolam into the septum increased open 
arm entries in the elevated plus-maze but did not affect shock-probe avoidance, whereas 
intra-amygdaloid midazolam dramatically impaired shock-probe avoidance but had no effect 
on open arm entries (Pesold and Treit, 1994). These findings suggest that distinct sub- 
populations of benzodiazepine receptors (e. g. those in the septum and the amygdala) may 
have differing roles in different types of anxiety or that a different GABA tone is generated in 
different brain regions in different tests of anxiety. Administration of the inverse agonist 
methyl ß-carboline-3-carboxylate (ß-CCM) significantly decreased the time rats spent in 
social interaction after administration into the DRN (Hindley et al., 1985). This effect was 
blocked by the co-administration of flumazenil. 
30 
General Introduction 
1.4.2 The Serotonergic System 
The serotonergic system has been thought to play an important role in anxiety 
responses in animals and humans for a number of years (for review see Griebel, 1995). 
The cell bodies of the 5-HT neurones are found in both the dorsal (DRN) and median 
(MRN) raphe nuclei, and ascending fibres project from these areas to regions such as 
hippocampus, septum and amygdala. 
G 
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Figure 1.3 Schematic diagram of the serotonergic pathways in the rat brain. The 
location of the main groups of cell bodies and fibre tracts are shown in 
black. Grey areas show the location of the serotonergic terminals. 
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It was suggested, very simplistically, that an increase in 5-HT transmission resulted in 
increased anxiety, and conversely that a decrease in transmission decreased anxiety 
(Iversen, 1984). It has been reported that one of the mechanisms of the anxiolytic 
actions of benzodiazepines is the reduction of 5-HT in the brain (Stein et al., 1977, 
1975). Indeed, biochemical and electrophysiological evidence has shown that 
benzodiazepines and GABA inhibit the synthesis and metabolism of 5-HT (Nishikawa 
and Scatton, 1986). Furthermore, benzodiazepines and GABA have been shown to 
have a depressant action on serotonergic activity (Collinge et al., 1983). Lesioning of 
the serotonergic pathways has been shown to produce anxiolytic effects in the social 
interaction test (File et al., 1979) and have anxiolytic effects in conflict tests (Tye et. al., 
1977; Stein et al., 1975). 
5-HT acts through heterogeneous groups of receptors and to date there are seven 
groups: 5-HTl-like, 5-HT2-like, 5-HT3,5-HT4,5-HT5,5-HT6 and 5-HT7 (Gerhardt and 
van Heerikhuizen, 1997). The receptors belonging to the 5-HTl-like family are G- 
protein coupled receptors that are negatively linked to adenylate cyclase via Gi or Go 
complexes. The most characterised of the 5-HT receptor subtypes is the 5-HT1A 
receptor. 5-HT1A receptors are densely distributed in the raphe nuclei and in limbic 
areas, such as the hippocampus, septum and amygdala (Gerhardt and van 
Heerikhuizen, 1997; Waeber and Moskowitz, 1995; Pazos et al., 1985; Pazos and 
Palacios, 1985). Agonists for the 5-HT1A receptors have been studied in a wide range 
of animal tests of anxiety but unlike the benzodiazepines, they show inconsistent 
effects after systemic administration. A possible explanation for these observations is 
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that stimulation of different 5-HTIA receptors may have different effects on anxiety. 
The 5-HT1A receptors in the raphe nuclei are situated on the cell bodies or dendrites 
and act as autoreceptors. Activation of these somatodendritic autoreceptors leads to a 
reduction in the neuronal firing rate of the 5-HT neurones (Sprouse and Aghajanian, 
1987), and thus to a suppression of 5-HT synthesis, 5-HT turnover and 5-HT release in 
the terminal regions of the limbic system (Bohmaker et al., 1993). The activation of 
these presynaptic receptors is believed to cause the anxiolytic effects of 5-HT1A 
agonists. In support of this theory, administration of 5-HTIA receptor agonists, such as 
8-OH-DPAT and buspirone, to the MRN and DRN has resulted in anxiolytic effects in 
the social interaction test (File et al., 1996a; Andrews et al., 1994; Hogg et al., 1994; 
Higgins et al., 1992,1988), the elevated plus-maze test (File and Gonzalez, 1996; File 
et al., 1996a) and in the footshock induced ultrasonic vocalisation (Schreiber and De 
Vry, 1993). File et al. (1996b) has reversed the anxiolytic effect seen in the social 
interaction test after co-administration of 8-OH-DPAT with the 5-HTIA receptor 
antagonist WAY 100,635 thus confirming that the anxiolytic effect was mediated by 
activation of the 5-HT1A receptors. Furthermore, knockout mice that lack 5-HT1A 
receptors show increased anxiety compared to wild-type mice (Parks et al., 1998; 
Heisler et al., 1998). This increased anxiety is thought to be due to the mice lacking 5- 
HT1A receptors in the DRN and thus having no inhibitory action on the neurone thereby 
causing an increase in 5-HT in the terminal regions. 
In contrast to these results, the administration of 5-HTIA receptor agonists at post- 
synaptic sites is more complex as administration in to the limbic structures results in 
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both anxiolytic and anxiogenic effects in animal tests of anxiety. After direct 
administration of 8-OH-DPAT to the dorsal hippocampus and lateral septum 
anxiogenic effects have been observed in the social interaction test (Cheeta et al., 
2000a; File et al., 1996b; Andrews et al., 1994) and the elevated plus-maze test (Cheeta 
et al., 2000a; File et al., 1996b). These anxiogenic effects have been show to be 
receptor specific as they have been reversed by the co-administration of 8-OH-DPAT 
with WAY 100,635 (Cheeta et al., 2000b; File et al., 1996b). Anxiogenic effects have 
also been observed in the social interaction test after administration of 8-OH-DPAT to 
the amygdala, but no effects have been observed in the elevated plus-maze (Gonzalez 
et al., 1996). In contrast, administration of 5-HTIA agonists to the dorsal hippocampus 
and septum has induced anxiolytic effects in conflict tests (Przegalinsk et al., 1994; 
Stefanski et al., 1993). Deakin and Graeff have attempted to reconcile this discrepancy 
and produce a unifying hypothesis by suggesting that the effects of 5-HT on anxiety 
may be neuroanatomically specific and dependent on the anxiety in question (Deakin 
and Graeff, 1991; Graeff et al., 1996). They propose that the panic-like reflexes 
elicited by exposure to acute unconditioned aversive stimuli arise because of activation 
of the PAG, and that the anxiolytic effects of 5-HT are mediated by this 
neuroanatomical substrate (Deakin and Graeff, 1991). This idea is supported by the 
observation that electrical stimulation of the PAG gives rise to panic-like responses 
similar to those evoked by unconditioned aversive stimuli in rats (Graeff et al., 1993) 
and humans (Nashold et al., 1974). Furthermore, enhanced serotonergic transmission 
within the PAG has been shown to decrease the aversiveness of direct stimulation of 
this brain structure (for review see Graeff, 1994). 
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Clinical trials have shown 5-HT2 receptor antagonists, such as ritanserin, to be 
important in the treatment of GAD and some phobias (Bersani et al., 1991; Bressa et 
al., 1987). The 5-HT2 receptor family consists of the 5-HT2A. 2c receptors. These 
receptors act through Gq proteins and stimulate phosphoinositol hydrolysis. 5-HT2A 
and 5-HT2c receptors are predominantly located in the basal ganglia and in the limbic 
system, where as 5-HT2B receptors have a restricted distribution with the greatest 
expression occurring in the lateral septum and dorsomedial hypothalamus (Menard and 
Treit, 1999; Griebel, 1995). As is seen for the 5-HT1A agonists, conflicting results have 
been seen in some animal models of anxiety after systemic administration of drugs 
acting on the 5-HT2 receptors (Menard and Treit, 1999; Griebel, 1995). 
1.5 The Cholinergic System 
The central cholinergic system in the rat projects throughout the brain. It arises within 
the basal forebrain cholinergic nuclei (medial septum, diagonal band nucleus, nucleus 
basalis and the substantia inominata) and the pedunculopontine tegmental nucleus. 
The basal forebrain nuclei innervate the cortex, hippocampus, amygdala and olfactory 
bulbs. The pedunculopontine tegmental nucleus projects to the basal forebrain 
cholinergic nuclei, lateral septum, thalamus, raphe nuclei, globus pallidus, locus 





Figure 1.4 Schematic diagram of the cholinergic pathways in the rat brain. The 
location of the main groups of cell bodies and fibre tracts are shown in 
black. Grey areas show the location of the cholinergic terminals. 
Cholinergic receptors fall into two classes, muscarinic (mAChRs) and nicotinic 
(nAChRs; discussed in section 1.5) acetylcholine receptors. Both types of receptors 
bind ACh, but they can be distinguished because there are agonists and antagonists that 
bind exclusively to one type of ACh receptor or the other. To date there are five 
muscarinic receptors (M1-M5) that have been cloned (Caulfield and Birdsall, 1998). 
All of these receptors are linked to GTP-binding protein and have the characteristic 7 
transmembrane spanning domains. M1, M3 and M5 receptors are positively coupled to 
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phospholipase C, and stimulation of these receptors result in an increase in inositol 
triphosphate and diacylglycerol. M2 and M4 receptors are negatively coupled to 
adenylate cyclase and stimulation results in a reduction of cAMP. 
1.6 The Nicotinic Acetylcholine Receptor Complex 
Nicotinic acetylcholine receptors (nAChRs) are the best characterised of the ligand- 
gated ion channel superfamily and share 20-30% sequence homology with the 
aforementioned GABAA receptor (Stroud et al., 1990). They are expressed on the 
postsynaptic membrane at skeletal neuromuscular junctions and in the CNS. nAChRs 
are pentameric structures composed of five homologous subunits around a central pore. 
Each subunit has an extensive N-terminal domain, four transmembrane spanning 
domains (M1-M4) and an extracellular C-terminus. It is believed that the M2 
transmembrane domain from each subunit forms the wall of the ion channel, whilst the 
other three domains form the outer crust (Lukas, 1999). In muscle, the nAChR is 
composed of five subunits, 2a and 1 each of ß, y and 5 subunits. However, in the 
CNS the nAChR is composed of only two different subunits, a and P. The a subunit 
exists in 8 isoforms (a2-9), while the 0 subunit exists in only 3 isoforms (02-4). These 
a and 0 sub-units can assemble into a wide diversity of combinations and produce 
receptors with distinct pharmacological and kinetic specificities (Picciotto et al., 2000; 
Galzi and Changeux, 1995). However, the a7-a9 subunits have been found to form 
homomeric nAChRs (Picciotto et al., 2000; Galzi and Changeux, 1995). 
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Within the mammalian CNS two major nAChR groups have been defined using 
radioligand binding techniques: 
" those with a high affinity binding site for (-)-nicotine and are labelled by [3H]- 
acetylcholine and [3H]-nicotine 
" those with a high affinity binding site for a-bungarotoxin (aBgTx) 
The branch of the family that binds [3H]-acetylcholine and [3H]-nicotine includes nAChRs 
composed of a2-a5 and 02 or ß4 subunits (Flores et al., 1992; Whiting et al., 1991; Whiting 
and Lindstrom, 1986). The high affinity (-)-nicotine binding sites of the brain are composed 
of nAChRs with the subunit stoichiometry ((X)2(ß)3 (Cooper et al., 1991). The a4ß2 subtype 
is the main nAChR seen in the brain and it binds nicotine with high affinity and is widely 
distributed (Galzi and Changeux, 1995; see Table 1.3). The branch of the nAChR gene 
family, which includes nAChRs that can bind aBgTx, is composed of a7, a8 and a9 
subunits (Seguela et al., 1993; Schoepfer et al., 1990). All of these subunits, when expressed 
from their cDNAs, can form homomeric riAChRs, which are characterised by rapid 
desensitisation and high permeability to Ca2+ (Gerzanich et al., 1994). a7 nAChRs are 
widely distributed in the brain and have an overlapping but distinct distribution pattern 
compared to the a4ß2 subtype. These receptors are rapidly desensitised and are involved in 
phasic synaptic responses. The a8 subunit has not been found in mammals, and the a9 




Table 1.3 Distribution of nAChR subunits in the rat brain. 
Subunit Brain area with high distribution References 
0 Hippocampus Wada et al., 1989; Goldman 
Thalamus et al., 1986 
Substantia nigra 
a4 Hippocampus 
Dorsal raphe nucleus 
Hypothalamus 










Ventral tegmental area 
02 Thalamus 
Hypothalamus 




04 Dentate gyrus 
Locus coeruleus 
Lobron et al., 1995; Bitner et 
al., 2000; Alkondon et al., 
1994; Goldman et al., 1987; 
Lena et al., 1999 
Lena et al., 1999; Le Novere 
et al., 1996 
Zarei et al., 1999; Seguela et 
al., 1993; Davies et al., 1999 
Dominguez del Toro et at, 
1994; Zarei et al., 1999; Lena 
et al. 1999; Hill et al., 1993; 
Deneris et al., 1989 




1.7 Nicotinic Acetylcholine Receptor Ligands 
General Introduction 
Nicotine has been the main nicotinic receptor agonist that has been used to study 
nAChR function. Nicotine is a tertiary amine consisting of a pyridine ring and a 
pyrolidine ring and it can exist in two forms; the (S)-nicotine isomer is the active form 
which binds to nAChRs and is found in tobacco, and (R)-nicotine which is a weak 
agonist at nAChRs and is found in only small quantities in tobacco (Royal College of 
Physicians, 2000). However, there are now a number of ligands available which 
selectively modulate the nAChR., such as ABT-418 (S)-3-methyl-5-(1-methyl-2- 
pyrrolidinyl)isoxazole, cytisine, 1,1 -dimethyl-4-piperazinium (DMPP) and 
epibatidine;. It has been shown that the sensitivity of the nAChRs to these nicotinic 
agonists depends on the subunit combination (see Table 1.4). Thus, the determination 
of potency rank order among nicotinic agonists is a powerful tool to distinguish 
nAChRs in native cells. Although small differences in affinity could be ascribed to 
different a subunits, the major factor in determining agonist affinity appears to be the 
nature of the 0 subunit. 02-containing nAChRs possess consistently higher affinities 
for ACh, cytisine, DMPP, and nicotine than do 04-containing nAChRs (Picciotto et al., 
2000). 
In addition to these nAChR agonists there are also a number of competitive and non- 
competitive antagonists to the nicotinic receptor that have been identified. The 
competitive antagonists, such as methylcaconitine (MLA), ctBgTx and dihrdro-ß- 
erythroidine (DH3E), compete with agonists for binding to the same overlapping sites 
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(for review, see Gotti et a1., 1997) Like for the agonists, the potency of these 
antagonists at the nAChR is dependent on the subunit composition. Both MLA and 
aBgTx preferentially bind to a7-type nAChRs, where as DH(3E blocks a402 nAChRs. 
The non-competitive antagonists, such as mecamylamine and chlorisondamine, do not 
bind to the agonist binding site. They act by occluding the ion channel of the nAChR. 
Table 1.4 Functional nAChR subtypes present in the rat brain with relative agonist 
potencies at each subtype. ABT-418 ((S)-3-methyl-5-(1-methyl-2- 
pyrrolidinyl)isoxazole); ACh, acetylcholine; Cyt, cytisine; DMPP. 1,1- 
dimethyl-4-piperazinium; Epi, epibatidine; Nic, nicotine. Modified from 
Royal College of Physicians (2000). 
Sub-unit Combination Rank order of potency 
a202 Nic > DMPP > ACh > Cyt 
a3ß2 DMPP = ACh z Nic > Cyt 
a402 Epi > Nic = ACh > DMPP > Cyt 




Cyt > Nic > ACh > DMPP 
a7 Nic > Cyt > DMPP > ACh 
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1.8 Allosteric Regulation of the Nicotinic Acetylcholine Receptor 
The nAChR is controlled allosterically by a ligand (e. g. acetylcholine or nicotine) 
binding to sites located on two of the subunits. On heteromeric nAChRs, the agonist 
binding site is thought to be at the interface between the a subunit and the adjacent 0 
subunit (Galzi and Changeux, 1995). However, this is not the case for the a5 receptor 
subunit as it is incapable of binding an agonist because it lacks a tyrosine residue that is 
essential for binding (Conroy et al., 1992). The homomeric nAChRs have five agonist 
binding sites located at the junction between neighbouring subunits. For both the 
heteromeric and homomeric nAChRs, binding of ligand at one of the binding sites 
increases the affinity of the second site for the ligand (Lena and Changeux, 1993). 
Activation of the nAChR results in opening of the associated central channel, which 
allows entry of Na+, K+ and Ca2+ (Cooper et al., 1991; Wonnacott, 1990). However, 
the channel only remains open for a short time before it undergoes a series of 
conformational changes that cause the receptor to become desensitised. There are 
several lines of experimental evidence to suggest that the nAChR may exist in a 
minimum of 4 interconvertible states, the resting (R), active (A), intermediate (I) and 
desensitised (D) states (Figure 1.3). In the active state (A), the receptor has low 
affinity for nicotinic agonists but in the two desensitised closed channel states, I and D, 
the receptor has enhanced affinity for these agonists. However, only the active state of 
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Figure 1.5 Proposed conformational states of the nicotine acetylcholine receptor. 
Modified from Galzi and Changeux, 1995. 
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The rate at which the nicotinic receptor proceeds through the various conformational 
states depends on many factors, including the subunit composition. The a7 and 0 
homomeric receptors desensitise very rapidly, whereas the heteromeric receptors 
undergo activation and desensitisation transitions with kinetics that vary with the a and 
0 subunit composition. The nAChRs composed a402 subunits, for which nicotine has 
a high affinity, desensitise much more rapidly when exposed to nicotine than do 
receptors made up of a304, for which nicotine has a low affinity. Thus, the higher the 
affinity of a specific agonist for a particular nAChR subtype, the faster the agonist 
activates and deactivates the receptor. 
Contrary to dogma that chronic agonist exposure leads to downregulation of its 
receptors, nicotine exposure induces increases in number ("upregulation") of CNS 
radioligand binding sites in both humans and animals. Post-mortem brains of smokers 
have an increased number of nicotinic receptors compared to non-smokers in a number 
of brain regions (Perry et al., 1999; Breese et al., 1997; Benwell et al., 1988). 
Continuous infusion and intermittent administration of nicotine treatment has been 
shown to increase the number of putative nAChR in the brain of both rats and mice 
(Collins et al., 1994,1990,1988; Ksir et al., 1987; Marks et al., 1985,1983). This 
increased receptor density is very widespread in rodent brain, with more than two- 
thirds of the brain areas examined by autoradiography showing this effect after chronic 
nicotine treatment (Marks et al., 1992; Kellar et al., 1989). The extent of the 
upregulation of these receptors varies considerably between brain regions, with 
increases of 60-100% in the cortex and hippocampus, whereas in other brain regions 
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there is no significant increases (Flores et al, 1997; Marks et al., 1992; Kellar et al., 
1989). 
In addition to this upregulation of receptors, chronic nicotine treatment can be 
associated with a long-lasting downregulation in receptor function (Hsu et al., 1996; 
Peng et al., 1994; Marks et al., 1993a, b). This decrease in function is thought to be 
due, at least in part, to receptor desensitisation. It is this long-lasting receptor 
desensitisation that is thought to induce the receptor upregulation (Schwartz and 
Kellar, 1985; Marks et al., 1993a, b). 
1.9 Functional Role of Nicotinic Acetylcholine Receptors 
Many of the neuronal nAChRs, unlike the postsynaptic nAChRs of muscle, are 
predominantly found on the presynaptic terminals (Wonnacott, 1997). They thus 
influence neuronal activity by altering the firing rate and/or pattern of the neurone via 
activation of somatodendritic receptors, and by activating the receptors on the nerve 
terminals they control neurotransmitter release. There is evidence that both of these 
mechanisms are implicated in the effects of nicotine in the brain. 
Presynaptic nAChRs in the brain modulate the release of several neurotransmitters (see 
Vizi and Lendvai, 1999; Wonnacott, 1997, for recent reviews). Nicotine and nicotinic 
agonists have been shown to increase the release of ACh, dopamine, noradrenaline 
(NA), 5-HT and GABA from synaptosomal and tissue slice preparations, and in whole 
animals using microdialysis (see Table 1.5). The rewarding effects of nicotine are 
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thought to be due to stimulation of dopamine release and thus there has been extensive 
research on the release of this transmitter. In the rat striatum nicotine, DMPP, 
epibatidine and cytisine have all been shown to increase dopamine release using 
synaptasomes (Grady et al., 1997; Clarke and Reuben, 1996; Rowell and Hillebrand, 
1994), in vitro slices (Sacaan et al., 1996) and in vivo (Dajas-Bailador et al., 1998). 
The dorsal hippocampus is a structure that has been shown to be crucial in mediating 
anxiety. A number of studies in rodents have shown that stimulation of presynaptic 
nAChRs in this area cause release of a number of neurotransmitters, including ACh, 
dopamine, GABA and NA (see Table 1.5). For example, the nicotinic agonists DMPP 
and epibatidine have also been shown to enhance the release of NA from the 
hippocampus and whole hippocampal slices in a [Ca2+]o-dependent and TTX-sensitive 
manner (Sershen et al., 1997). The effect of nicotine on 5-HT release has been studied 
less extensively. Lendvai et al. (1996) have shown DMPP and lobeline can increase 5- 
HT release from the hippocampus, but nicotine, cytisine, and epibatidine have no 
effect. However, a recent study by Kenny et al. (2000a) showed that nicotine (50- 
500pM) caused a concentration-dependent increase in 5-HT release, that was 
antagonised by mecamylamine indicating the involvement of nicotinic receptors. 
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Table 1.5 Neurotransmitters that are modulated by presynaptic nicotinic receptors within 
various rat brain structures. ACh, acetylcholine; 5-HT, 5-hydroxytryptamine; 
GABA, y-aminobutyric acid; DRN, dorsal raphe nucleus. 
Transmitter Brain Region Reference 
ACh Hippocampus Wilkie et al., 1996; Toide and Arima, 1989; 








Kaiser et al., 1998; Toth et al., 1992 
Kenny et al., 2000a; Li et al., 1998; Lendvai 
et al., 1996 
Alkondon et al., 1999,1997; Yang et al., 
1996 
Noradrenaline Hippocampus Kiss et al., 1997; Sershen et al., 1997; Clarke 
and Reuben, 1996; Sacaan et al., 1996 
1.10 Nicotine and Behaviour 
Nicotine has a complex neuropharmacological profile and it influences several 
neurotransmitters and thus produces a range of physiological and behavioural effects in 
both laboratory animals and humans (Stolerman et al., 1995). These effects range from 
changes in body temperature, locomotor activity and reward, to enhancement of 
cognitive function and attention. These effects can be influenced by a number of 
factors including dose, route of administration, species and strain of animal. 
1.10.1 Nicotine and Reward 
Nicotine, like other drugs of addiction such as the psychomotor stimulants, depressants 
and opiate narcotics, is thought to express its rewarding effects by stimulating the 
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mesolimbic dopamine system (Pontieri et al., 1996; Schulteis & Koob, 1994; Koob, 
1992; Wise and Bozarth, 1987). Acute nicotine administration potently stimulates 
dopamine release from the nucleus accumbens (Nacc), particularly from within the 
shell region. This effect on NAcc dopamine release is blocked by intra-ventral 
tegmental area (VTA) injection of the nicotinic receptor antagonist, mecamylamine, 
but not by NAcc mecamylamine injection (Nisell et al., 1994). This suggests that the 
nicotinic receptors located within the VTA, and not within the NAcc, predominately 
mediate the effect of nicotine on dopamine release in vivo. 
The ability of nicotine to support self-administration in rats under a limited access 
schedule (Corrigall & Coen, 1989) and to condition a place preference (Risinger & 
Oakes, 1995; Shoaib et al., 1994) are thought to reflect the `rewarding' properties of 
nicotine produced by it's ability to evoke NAcc dopamine release. Accordingly, 
Picciotto et al (1997) have recently demonstrated that nicotine can no longer elicit 
mesolimbic dopamine release in mice lacking the 02 subunit and that this decrease in 
dopamine release -is accompanied by a dramatic decrease in nicotine self- 
administration in these mutant mice. Furthermore, lesioning of the mesolimbic 
dopamine neurones significantly attenuates nicotine self-administration in rats 
(Corrigall et al., 1992). Recent data suggests that dopamine release in the NAcc may 
not mediate the rewarding effects of nicotine per se, but may be more related to 
signalling in the brain that a rewarding effect is about to take place. For example, 
neutral stimuli which by themselves have no rewarding value, have been shown to 
elicit NAcc release after they have been associated with rewarding stimuli (Phillips et 
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al., 1993; Damsma et al., 1992). Further, novel stimuli (Rebec, 1998; Ljungberg et al., 
1992), stress and aversive stimuli (McCulloch et al., 1993; Young et al., 1993) and 
stimuli which have been temporally associated but are not rewarding nor aversive 
(Young et al., 1995) have also been shown to increase NAcc dopamine release. 
However, Di Chiara has noted that non-rewarding stimuli, as described above, 
preferentially stimulate dopamine release within the core of the nucleus accumbens, 
whereas rewarding stimuli and drugs of abuse preferentially stimulate dopamine 
release in the shell (see Di Chiara, 2000). Nevertheless, these observations have led 
Joseph et al. (1996) to speculate that NAcc dopamine release may be involved in 
attributing salience to a particular stimuli rather than mediating a rewarding effect of 
that stimuli. Accordingly, although accumbal dopamine release has recently been 
shown to be involved in acquiring intracranial self-stimulation (ICSS) behaviour once 
established, there was no change in accumbal dopamine release during ICSS behaviour 
(Garnis et al., 1999). Therefore, it appears that dopamine plays a complex role in 
mediating reward and that neurotransmitters other than dopamine are also likely to be 
involved in mediating the effects of nicotine. One possible candidate is 5-HT, which 
has been suggested to play a role in maintaining cocaine self-administration in mutant 





1.10.2 Nicotine and Cognition 
There is substantial evidence to suggest that the cholinergic system plays an important 
role in cognition, in both humans and animals (Rezvani and Levin, 2001; Mancuso et 
al., 1999; Rusted et al., 1998; Warburton and Mancuso, 1998; Levin and Simon, 1998; 
Levin, 1992), particularly those involving attentional processes. Indeed, marked 
impairment of cognitive skills can be seen after the disruption of cholinergic 
neurotransmission in the brain, either by neurodegeneration or pharmacological 
intervention. The development of conditions such as Alzheimer's disease, in which 
cognitive impairment is the principal symptom, is thought to be due to degeneration of 
the cholinergic system. A significant loss in the density of high affinity [3H]-nicotine 
binding sites is seen in post-mortem brains of Alzheimer disease patients (Newhouse et 
al., 1997). Nicotine administration via skin patches or injection has been shown to 
significantly improve attention (White and Levin, 1999; Jones et al., 1992a), learning 
(White and Levin, 1999) and memory (Parks et al., 1996; Newhouse et al., 1988) in 
patients with Alzheimer's disease. Disruption of the cholinergic system with 
muscarinic or nicotinic antagonists, such as atropine or mecamylamine, has shown 
memory deficits on a number of behavioural tests (Levin et al., 1997; Levin, 1992). 
The effects of nicotine on cognition have been studied in animals using a number of 
tests of learning and memory. Acute treatment with nicotine has been found to 
improve working memory function in the radial-arm maze (Levin et al., 1998,1997; 
Decker et al., 1995), in passive avoidance (Zarrindast et al., 1996; Decker et al., 1994; 
Brioni and Arneric, 1993), Morris water maze (Socci et al., 1995) and delayed-match- 
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to-sample tasks (Buccafusco et al., 1996,1995; Buccafusco and Jackson, 1991; Elrod 
et al., 1988). Interestingly, after chronic treatment with nicotine no tolerance is seen to 
the memory improvement effects, and in fact the improvement appears to become more 
robust (Levin et al., 1993,1990). Mecamylamine, the non-competitive nAChR 
antagonist, impairs cognitive function in normal animals and blocks the improvements 
seen in cognitive performance after both acute (Levin et al., 1997) and chronic (Levin 
et al., 1999) nicotine treatment. 
Nicotinic agonists, such as ABT-418 and epibatidine, that are thought to potently act at 
the a402 subtype, have been shown to significantly improve cognitive performance in 
rodents (Decker et al., 1994). ABT-418 has also been shown to significantly enhance 
delayed-match-to-sample performance in monkeys (Buccafusco et al., 1996). The a7 
agonist, GTS-21, has also been shown to improve performance in a variety of tests 
(Arendash et al., 1995). Thus, these results suggest that both the a402 and a7 
subtypes may be important in mediating the effects of nicotine on cognition. 
Recent studies have investigated particular neuroanatomical sites where nicotine and 
nicotinic agonists may be mediating their effects. The hippocampus has been known 
for a long time to be involved in memory and attention (Jarrard, 1995) and it is known 
to contain a number of nAChRs. Indeed, local administration of mecamylamine 
directly into the hippocampus caused a significant memory deficit (Ohno et al., 1993). 
Furthermore, administration of DHf3E, the a402-selective antagonist, or MLA, the a7- 
selective antagonist, causes significant memory impairment after infusion in to the 
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hippocampus. Therefore giving further evidence of the involvement of the a4ß2 and 
a7 subtypes in mediating the effects of nicotine on cognition. 
1.10.3 Nicotine and Anxiety 
There is growing evidence suggesting that the cholinergic system is involved in the 
modulation of anxiety. It is often reported by smokers that smoking reduces anxiety 
and tension (Ikard, 1969) and smoking tends to increase during episodes of stress and 
depression (Breslau et al., 1991; Hughes et al., 1986). However, not all smokers 
experience anxiolytic effects from smoking (Parrott and Garnham, 1998), and 
Newhouse et al. (1990) found nicotine increased anxiety in non-smokers. Netter et al. 
(1998) found that smokers with high neuroticism scores became more anxious and 
tense after smoking a cigarette. There is general agreement that there is increased 
anxiety during nicotine withdrawal in smokers (West and Russell, 1985; Shiffman and 
Jarvik, 1976) and those using nicotine gum (Parrott et al., 1996; Hughes et al., 1990; 
Keenan et al., 1989). Nicotine patches and tablets have been shown to reduce anxiety 
in smokers (Netter et al., 1998; Warburton and Mancuso, 1998; Wesnes and 
Warburton, 1983), which may reflect a reversal of withdrawal anxiety. 
In animal studies, nicotine and nicotinic agonists have anxiolytic effects after acute 
systemic administration in the elevated plus-maze test (Brioni et al., 1993,1994), the 
mirrored chamber test (Cao et al., 1993), the light-dark exploration test (Costall et al., 
1989b) and the potentiated startle test (Vale and Green, 1986). In contrast to Brioni's 
report of anxiolytic effects after acute systemic administration in the elevated plus 
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maze (Brioni et al., 1993,1994), anxiogenic effects have been reported in this test 
(Ouagazzal et al., 1999a). In this test the direction of nicotine's effects is not dose- 
related, since the dose (0.3 mg/kg) that was reported to be anxiolytic by Brioni et al. 
(1994) fell in the dose-range found to be anxiogenic by Ouagazzal et al. (1999a), and 
Benwell et al. (1994) found 0.4 mg/kg to be ineffective. Lower doses (0.001-0.1 
mg/kg) were shown to be ineffective by Ouagazzal et al. (1999a). These differences in 
response to an acute injection of nicotine could be due to strain differences and/or 
differences in the baseline scores. Aversive effects of nicotine have also been reported 
in operant tests of punished behaviour, and nicotine has been reported to both suppress 
punished responding (Morrison, 1969), and to function as a punishing stimulus 
(Takada et al., 1992). 
In the social interaction test, it has been shown that acute systemic nicotine produces 
both anxiolytic and anxiogenic effects that are dose and test-condition dependent (File 
et al., 1998). In the social interaction test, nicotine has been shown to be dose- 
dependent, with low doses (0.01 and 0.1 mg/kg) having an anxiolytic effect after acute 
systemic administration and high doses (0.5 and 1.0 mg/kg) an anxiogenic effect, when 
animals were tested 30 min after an i. p. injection (File et al., 1998). This study also 
showed that the effects on anxiety were also dependent on the test condition, with 
effects only being observed in conditions of moderate anxiety (HF: high light familiar 
or LU: low light unfamiliar). Similarly, using the technique of self-administration, the 
dose and test condition determines whether the maintenance of lever pressing 
behaviour results in, or prevents, nicotine infusions (Goldberg et al., 1983). 
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As mentioned before, the dorsal hippocampus is a structure that is crucially involved in 
anxiety disorders. Administration of nicotine bilaterally into the dorsal hippocampus 
has been shown to induce anxiogenic effects in the social interaction test (File et al., 
1998). These effects have also been shown to be dependent on the test condition and 
as before are only seen in conditions of moderate anxiety (HF, 0.1-8µg; LU, 8µg). The 
5-HTIA receptors were implicated in this action, because co-administration into the 
dorsal hippocampus of the 5-HT1A receptor antagonist, WAY 100,635, reversed the 
anxiogenic effect of nicotine (Kenny et al., 2000b). Furthermore, it has been shown 
that nicotine increases 5-HT release in the dorsal hippocampus (Kenny et al., 2000a)>, 
thus, 
suggesting that nicotine exerts its anxiogenic effect by stimulating 5-HT release 
in this region and activating 5-HT1A receptors. Intra-hippocampal injections of 
nicotine (0.1-8µg) were ineffective on Trial 1 but on Trial 2 an anxiolytic effect was 
observed (Ouagazzal et al., 1999a). 
The lateral septum has also been identified as an important neuroanatomical substrate 
mediating nicotine's anxiogenic effects. Anxiogenic effects have been observed in 
both the social interaction (1-8µg; Ouagazzal et al, 1999b; Cheeta et al., 2000b) and 
elevated plus maze (1 and 4µg; Ouagazzal et al, 1999b) tests after direct administration 
of nicotine to this structure. These anxiogenic effects were also antagonised by co- 
administration of the specific 5-HT1A receptor antagonist WAY 100,635 (Cheeta et al, 
2000b), suggesting an important role for 5-HT1A receptors in this brain area in 
mediating nicotine's anxiogenic effects. 
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1.11 Tolerance Mechanisms and Withdrawal 
The development of behavioural tolerance following the repeated administration results 
in a reduced response to a given dose of drug, or the need to increase the dosage to 
maintain the same original effects (Jaffe, 1990; Nestler, 1992). There is thought to be 
two different types of tolerance. The first is dispositional tolerance (pharmacokinetic) 
which results from changes in the absorption, distribution or metabolism of a drug and 
might lead to a reduction in the intensity and duration of contact between a given drug 
and the tissue on which it exerts its characteristic action. The second is functional 
tolerance (pharmacodynamic) which is usually taken to be tolerance that is mediated 
by changes in the sensitivity of the neuronal, receptor or neurochemical system which 
may limit a drug's actions (Goudie, 1989). Littleton and Little (1989) have suggested 
that there may be two distinct models of functional tolerance whereby adaptive 
changes are recruited to in an attempt to maintain homeostatic balance, decremental 
and oppositional. An example of decremental tolerance is when the receptor number 
or the properties of the receptor are changed. With this form of tolerance there is not 
an obvious indication that the drug is not present. Oppositional tolerance suggests that 
continued drug treatment results in an oppositional process that comes into effect to 
counteract the effect of the drug. This oppositional effect could explain the withdrawal 
syndrome that is often seen when drug treatment is discontinued. There is now 
evidence to suggest that learning may play an important part in drug tolerance (Young 
and Goudie, 1995; Goudie and Griffiths, 1996). It is thought that classically 
conditioned processes may occur following the repeated administration of a drug when 
it is paired with a known stimulus, such as an environmental cue. These stimuli may 
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induce compensatory'conditional responses, which become paired with the drug and cause a 
reduction or oppose the direct effect of the drug leading to the development of tolerance. 
Therefore, tolerance to the behavioural effects of the drug is greater when measured in the 
environment associated with drug treatment, i. e. the tolerance is context or situation-specific. 
Withdrawal refers to the syndrome that emerges following the discontinuation of drug 
treatment. There are though to be at least three distinct discontinuation syndromes that 
occur after drug treatment is terminated and patients may have any combination of 
these: 1) recurrence, when the symptoms that were seen before drug treatment occur, 2) 
rebound, when the symptoms that occurred before treatment return but with a greater 
intensity and 3) withdrawal, when symptoms are seen that were not seen before drug 
treatment (Greenblatt et al., 1990). These syndromes are able to be distinguished as 
they have different rates of onset and the intensity of the syndromes is varied. 
1.11.1 Tolerance to Nicotine's Behavioural Effects 
One view of the onset of regular smoking suggests that repeated exposure to nicotine 
gradually leads to reduced magnitude of its effects, i. e. chronic tolerance. Chronic 
tolerance to nicotine in smokers leads to a greater effort by the smoker to continue to 
obtain the same magnitude of reinforcing effects of nicotine and thus is important in 
nicotine dependence. Repeated exposures to nicotine during the course of a single day 
may also lead to reduced responding across these exposures, a change that may reflect 
acute tolerance. Chronic tolerance and acute tolerance in smokers and non-smokers 
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has been demonstrated for many of nicotine's effects, including subjective and 
cardiovascular effects (Fattinger et al., 1997; Perkins et al., 1994,1993,1989; Arcavi et 
al., 1994; Russell et al., 1990). 
Initial exposure to cigarettes is typically reported as aversive, and many studies have 
shown that have shown that smokers respond less to the dysphoric effects of nicotine 
(e. g. tense, dizzy, jittery, light-headed) than non-smokers, thus demonstrating chronic 
tolerance (Perkins et al., 1994,1993). Heishman and Henningfield (2000) have shown 
that non-smokers treated with nicotine for 8 days show tolerance to some of these 
aversive effects of nicotine and to the sedative effects of nicotine. There is also 
evidence for acute tolerance to some of these subjective effects of nicotine (e. g. dizzy, 
light-headed) in both smokers and non-smokers suggesting that novice smokers may be 
able to adapt rapidly to some of the initial aversive effects of nicotine during a smoking 
episode, and thus leading to increased ability to smoke more cigarettes per episode. 
Nicotine produces a wide range of acute dose-dependent cardiovascular effects in 
smokers, the most common effects being increased heart rate and blood pressure. 
Acute (Fattinger et al., 1997; Arcavi et al., 1994; Perkins et al., 1994,1991) and 
chronic (Perkins et al., 1994,1989) tolerance has been shown to both of these 
cardiovascular effects. 
Animal research has shown that there are adaptions to many behavioural and 
physiological effects of nicotine after chronic treatment with nicotine. The most 
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studied is nicotine's effect on locomotor activity. An acute injection of nicotine 
produces a biphasic effect on locomotor activity in rats. After an acute injection of 
nicotine there is an initial decrease in locomotor activity and approximately 40-60 min 
after injection a stimulant effect is observed. With repeated nicotine injections, 
tolerance develops to the initial depressant effects (Stolerman et al., 1995,1974,1973; 
Ksir, 1994; Benwell and Balfour, 1992). The increase in locomotor activity following 
repeated nicotine injections, which is similar to the increase in activity following other 
psychostimulants, such as amphetamine and cocaine, has been referred to by many 
investigators as locomotor sensitisation. There is much evidence to show that tolerance 
does not develop to this stimulant effect and is in fact enhanced (Shoaib et al, 1997; 
Ksir et al, 1987). The expression of locomotor sensitisation is blocked by 
mecamylamine or DHf3E (Stolerman et al., 1997; Benwell and Balfour, 1992; Clarke 
and Kumar, 1983a, b), indicating the involvement of nicotinic receptors. 
A number of studies have shown that tolerance can develop very rapidly to the effects 
of nicotine on antinociception (McCallum et al., 2000,1999; Wewers et al., 1999). 
Wewers et al. (1999) demonstrated that male and female rats treated with nicotine (0.3 
mg/kg) displayed significantly greater antinociceptive responses, as evidenced by 
prolonged hot-plate latency during the initial phases of the protocol. However, by day 
7 of nicotine treatment the antinociceptive response had disappeared, suggesting 
tolerance to nicotine (Wewers et al., 1999). McCallum et al. (2000) showed that in 
rats administered a short (once-daily for 6 days; 0.35 mg/kg) or long (twice-daily for 
11 days; 0.66 mg/kg) series of injections tolerance to nicotine-induced antinociception. 
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Pairings of mecamylamine (1 mg/kg) with nicotine (0.35 mg/kg) for both these 
treatment regimens blocked the development of tolerance, indicating nicotinic receptor 
activation was necessary for tolerance to occur. 
Acute nicotine causes a decrease in milk intake, but after 6 days of treatment (0.66 
mg/kg) with this dose of nicotine tolerance is seen to this effect (McCallum et al., 
1999). Mecamylamine blocked tolerance to the effects of nicotine Six daily pairings 
of mecamylamine (1 mg/kg) with nicotine blocked the development of tolerance to the 
ability of nicotine to suppress milk intake (0.66 mg/kg). Thus, again indicating the 
involvement of nicotinic receptors. 
A limited number of studies have investigated the development of tolerance to the 
discriminative stimulus effects of nicotine. It has been shown that acute tolerance can 
develop to the nicotine discrimination following single boluses of nicotine (0.8 mg/kg) 
injected 90 min apart (James et al., 1994) or after several days of nicotine treatment 
(Schechter and Rosecrans, 1972). However, Shoaib et al. (1997) did not show 
tolerance to the discriminative stimulus of nicotine after once or thrice daily injections 
of nicotine or continuous infusion for 7 days. These contradictory results suggest that 
chronic tolerance to nicotine's discriminative stimulus does not develop readily. 
With regards to tolerance to anxiety the literature at present is very limited. Costall et 
al. (1989b) has shown that after 3,7 and 14 days of chronic nicotine (0.1 mg/kg, i. p. ) 
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treatment tolerance did not develop to the acute anxiolytic effect seen in the light-dark 
exploration test. 
1.11.2 Nicotine Withdrawal 
In humans, withdrawal from chronic nicotine results in an abstinence syndrome that is 
characterised by a number of different symptoms. The most prominent of these 
symptoms being anxiety, irritability, restlessness, lack of concentration, light- 
headedness, insomnia, increased hunger and weight gain (Hughes et al., 1991). It is 
these withdrawal symptoms that are thought to be the cause of the high relapse rate 
observed during the first few days of smoking cessation (Hildebrand et al., 1997; 
Hughes et al., 1992). Nicotine patches have been shown to reduce anxiety in smokers 
(Netter et al, 1998; Warburton and Mancuso, 1998; Wesnes and Warburton, 1983), 
which may reflect a reversal of withdrawal. 
Animal models are an important tool for understanding the neurobiological 
mechanisms underlying nicotine abstinence. Malin et al. (1992) has described an 
abstinence syndrome in rats that is characterised by teeth chattering/chews, 
writhes/gasps, ptosis, tremors/shakes and yawns. These characteristics were seen after 
7 days of subcutaneous infusion of 3 or 9 mg/kg/day nicotine, and were shown to be 
dependent on the rate of nicotine infusion with more signs being observed at the higher 
dose of nicotine. This model has met a number of validity criteria, including potent 
reversibility of abstinence signs by nicotine injection and comparative lack of signs in 
saline infused animals. This nicotine abstinence syndrome has also been shown to be 
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precipitated by injection of the nicotinic antagonists mecamylamine (s. c.; Hildebrand et 
al., 1999,1997; Malin et al, 1994), dihydro-ß-erythroidine (DHIE; i. c. v.; Malin et al, 
1998) and hexamethonium (i. c. v.; Malin et al., 1998). 
Brain stimulation reward thresholds have been shown to be a valid and reliable 
measure of the diminished reward and motivation associated with withdrawal from 
several drugs of abuse including cocaine, amphetamine, opiates and ethanol. 
Withdrawal from chronic nicotine resulted in elevations in brain stimulation reward 
thresholds (Epping-Jordan et al., 1998). These elevations in brain stimulation reward 
thresholds were also observed after DHjE, and mecamylamine precipitated withdrawal 
from nicotine (Watkins et al., 2000; Epping-Jordan et al., 1998). 
A consistent symptom of nicotine withdrawal is increased anxiety and a number of 
groups have shown this using animal models. Costall et al. (1990b, c) showed an 
anxiogenic withdrawal response in the light-dark exploration test. An enhanced 
acoustic startle response was also seen for the first 4-5 days after nicotine withdrawal 
in animals receiving 0.3 and 0.6 mg/kg/day (Helton et al., 1993). Sorenson and 
Wilkinson (1983) demonstrated that rats given nicotine in their drinking water for 10 
days showed increase startle responding 3 days following the termination of nicotine 
exposure. This withdrawal response has been shown to be reversed by administration 
of the normal daily dose of nicotine (Malin et al., 1992). 
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The 5-HT system is thought to be involved in the anxiogenic withdrawal response 
following termination of nicotine administration, as a number of drugs that modify this 
system have been shown to reverse this withdrawal effect. In humans, the 5-HT1A 
receptor agonist, buspirone, has been shown to have beneficial effects on nicotine 
withdrawal symptoms and in helping patients achieve smoking cessation (Hilleman et 
al., 1994,1992; West et al., 1991). Costall et al. (1990b, c) have shown using the light- 
dark exploration test that administration of the selective 5HT3 receptor antagonist 
ondansetron administered either systemically or directly into the DRN or amygdala 
reverses the anxiogenic withdrawal response. Rasmussen et al. (1997) have shown that 
during nicotine withdrawal there is an enhanced acoustic startle response that is 
reversed by 5HT1A receptor antagonists such as NAN190, LY2063310 and 
WAY100,635. 
1.12 Aims of this Thesis 
Acute nicotine treatment has been shown to have both anxiolytic and anxiogenic 
effects that are dose-dependent (Ouagazzal et al., 1999a; File et al., 1998). Thus, the 
initial section of this thesis investigated the acute effects of sub-cutaneous nicotine 
injections on singly housed male rats at varying times after injection, using both the 
social interaction (Chapter 2) and the elevated plus-maze (Chapter 3) tests. These 
chapters also investigated whether tolerance would develop to the acute effects -on 
anxiety after chronic treatment (7-14 days) with a low dose of nicotine (0.1 mg/kg) and 
whether there was a change in anxiety after withdrawal from this treatment. Social 
isolation has been shown to modify anxiety-related behaviours (Hall et al., 1998; 
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Smith et al., 1997; Fone et al., 1996; Lopes da Silva et al., 1996) and so Chapter 4 
investigated whether the effects of housing conditions would modify the effects of 
nicotine in the two aforementioned animal tests of anxiety. Animals were either 
housed singly or in groups of five. 
Nicotine is one of the most widely abused psychostimulant drugs in the world. Thus, 
Chapter 5 investigated the changes in anxiety (using the social interaction test) that 
occur when rats are self-administering nicotine (15 infusions of 0.03 mg/kg, totalling 
0.45 mg/kg/session; i. v. ) and when they are withdrawn from 4 weeks of self- 
administration. In order to determine if the effects seen in Chapter 5 were due to the 
dose of nicotine or because the animals were self-administering nicotine, Chapter 6 
investigated the effects on the development of tolerance and withdrawal of chronic 
nicotine using different routes of administration. Rats received nicotine either by 
passively administered i. v. doses of nicotine in the same pattern as that used for self- 
administration, by once daily sub-cutaneous injections or by continuous sub-cutaneous 
infusion using osmotic mini-pumps. In all cases, the rats received the same daily dose 
of nicotine (0.45 mg/kg). 
The involvement of neuroanatomical substrates in the development of tolerance to 
nicotine's anxiolytic and anxiogenic effects was investigated using the social 
interaction test. To date, the neuroanatomical site involved in mediating the anxiolytic 
effect of nicotine has not been elucidated. Thus, Chapter 7 investigated the role of the 
DRN as a site mediating the anxiolytic effect of nicotine and whether the effect was 
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mediated through the serotonergic system by co-administering nicotine with the 5- 
HT1A antagonist WAY 100,635. This Chapter also explored the role of the DRN in 
mediating tolerance to the anxiolytic effect of nicotine. The dorsal hippocampus has 
been shown to be one neuroanatomical site mediating the anxiogenic effect of nicotine 
in the social interaction test. The anxiogenic effect is thought to be due to nicotine 
increasing 5-HT in this area and acting on 5-HT1A receptors. Therefore, Chapter 8 
investigated the involvement of the dorsal hippocampus in mediating tolerance to the 
anxiogenic effect of nicotine. In order to investigate a possible mechanism underlying 
the development of tolerance to anxiogenic effect of nicotine in the dorsal 
hippocampus, [3H]-5-HT release was measured in superfused dorsal hippocampal 
slices taken from rat that had been chronically treated with nicotine. 
Like nicotine, benzodiazepines have a high incidence of dependence in humans. 
Benzodiazepines are widely used as anxiolytics and tolerance develops to their 
anxiolytic effects after about 3 weeks of treatment. Thus, the final chapter investigated 
whether a short period of nicotine pre-treatment modified the anxiolytic effects of 
benzodiazepines. The dorsal hippocampus and DRN are two sites that mediate the 
anxiolytic effects of benzodiazepines (Nazar et al., 1999; Gonzalez et al, 1998; 
Gonzalez and File, 1997; Stefanski et al., 1993; Thiebot et al, 1982) and therefore 
midazolam was directly administered into these two brain regions. In order to 
determine if there were any changes in benzodiazepine receptor binding in either of 
these two brain areas after chronic nicotine treatment radioläbelled ligand binding 






Time course of nicotine's effects on anxiety 
CHAPTER 2 
Time-course of changes in the social interaction 
test of anxiety following acute and chronic 
administration of nicotine 
2.1 Introduction 
Nicotinic agonists have been shown to have anxiolytic effects after acute systemic 
administration in many animal tests of anxiety (Brioni et al., 1994,1993; Cao et al., 
1993; Costall et al., 1989b; Vale and Green, 1986). In contrast to Brioni's report of 
anxiolytic effects after acute systemic administration of nicotine in the elevated plus 
maze (Brioni et al., 1994,1993), Ouagazzal et al. (1999a) have reported anxiogenic 
effects. In the social interaction test, both anxiolytic and anxiogenic effects have been 
observed 30min after an acute systemic nicotine injection that are dose and test- 
condition dependent (File et al., 1998). Thus, a complex pattern of nicotine's effects 
on anxiety are seen after acute administration. 
In the mouse black/white crossing test of anxiety no tolerance to the acute anxiolytic 
effect of nicotine (0.1mg/kg; i. p. ) was found following 3,7 and 14 days of twice daily 
nicotine injections (Costall et al., 1989b). However, a significant anxiogenic effect 
was seen 8,48 and 96 h after withdrawal from this treatment of 14 days of twice daily 
injections of nicotine (Costall et al., 1989b). The anxiogenic withdrawal response is 
difficult to reconcile with the finding that acute nicotine treatment can also result in an 
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anxiogenic effect in the social interaction test. Thus, the purpose of the present study 
was therefore to examine whether tolerance developed to this anxiogenic effect after 4, 
7 and 14 days of treatment. It also examined whether there would be changes in 
anxiety when the animals were tested in the social interaction test 72 h after 
withdrawal from a period of chronic treatment. Since the effects of nicotine 5 min 
after injection has not been examined, experiment 1 was a dose response study, 
conducted in the low light, unfamiliar (LU) test condition, to determine an anxiogenic 
dose of nicotine for use in subsequent experiments. From this study, the dose 0.1 
mg/kg (s. c. ) was selected, and experiment 2 examined the effects after 4 days of 
nicotine treatment. Since tolerance had not developed at this stage, experiment 3 
examined whether tolerance had developed to the anxiogenic effect after 7 and 14 
day's nicotine treatment and whether there were any changes when rats were tested 
after 72 h withdrawal from 7 and 14 day's treatment with nicotine. 
As an anxiogenic effect was seen both acutely and after withdrawal, it was thought that 
perhaps there was a change in the effect of nicotine on anxiety with time, with an 
anxiogenic effect occurring shortly after injection, which over time became anxiolytic, 
as is the case for locomotor activity, which changes from a depressant to a stimulant 
effect over time (Clarke and Kumar, 1983a, b). Therefore, experiment 4 examined the 
time course of effects of 0.1 mg/kg (s. c. ). An anxiolytic effect was observed 30 
minutes after injection and the rats were therefore tested 30 min after 7 days of 
treatment to see whether tolerance developed to this effect. 
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2.2 Materials and Methods 
Animals 
In all experiments, male hooded Lister rats (Charles River, UK) were housed in groups 
of five until 5 days before testing, when all animals were singly housed. At testing, 
the animals weighed 150-200 g (experiment 1) and 250-300 g (experiments 2,3 and 
4). All animals were housed in the same animal room, maintained at 22°C, with lights 
(<50 scotopic lux) on from 0700-1900 h. Food and water were freely available. 
Apparatus 
The social interaction test (Figure 1.1) was a wooden box 60 x 60 cm, with 35 cm high 
walls; the light levels were 300 and 30 radiometric lux for the high and low light 
conditions, respectively. A closed circuit television camera was mounted vertically 
above the arena and the rats were observed on a monitor in an adjacent room by an 
observer who was blind to the drug treatment. The time spent in social interaction 
(sniffing, following and grooming the partner, boxing and wrestling) provided the 
measure of anxiety. The interruption of infrared beams from photocells mounted in 
the walls, 4.5 cm from the floor, provided an automated measure of locomotor activity 
(File, 1980). 
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Drugs 
For all experiments (-)-nicotine hydrogen tartrate (Sigma) was dissolved in distilled 
water, in a volume of 1 ml/kg body weight. Control animals received equal volume 
injections of distilled water, and all injections were sub-cutaneous (s. c. ). 
The doses of nicotine used in experiment 1 were 0.05,0.1 and 0.5 mg/kg (free base). 
It was decided from experiment 1 that the most suitable dose to use for the subsequent 
experiments was 0.1 mg/kg nicotine. 
Procedure 
Within each experiment, animals were allocated to test partners on the basis of weight, 
such that members of a pair did not differ by more than 10 g. On the test day pairs of 
rats were tested for 4.5 min and their behaviour scored by an observer with no 
knowledge of their drug treatment. In experiment 1, rats were tested in an unfamiliar 
arena, lit by low light. In all the other experiments, rats were tested in a brightly lit, 
familiar arena. In order to familiarise the animals with the test arena, each rat was 
placed singly in the brightly lit arena on the day prior to testing, for a 10 min 
familiarisation trial. These two test conditions were selected since they allow 
detection of both anxiolytic and anxiogenic effects (File et a1., 1998). At the end of 
the test, the rats and any faecal boluses were removed and the arena wiped with a 
damp cloth. All animals were tested in an order randomised for drug treatment, 
between 0800 and 1300 h. In experiments when nicotine was given chronically, all the 
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animals were given daily injections of vehicle or nicotine, as appropriate, to equate 
handling and injection experience. 
In experiments 1,2 and 3a animals were tested 5 min after s. c. injection of nicotine or 
vehicle, with both animals in the pair receiving the same dose. In experiment 3b, the 
animals were tested uninjected and undrugged 72 h after withdrawal from 7 and 14 
days nicotine treatment. In experiment 4, the animals were tested at various times after 
injection. 
Experiment 1 
Sixty-two animals were randomly allocated (n=7 or 8 pairs/group) to the following 
groups: vehicle, 0.05,0.1 and 0.5 mg/kg nicotine. 
Experiment 2 
Thirty-two animals were randomly allocated to the following two groups (n=8 
pairs/group): vehicle or 4 days nicotine (0.1 mg/kg) treatment. 
Experiment 3a 
Sixty-two animals were randomly allocated to the following groups (n=7 or 8 
pairs/group): vehicle, acute nicotine, 7 and 14 days nicotine (0.1 mg/kg) treatment. 
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Experiment 3b 
Forty-eight animals were randomly allocated to the following three groups (n=8 
pairs/group) vehicle, 7 and 14 days of nicotine (0.1 mg/kg) treatment. The animals 
were first tested following an acute dose of nicotine to confirm an anxiogenic effect 
and were then tested uninjected and undrugged 72 h after their last s. c. injection, to 
examine the effects of withdrawal from chronic nicotine. 
Experiment 4 
Sixty-eight animals were divided into three groups to examine the effects of acute 
nicotine administration on the time spent in social interaction at varying times after 
injection. Group A (n=6 pairs/vehicle group and n=8 pairs/nicotine group) was tested 
30 min after injection, group B (n=4 pairs/vehicle group and n=6 pairs/nicotine group) 
was tested 1 and 3h after injection and group C (n=4 pairs/vehicle group and 6 
pairs/nicotine group) 30 h after the Ist nicotine injection and then 30 min following a 
2nd injection of nicotine administered on day 2. Following their Ist injection and test, 
both groups A and C were treated for a further 6 days with once daily injections of 
nicotine (0.1 mg/kg, s. c. ) and then tested 30 min following their seventh injection. 
Statistics 
In all experiments, the scores were analysed by one-way analysis of variance 
(ANOVA), and comparisons between individual groups were then made with Fisher's 
post-hoc tests. When there were significant changes in both social 
interaction and 
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motor activity, analysis of covariance (ANCOVA) were conducted in order to 
determine the independence of the changes. 
2.3 Results 
Experiment 1 
Acute nicotine administration produced a dose-dependent decrease in the time spent in 
social interaction [F(3,27)=12.1, p<0.0001], and post-hoc tests demonstrated that 0.1 
and 0.5 mg/kg reached statistical significance (p<0.05 and 0.01, respectively; Table 
2.1). Nicotine significantly reduced locomotor activity (F(3,27)=12.1, p<0.0001; 
Table 2.1), but only the 0.5 mg/kg group was significantly reduced compared with the 
vehicle group (p<0.01). Analysis of covariance confirmed that the decrease in social 
interaction was independent of the reductions in locomotor activity [F(1,12)=10.6, 
p<0.01]. However the dramatic decrease in locomotor activity was mainly secondary 
to the decrease in social interaction, and when the latter was accounted for, the 
locomotor activity was no longer significantly decreased [F(1,12)=3.7, p=0.08]. 
Experiment 2 
After 4 days treatment with nicotine (0.1 mg/kg) there was a significant decrease in the 
time spent in social interaction [F(1,14)=6.4, p<0.05], but no change in locomotor 
activity (Table 2.2), indicating a specific anxiogenic effect. 
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Table 2.1 Mean (± sem) time (s) spent in social interaction and locomotor activity (beam 
breaks) made by rats tested 5 min after an acute dose of nicotine (0.05,0.1 and 
0.5 mg/kg s. c. ) and tested in the low light, unfamiliar (LU) test condition. ** 
p<0.01 compared with vehicle control; # no longer significant after analysis of 
covariance (see text for details). 
Nicotine (mg/kg) 
Vehicle 0.05 0.1 0.5 
Social Interaction 87.5 ± 10.5 68.6 ± 9.0 45.9 ± 14.1 ** 7.2 ± 2.7 ** 
Locomotor Activity 273.7 ± 22.8 286.0 ± 21.2 225.9 ± 29.7 61.0 ± 21.6 # 
Table 2.2 Mean (± sem) time (s) spent in social interaction, locomotor activity (beam 
breaks) and number of rears after 4 days treatment with vehicle or nicotine 
(0.1mg/kg). Rats were tested in the high light, familiar (HF) test condition, 5 
min after injection. **p<0.01 compared with vehicle control. 
Vehicle (s. c. ) Nicotine (0.1 mg/kg; s. c. ) 
4 Days 4 Days 
Social Interaction 142.2 ± 9.8 103.3 ± 4.8 ** 
Locomotor Activity 367.6 ± 26.4 322.6 ± 27.7 
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Experiment 3a 
In this experiment, nicotine significantly changed social interaction [F(3,27)=4.0, 
p<0.05] and comparisons between the individual groups showed that the acute dose 
(0.1 mg/kg) was significantly different from both the vehicle control (p<O. 01) and the 
7 day treatment group (p<0.05), see Figure 2.1. Neither the 7 nor 14 day treatment 
group differed from the control group. In this experiment, the animals treated with 
acute nicotine also showed a decrease in locomotor activity, but after analysis of 
covariance this was no longer significant [Mean ± sem: vehicle = 362.6 ± 23.6; acute 
nicotine, 264.2 ± 56.7; F(1,12)=1.6, p>0.2]. 
Experiment 3b 
Withdrawal from 7 and 14 day's treatment with nicotine (0.1 mg/kg/day) significantly 
decreased the time spent in social interaction [F(2,21)=5.2, p<0.05], and both groups 
showed significant decreases in the time spent in social interaction (p<0.05 and 
p<0.01, respectively; Figure 2.2) compared with controls. There was no change in 
locomotor activity in these groups (Table 2.3). 
Table 2.3 Mean (± sem) locomotor activity (beam breaks) made by rats injected with 
nicotine (0.1 mg/kg s. c. ) after 72 h withdrawal from 7 (7W) and 14 (14W) 
days treatment with nicotine (0.1 mg/kg s. c. ). Rats were tested in the high 
light, familiar (HF) test condition, 5 min after injection. 
Vehicle 7W 14W 
Locomotor Activity 367.6 ± 26.4 411.6 ± 24.3 364.0 ± 21.7 
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Figure 2.1 Mean (± sem) time spent in social interaction by rats injected with 
nicotine (0.1 mg/kg s. c. ) after vehicle, acute nicotine (AC), or 7 (7D) 
and 14 (14D) days nicotine. All doses of nicotine were 0.1 mg/kg s. c. 
and rats were tested 5 min after injection. ** p<0.01 compared with 
vehicle control, + p<0.05 compared with 7D group. 
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Figure 2.2 Mean (± sem) time spent in social interaction by rats injected with 
nicotine (0.1 mg/kg s. c. ) after 72 h withdrawal from 7 (7W) and 14 
(14W) days treatment with nicotine. Rats were tested in the high light 
familiar (HF) test condition, 5 min after injection. * p<0.05 and ** 
p<0.01 compared with vehicle control. 
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Experiment 4 
The left panel in Figure 2.3 shows the time-course of effects on social interaction 
following an acute injection of nicotine. For illustrative purposes the scores of all the 
groups are expressed as a% change from their respective control group, but the 
statistics were all conducted on the raw scores. There was no significant differences 
between the baseline scores of the control groups [F(5,26)=1.2, p>0.05; Table 2.4] 
suggesting that there are no consistent effects of re-testing. Animals tested 30 min 
after an acute injection of nicotine showed a significant increase in the time spent in 
social interaction [F(1,12)=5.6, p<0.05], indicating an anxiolytic effect. This was 
replaced at 1h by a significant decrease in social interaction [F(1,8)=5.3, p=0.05], 
indicating an anxiogenic effect. The scores gradually returned to control levels 
between 3 and 30 h. An increase in social interaction was again seen 30 min after 
injection on day 2 [F(1,8)=13.0, p<0.01; Figure 2.3, right panel]. After 7 days of 
nicotine treatment, the group tested 30 minutes after injection showed no change in 
social interaction compared with the controls (Figure 2.3, right panel). 
Table 2.4 Mean (± sem) time (s) spent in social interaction by rats treated with vehicle 
(in experimental groups A, B and C) and tested 30 min, 1,3, or 30h after a 
single injection, or 30 min after their 2nd or 7th injection. All animals were 
tested in the high light familiar (I-IF) test condition. 
2nd 7th 
1st Injection Injection Injection 
Time after Injection 30 min 1h 3h 30 h 30 min 30 min 
Group A B B C C A+C 
Social Interaction (s) 178.0 207.4 174.0 187.0 221.7 182.1 
± 8.5 ± 18.7 ± 15.7 ± 9.0 ± 15.0 ±15.5 
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The animals that were tested 30 min after their first dose of nicotine showed a 
significant decrease in locomotor activity [vehicle = 315.5 ± 18.7 and acute nicotine = 
254.9 ± 19.5; F(1,12)=4.8, p<0.05]. In contrast, the animals that were tested 30 min 
after their second nicotine injection showed an increase in locomotor activity. 
However, after analysis of covariance the increase in locomotor activity was no longer 
significant [F(1,7) = 4.0, p<0.1], suggesting that it was, at least in part, secondary to 
the increase in social interaction. None of the other groups showed any change in 
locomotor activity, compared with their respective control group. 
2.4 Discussion 
This study has shown that after an acute administration of a low dose of nicotine (0.1 
mg/kg; s. c. ) both anxiolytic and anxiogenic effects can be observed in the social 
interaction test, at different times after injection. Although the animals tested after 5 
min were investigated in a separate experiment from the other time points, the acute 
anxiogenic effect was seen in both the LU and HF test condition (Experiments 1 and 
3a). The effects that were seen 5 min, 30 min and 1h after a nicotine injection were 
observed in animals that had been tested only once. File et al. (1998) have shown that 
30 min after an i. p. injection of nicotine, high doses can have anxiogenic, and low 
doses anxiolytic, effects in this test. This suggests that the effect of an acute dose of 
nicotine is both dose- and time-dependent. Nicotine has also been shown to have 
complex effects on locomotor activity and intracranial self-stimulation, with both 
decreases and increases in these behaviours observed (Herberg et al., 1993; Clarke and 
Kumar, 1983a, b), dependent on both the dose and time after administration. 
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Interestingly, it appears that the time-course of change from an anxiogenic to an 
anxiolytic effect is similar to that seen in the change from decreases to increases in 
locomotor activity and intracranial self-stimulation. 
The decreased social interaction following acute nicotine treatment and during 
withdrawal from chronic treatment was not accompanied by decreases in locomotor 
activity. That nicotine withdrawal does not produce changes in locomotor activity is 
in agreement with previously published results (Helton et al, 1993; Clarke and Kumar, 
1983a). The increased social interaction following the first nicotine injection was 
accompanied by a decrease in locomotor activity, providing a very clear dissociation 
between the two measures. Only after the second nicotine injection were there 
increases in both measures, but analysis of covariance showed that the increase in 
locomotor activity was secondary to the increased social interaction. In the black- 
white crossing test of anxiety, no tolerance was found to the anxiolytic effect of 
nicotine (Costall et al, 1989b), but this could be because measures of anxiety in this 
behavioural test are heavily contaminated by changes in locomotor activity. Tolerance 
does not develop to the locomotor stimulant effect of nicotine, and this stimulatory 
effect becomes more marked with chronic treatment (Shoaib et al., 1997; Ksir et al., 
1987; Schwartz and Kellar, 1985). 
After 7 days of chronic nicotine treatment, tolerance was found to both the anxiogenic 
and anxiolytic effects that were observed in the social interaction test at 5 and 30 min 
after acute administration, respectively. It is thought that an oppositional process may 
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account for tolerance to the anxiolytic effect since after 7 and 14 days of treatment as 
there was an anxiogenic withdrawal effect at 72 h. Further evidence for the 
involvement of such a mechanism is that there appears to be a rebound anxiogenic 
effect 1h after injection suggesting that after an acute injection an oppositional 
process comes into play. An oppositional mechanism involves the recruitment of 
processes that oppose the anxiolytic effect of the acute administration of nicotine, 
leading to behavioural tolerance (Young and Goudie, 1995). Following drug 
withdrawal, these processes work unopposed, resulting in the appearance of 
behavioural changes, such as the decrease in social interaction. Such a mechanism 
also seems to underlie the development of tolerance to the anxiolytic effects of 
benzodiazepines (e. g. File et al., 1987a). In contrast to an oppositional mechanism 
which seems to underlie the development of tolerance to the anxiolytic effects of 
nicotine, the mechanism underlying tolerance to the anxiogenic effects is more likely 
to be a decremental one. A decremental process of tolerance is one in which the 
impact of a drug is reduced (e. g. by receptor desensitisation), but which is without 
behavioural consequence in the absence of the drug (Young and Goudie, 1995). 
If the anxiogenic effect observed 5 min after injection were subject to rapid 
desensitisation (Fenster et al., 1997), this would then reveal the anxiolytic effect, as 
long as this was not also subject to a similar desensitisation. It is certainly possible 
that different behavioural effects of nicotine will be subject to different rates of 
desensitisation since there is evidence that different nicotinic subunit assemblies show 
different rates of desensitisation and recovery (Fenster et al., 1997). If a decremental 
82 
Time course of nicotine's effects on anxiety 
process underlies the development of tolerance to the anxiogenic effect of nicotine, 
this could result from a deactivation of receptors. Chronic exposure to nicotine 
irreversibly inactivates some nicotinic subunits, whereas others are much less affected 
(Olale et al., 1997). Thus, a deactivation of subunits in a particular brain region, such 
as the dorsal hippocampus or lateral septum, could lead to tolerance to the anxiogenic 
effect. If other subunits in a different brain region were mediating the anxiolytic 
effect, these might be subject to less deactivation after chronic treatment, with an 
oppositional mechanism mediating the tolerance to this action and the anxiogenic 
withdrawal response. 
In summary, the results of the present experiments have revealed a complex pattern of 
changes in social interaction induced by nicotine, with both anxiolytic and anxiogenic 
effects emerging at different time-points. After 7 days of nicotine treatment, tolerance 
was found to both the initial anxiogenic effect and anxiolytic effect. Further 
experiments will be needed to determine which brain regions are involved in 
mediating tolerance to these effects. 
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CHAPTER 3 
Tolerance to nicotine's effects in the elevated plus-maze 
and increased anxiety during withdrawal 
3.1 Introduction 
The effects of nicotine on anxiety are unusual in that it can have both anxiolytic and 
anxiogenic effects in animal tests (Ouagazzal et al., 1999a; File et al., 1998; Brioni et 
al., 1993; Cao et al., 1993; Costall et al., 1989b; Vale and Green, 1986), in non- 
smoking volunteers (File et al., 2000a; Newhouse et al., 1990) and in smokers (Netter 
et al., 1998; Ikard et al., 1969). In the social interaction test, the direction of nicotine's 
effects have been shown to be dependent on dose, with low doses being anxiolytic and 
high doses anxiogenic. The anxiogenic effect of nicotine has been shown to be 
mediated by the dorsal hippocampus and lateral septum (Cheeta et al., 2000a; Kenny et 
al., 2000b; Ouagazzal et al., 1999b). In the rat elevated plus-maze test of anxiety, both 
anxiolytic (Brioni et al., 1994) and anxiogenic (Ouagazzal et al., 1999a) effects have 
been reported, but in this test the direction of nicotine's effects was not dose-related. 
Chapter 2 showed that the direction of nicotine's effects on anxiety, as measured in the 
social interaction test depends on the time since injection. Nicotine (0.1 mg/kg; s. c. ) 
had an anxiogenic effect 5 min after injection, but an anxiolytic action after 30 min 
(Chapter 2). 
The effects of nicotine (0.1 mg/kg) on anxiety have not yet been examined in the plus- 
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maze 5 min after injection. The purpose of the present experiment was therefore to 
examine the effects of nicotine (0.1 mg/kg; s. c. ) 5 and 30 min after injection of a single 
dose and after a period of chronic treatment. In the social interaction test, after a week 
of pretreatment, tolerance developed to both the anxiogenic effect observed 5 min after 
injection and to the anxiolytic effect found at 30 min (Chapter 2), but to date tolerance 
to the effect of nicotine has not been examined in the plus-maze. In order to determine 
whether tolerance was due to an oppositional mechanism (Young and Goudie, 1995), 
animals were also tested undrugged 24h after the last of the chronic injections. 
Increased anxiety has been reported on withdrawal from nicotine in animal tests 
(Chapter 2; Costall et al, 1989b), in smokers (Parrott and Garnham, 1998; Parrot et al., 
1996; West and Russell, 1985; Shiffman and Jarvik, 1976) and in those withdrawing 
from nicotine gum (Hughes et al., 1990; Keenan et al., 1989). The dorsal hippocampus 
does not seem to play a role in the acute effects of nicotine in the plus-maze 
(Ouagazzal et al., 1999b), but it does seem to play a very general role in mediating 
stress-induced changes in a variety of other test situations (File et al., 2000b). Thus, 
this chapter also examined whether a low dose of nicotine would be effective when 
administered to the dorsal hippocampus of rats in 24h withdrawal from nicotine. 
3.2 Materials and Methods 
Animals 
Male hooded Lister rats (Charles River, Margate, Kent, UK) weighing between 220- 
250g were housed singly. The animals in the withdrawal study that had undergone 
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surgery were allowed to recover for 4 days prior to the start of chronic injections. Food 
and water were freely available, and the room in which they were housed was lit with 
dim light and maintained at 22°C. Lights were on from 0700-1900 h. 
Elevated Plus-Maze Test 
The elevated plus maze (Figure 1.2) was made of wood and consisted of two opposite 
open arms 50x10cm, and two opposite equal sized arms enclosed by 40cm high walls. 
The arms were connected by a central 10x10cm square, and thus the maze formed a 
"plus" shape. The maze was elevated 50cm from the floor and lit by dim light. A 
closed-circuit TV camera was mounted vertically over the maze, and the behaviour was 
scored from a monitor in an adjacent room by an observer who was blind to the drug 
treatment. The number of entries onto, and the times spent on, open and closed arms 
were recorded by an observer blind to the drug treatment. Four paws into, and two 
paws out of, an arm defining an arm entry and exit, respectively. The percentage 
number of open arm entries [open entries/(open+closed entries)xlOO] was calculated, 
as was the percentage of time spent on the open arms. The percentage of entries onto, 
and the percentage of time spent on the open arms of the maze provide the measure of 
anxiety, and the number of closed arm entries provides the best measure of locomotor 
activity in this test (File, 1992; Pellow et al., 1985). At the end of each trial, any faecal 
boluses were removed from the maze, which was wiped clean with a damp cloth. 
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Surgery 
Rats were anaesthetised by inhalation of 3% isofluorane (May and Baker, Dagenham, 
Essex, UK) in oxygen and positioned in the stereotaxic frame (Kopf Instruments, 
Tujunga, California, USA). The skull was exposed and the incisor bar adjusted such 
that bregma and lambda were at the same height. Three indentations were made in the 
skull to accommodate screws, which, together with the application of dental cement, 
held the cannulae in place. For bilateral cannulation of the dorsal hippocampus, 7 mm 
long steel guide cannulae (23 gauge, Cooper's Needle Works Ltd, Birmingham, UK) 
were positioned at 3.3 mm posterior to bregma, ± 2.4 mm lateral, and -1.2 mm 
vertical, thus siting them 2 mm above the target area (according to the atlas of Paxinos 
& Watson, 1986). Cannulae were kept patent using 7 mm long stainless steel stylets 
(30 gauge, Cooper's Needle Works Ltd, Birmingham, UK). On the test day, rats were 
gently wrapped in a cloth and injected using needles constructed from 30 gauge steel 
tubing that extended 2mm below the tip of the in-dwelling cannulae, into the dorsal 
hippocampus. In order to accustom the animals to handling and to keep the stylets 
patent, each day following surgery the rats were gently wrapped in a cloth and the 
stylets were replaced. 
Drugs and chemicals 
For the chronic subcutaneous injections, (-)-nicotine hydrogen tartrate (Sigma, Poole, 
UK) was dissolved in distilled water, in a volume of 1 ml/kg body weight and a dose of 
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0.1 mg/kg was used; control animals received equal volume injections of distilled 
water. 
For the central injections, (-)-nicotine hydrogen tartrate was dissolved in artificial 
cerebrospinal fluid (aCSF) of the following composition (in mM): 126.6 NaCl, 27.4 
NaHCO3,2.4 KCI, 0.5 KH2PO4,0.89 CaC12,0.8 MgClz, 0.48 Na2HPO4 and 7.1 
glucose, pH 7.4. Injections were O. 51i1, and were made over a period of 30 sec using a 
CMA/102 microdialysis pump (Biotech Instruments Ltd, Stockholm, Sweden) and the 
needles were left in position a further 30 sec to allow drug diffusion; control animals 
received O. 5µ1 infusions of aCSF. All doses are given as free base. 
Behavioural Testing 
Development of tolerance 
Forty-eight animals were randomly allocated to the following drug groups: vehicle, 
acute nicotine (0.1 mg/kg) and 7 days of nicotine (0.1 mg/kg/day) and in each group 
half were tested 5 min and half 30 min after- injection. Because an anxiolytic effect 
emerged in the animals that had been treated for 7 days with nicotine and were tested 
after 5 min, a second group of animals was randomly allocated to the following groups: 
vehicle (n=9) and 14 days of nicotine (n=8; 0.1 mg/kg/day) and tested 5 min after the 
last injection to see if tolerance occurred to the anxiolytic effect after the longer 
pretreatment period. 
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Reversal of nicotine withdrawal response in the elevated plus-maze 
Animals were randomly allocated to pretreatment with either vehicle or nicotine (0.1 
mg/kg/day, s. c. ) for 6 days. On the 7th day, no s. c. injections were given but rats from 
both pretreatment groups were randomly assigned to be tested 3 min after a bilateral 
injection into the hippocampus with aCSF or (-)-nicotine (5ng). The numbers in each 
group ranged from 7-9 after verification of the cannula placements. 
Histology 
At the end of behavioural testing the cannulated animals were sacrificed, the brains 
removed and the injection sites verified histologically (Paxinos and Watson, 1986) by a 
person blind to drug treatment. Figure 3.1, depicting coronal slices through the dorsal 
hippocampus, shows the site of the injections for the rats whose data were included in 
the statistical analysis. 
Statistics 
The data were analysed with one-way ANOVA and comparisons with individual 
groups were then made with Fisher's post-hoc tests; it is the significances of these that 
are shown in the figure and table. Because of the large number of zero scores in the 
withdrawal group, this group was compared with other groups using Mann-Whitney U- 
tests (although for ease of comparison all the scores in Figure 3.3 are presented as 
means ± sem). 
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Figure 3.1 Diagrammatic representation of coronal sections (3.14 to 3.6 mm 
posterior to bregma) through the rat brain showing the placements 
accepted as falling within the dorsal hippocampus (filled circles). 
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3.3 Results 
Development of tolerance 
In animals that were tested 5 min after s. c. injection there was a significant effect of 
nicotine (0.1 mg/kg) on the percentage of time spent on the open arm [F(2,20)=8.9, 
p<0.01] and the percentage of open arm entries [F(2,20)=3.5, p=0.05]. This arose 
because, although acute administration was without effect, the rats tested after their 7th 
injection with nicotine showed a significant increase in both measures (p<0.01 and 
p<0.05, respectively), compared with both the vehicle control group and the acute 
nicotine group, see Figure 3.2. There were no significant effects of nicotine on the 
number of closed arm entries [F(2,20)=1.0], see Figure 3.2. Thus, a specific anxiolytic 
effect had emerged after 7 days of chronic treatment when rats were tested 5 min after 
nicotine (0.1 mg/kg s. c. ) injection. However, after 14 days of pretreatment, tolerance 
developed to this anxiolytic effect and nicotine was without effect on the percentage of 
time spent on the open arms [F(1,15)=0.3] or the percentage of open arm entries 
[F(1,15)<O. 11, see Figure 3.2. However, it can be seen from Figure 3.2 that the animals 
that had received 14 days of nicotine injections showed a significant increase in the 
number of closed arm entries [F(1,15)=9.9, p<0.01] compared with vehicle controls. 
In animals that were tested 30 min after injection there was a significant effect of 
nicotine on the percentage of time spent on the open arms [F(2,22)=3.6, p<0.05] and 
the percentage of open arm entries [F(2,22)=5.2, p<0.05], but in this case the 
significance arose because of the significant reductions in these measures caused by the 
acute administration of nicotine (p<0.05 and p<0.05, respectively), compared with both 
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the control group of animals and the chronic nicotine group, see Figure 3.2. Thus, after 
7 injections, tolerance had developed to the anxiogenic effect of nicotine. The acute 
administration of nicotine did not change the number of closed arm entries, but there 
was a significant effect on the number of closed arm entries [F(2,22)=3.7, p<0.05], due 
to the rats tested after their 7th injection having a decrease compared with vehicle 
controls (p<0.05, Figure 3.2). 
Reversal of nicotine withdrawal response 
When rats were withdrawn for 24h after 6 days of nicotine pretreatment, there was a 
significant anxiogenic effect, shown by a decrease in the percentage of time spent on 
the open arms (U=3, p<0.01) and the percentage of open arm entries (U=10, p<0.05). 
There was no change in the number of closed arm entries [F(1,15)=3.2]. Bilateral 
administration of nicotine (5ng) into the dorsal hippocampus significantly reversed the 
withdrawal response on both measures (U=9, p<0.05 for % time and U=11, p<0.01 for 
entries), see Figure 3.3. In the vehicle-pretreated animals this dose of nicotine 
administered to the dorsal hippocampus was without effect on the percentage of time 
spent on the open arms [F(1,15)=0.3], the percentage of open arm entries [F(1,15)=0.3] 
or the number of closed arm entries [F(1,15)=0.7], see Figure 3.3. 
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Figure 3.2 Mean (± sem) percentage time spent on open arms, percentage open arm 
entries and number of closed arm entries in the plus-maze 5 and 30 min 
after s. c. injection of vehicle (V), acute nicotine (0.1 mg/kg; AC), or 7 
days of nicotine (0.1 mg/kg; 7D) and 5 min after s. c. injection of 
vehicle or 14 days of nicotine (0.1 mg/kg; 14D). * p<O. 05 and ** p<0.01 
compared with the vehicle control and acute nicotine group, + p<0.05 
compared with the vehicle control and chronic nicotine group, j'p<0.05 
compared with the vehicle control . 
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Figure 3.3 Mean (±sem) percentage of time spent on open arms, percentage of open 
arm entries and number of closed arm entries in the plus-maze in 
animals pretreated for 6 days with vehicle or nicotine (0.1 mg/kg/day; 
s. c. ) and tested 24h later, 3 min after bilateral dorsal hippocampal 
injections of vehicle (aCSF) or nicotine (5ng). *p<0.05 and ** p<0.01 
compared with the vehicle control (VEH, aCSF), tp<0.05 and ttp<0.01 
compared with the withdrawal group (NIC, aCSF). 
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3.4 Discussion 
Tolerance developed rapidly to the anxiogenic effect of nicotine (0.1 mg/kg) in the 
elevated plus-maze and thus after one week this dose no longer had an anxiogenic 
effect 30 min after injection. This is similar to the rapid development of tolerance to 
the anxiogenic effect of this dose observed in the social interaction test 5 min after 
injection (Chapter 2). However, the effects in the plus-maze differed from those in the 
social interaction test in that acutely this dose was ineffective 5 min after injection and 
an anxiolytic effect emerged when the rats were tested 5 min after their seventh 
injection. This is in concordance with previous reports showing nicotine to have 
anxiolytic effects in the plus-maze after 14-15 days of nicotine treatment (Ericson et 
al., 2000; Pandey et al., 2000; Bhattacharya et al., 1995). Tolerance to the anxiolytic 
effects in the social interaction test, observed 30 min after an acute dose of 0.1 mg/kg, 
also developed after 7 injections (Chapter 2). Thus, tolerance develops much more 
rapidly to the anxiolytic effects of a low dose of nicotine than it does to the anxiolytic 
effect of benzodiazepines, which normally takes 21 days to develop (Fernandes and 
File, 1999; Chopin et al., 1993; File et al., 1987a; Treit, 1985; Vellucci and File, 1979). 
There was a dissociation in the time-course of changes in locomotor activity, as 
measured by closed arm entries, and the measures of anxiety. Thus, in the rats tested 5 
min after injection, there were no changes in locomotor activity when the anxiolytic 
effect emerged at 7 days, but after 14 days when there were no changes in the measures 
of anxiety there was evidence of locomotor stimulation. This increase in locomotor 
activity after chronic nicotine treatment is in accordance with other studies (Ericson et 
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al., 2000; Clarke and Kumar, 1983a, b). In the rats tested 30 min after injection, there 
were no changes in locomotion after acute treatment, when nicotine had an anxiogenic 
effect, but a reduction in locomotor activity occurred after 7 days, when there was no 
change in the measures of anxiety. 
When rats were tested 24h after the last of 6 daily injections a significant anxiogenic 
effect was noted, as has been previously reported (Bhattacharya et al., 1995). This 
anxiogenic effect was not accompanied by any change in locomotor activity which is 
consistent with other studies that have measured locomotor activity 24h after 
withdrawal of nicotine (Robinson et al., 1994; Helton et al., 1993). The studies in 
which a decrease in locomotor activity was found at 24h after withdrawal of nicotine 
used higher doses and longer periods of treatment (Hildebrand et al., 1999; Fung et al., 
1996). As was reported by Bhattacharya et al. (1995), we observed no somatic signs of 
withdrawal in our animals, but the fact that the anxiogenic effect could be reversed by 
an injection of nicotine strengthens the interpretation that it is a withdrawal response. 
An anxiogenic effect has not found as of yet at this time-point in the social interaction 
test, but does occur at 72h (Chapter 2). In the mouse black-white crossing test an 
anxiogenic response was observed 8-96h after withdrawal from 14 days of twice daily 
nicotine (0.1 mg/kg/day; Costall et al., 1989b). Thus, the duration and timing of these 
withdrawal responses may depend both on the particular test and on the duration of 
treatment. However, it is clear that a withdrawal response can be observed following a 
relatively short period of treatment with a low dose of nicotine. Again, this contrasts 
with the effects of the benzodiazepines, where increased anxiety is usually only 
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observed after withdrawal from 3 weeks of treatment (Ward and Stephens, 1998; 
Andrews et al., 1997; Chopin et al., 1993; File et al., 1991a; File and Andrews, 1991; 
File et al., 1987a). 
The incidence of a withdrawal response in the opposite direction to the acute effects of 
a drug is an indication of an oppositional mechanism of tolerance. Thus, 
benzodiazepines initially have an anxiolytic effect, tolerance develops to this and an 
anxiogenic response is seen on drug withdrawal. A similar pattern can be seen 
following repeated injections with the anxiogenic drug, pentylenetetrazole, where an 
anxiolytic effect is seen on withdrawal (File et al., 1996b). This is not the pattern seen 
in the elevated plus-maze or the black-white crossing test (Costall et al., 1989b) where 
both the acute response to nicotine and that seen during withdrawal are in the same 
direction, i. e. increased anxiety. Furthermore, a withdrawal response was observed 
after 6 days of treatment, at the same time that an anxiolytic effect could be seen in 
response to a nicotine injection. In the social interaction test, tolerance was observed 
after 6 days to the anxiogenic effect, but in this test no withdrawal response was found 
at the 24h time-point. It therefore seems unlikely that an oppositional mechanism 
underlies the development of tolerance to the anxiogenic effects of nicotine in any of 
the animal tests thus far investigated. 
Whilst a decremental mechanism of tolerance can account for the development of 
tolerance, without the occurrence of a withdrawal response, it alone cannot explain the 
incidence of a withdrawal response in the same direction as the acute effect. One 
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possibility is that the withdrawal response is mediated by changes in a neural system 
different from that which is manifesting the changes of tolerance. This possibility is 
strengthened by our finding that although dorsal hippocampal administration of 
nicotine was without effect in the control animals, it was able to reverse the effects of 
nicotine withdrawal. In the present experiment only a single dose of nicotine was 
investigated, but other studies have shown a wide range of doses to be ineffective in 
the plus-maze (Cheeta et al., 2000a; Ouagazzal et al., 1999a). One area that mediates 
the anxiogenic effects of acute nicotine is the lateral septum (Cheeta et al., 2000a, b) 
and there seems to be a reciprocal inhibition between the dorsal hippocampus and the 
lateral septum in mediating behaviour in the plus-maze. The 5-HT1A receptors have 
been implicated in this anxiogenic effect, because the co-administration into the lateral 
septum with the 5-HT1A antagonist WAY 100,635, reversed the anxiogenic effect of 
nicotine (Cheeta et al., 2000b). Thus, when the baseline scores are low (e. g. 10% open 
arm entries) a 5-HT1A receptor agonist administered to the dorsal hippocampus has an 
anxiolytic effect (Menard and Treit, 1998), whereas with higher baseline scores (30%) 
neither benzodiazepines nor a 5-HT1A receptor agonist has any action (Gonzalez et al., 
1998; File et al., 1996b). In contrast, when baseline scores are high an anxiogenic 
effect can be seen after administration of a 5-HT1A receptor agonist to the lateral 
septum (Cheeta et al., 2000a), whereas it is without effect if baseline scores are low 
(Menard and Treit, 1998). The dorsal hippocampus has been implicated in the 
anxiogenic effect that can be detected in the plus-maze after restraint stress (Netto and 
Guimaraes, 1996; McBlane and Handley, 1994; Titze-de-Almeida et al., 1994) and in 
the stress-induced decrease in locomotor activity (Carli et al., 1993). It is therefore 
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possible that the anxiogenic response observed during nicotine withdrawal is an 
example of a wide range of stress-induced responses in which the dorsal hippocampus 
plays a role. Thus, the nicotine-cholinergic system in this brain region may be 
implicated in several stressful situations and withdrawal from nicotine may have been 
stressful because it constituted a major change in state. It would be interesting to see 
whether dorsal hippocampal administration . of nicotine could reverse the anxiogenic 
effect seen after restraint stress in the elevated plus-maze. 
The results of this study show that chronic administration of a low dose of nicotine 
results in the rapid development of tolerance to its acute anxiogenic effects and an 
anxiogenic response on drug withdrawal that could be reversed with an intra- 
hippocampal injection of nicotine. 
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CHAPTER 4 
Social Isolation Modifies Nicotine's Effects In 
Animal Tests Of Anxiety 
4.1 Introduction 
Calming and anxiety-reducing effects are frequently cited by smokers as reasons for 
their smoking, and this is particularly prevalent amongst teenage girls (Royal College 
of Physicians, 2000). However, some have queried whether nicotine really does have 
anxiolytic effects, other than reversing the increased anxiety that results from nicotine 
withdrawal (Heishman et al, 1994; West, 1993). Indeed, there is evidence that under 
some circumstances nicotine can actually increase stress and anxiety (Netter et al, 
1998; Parrott et al, 1996; Newhouse et al, 1990). The data from the previous two 
chapters show that even following acute administration, nicotine has complex effects 
on anxiety. 
Anxiolytic effects of nicotine have been reported in several experimental models of 
anxiety in both mice (Brioni et al, 1993; Cao et al, 1993; Costall et al, 1989b), and rats 
(Brioni et al, 1994; Vale & Green, 1986). In the social interaction test of anxiety, the 
effects of nicotine in rats have been found to be dose- and time-dependent (Chapter 2; 
File et al, 1998). Both anxiolytic and anxiogenic effects have also been found in rats 
tested in the elevated plus-maze. However, it is less clear in this test that the effects are 
dependent on dose. Ouagazzal et al (1999a) found low doses (0.001-0.1mg/kg i. p) 
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were ineffective, but high doses had an anxiogenic effect (0.5-1mg/kg i. p. ). In 
contrast, Brioni et al (1994) reported an anxiolytic action with 0.3 mg/kg nicotine. It is 
possible that this discrepancy can be explained by intrinsic differences between the rat 
strains that were used in these two studies. It is also possible that differences in the 
housing conditions can explain some of the discrepancies in the literature, especially 
between the findings in rats and mice. Anxiolytic effects have been universally 
reported in mice, where group housing has always been used (Brioni et al, 1993; Cao et 
al, 1993; Costall et al, 1989b), whereas anxiogenic effects have tended to dominate in 
rat studies which have used single housing (Chapter 3; Ouagazzal et al., 1999a). 
Social isolation has been shown to modify anxiety-related behaviours. In the elevated 
plus-maze, an anxiogenic profile and a greater sensitivity to the anxiolytic effects of 
diazepam was seen in rats that were reared in isolation from weaning (Fone et al, 1996; 
Lopes da Silva et al, 1996; Wright et al, 1991; Morinan & Parker, 1985). Isolation- 
reared rats have also been found to be more sensitive to the effects of amphetamine, 
cocaine and ethanol (Hall et al, 1998; Smith et al, 1997; Fowler et al, 1993; Jones et al., 
1990). The effects of a short period of isolation housing in adult rats have not been 
extensively investigated. Singly housed rats showed greater locomotor stimulation in 
response to amphetamine (Ahmed et al., 1995) and enhanced chloride uptake in 
response to GABA and flunitrazepam (Thielen et al, 1993). In contrast, pair-housed 
adult rats were more sensitive than singly housed rats to the anxiolytic effects of 
diazepam in the social interaction test of anxiety (Gardner & Guy, 1984). The purpose 
of the present experiments was therefore to determine whether the housing conditions 
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of adult rats would modify the effects of nicotine in two animal tests of anxiety, the 
social interaction test and the elevated plus-maze. In addition, because this has not 
previously been studied, the time-course of nicotine's effects on the plus-maze was 
also examined in the isolated and socially grouped animals. 
4.2 Materials and Methods 
Animals 
A total of 447 male Lister hooded rats (Charles River, Margate, Kent, UK) weighing 
between 250-300g were used. Rats were housed either in isolation or in social groups 
of five for 7 days prior to the start of behavioural testing. Isolation housed rats were 
housed singly in a cage, 45cm x 28cm x 20cm high. The group housed cages were 
56cm x 38cm x 20 cm high. All the cages were in racks that allowed the rats to see, 
hear and smell other rats. Food and water were freely available to all the animals. The 
room in which animals were housed was lit with dim light and maintained at 22°C. 
Lights were on from 0700-1900 h. 
Apparatus 
The social interaction and elevated plus-maze tests were used in these experiments. 
See Chapters 2 and 3 for descriptions of these tests. 
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Drug 
(-)-Nicotine hydrogen tartrate (Sigma, Poole, UK) was dissolved in distilled water, and 
doses of nicotine were calculated as the base. All drug injections were given sub- 
cutaneously (s. c. ), in a volume of 1 ml/kg body weight. Control animals received equal 
volume injections of distilled water. 
Procedure 
Social Interaction 
Each rat was placed individually in the test arena for a5 min familiarisation trial on the 
day prior to the social interaction test. Rats were allocated to test partners on the basis 
of weight, so they did not differ by more than 10g. For the group-housed rats, the test 
partner was always taken from a different cage. After testing, the rats were returned to 
their home cages, so that group-housed animals always remained in a group of at least 
four. In the main study, 48 pairs of singly housed rats and 42 pairs of group-housed 
rats were randomly allocated among the 6 drug groups (vehicle or (-)-nicotine 0.025, 
0.05,0.1,0.25 or 0.45mg/kg; s. c. ). On the basis of the results, a further 21 pairs of 
animals were housed in social groups for 7 days and then tested with vehicle or (-)- 
nicotine (0.01 or 1mg/kg; s. c. ). In all experiments, both members of a test pair 
received the same dose of nicotine on the test day. On the test days, 30 min after 
injection, pairs of rats were placed in the centre of the arena and their behaviour scored 
for 4.5 min from a monitor in the adjacent room, by an observer with no knowledge of 
the drug treatment. The scores that were analysed were the total times spent interacting 
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by each pair of rats (i. e. a single score for each pair of rats). At the end of the trial any 
faeces were removed and the arena wiped with a damp cloth. Rats were tested between 
0900-1300h. 
Elevated Plus-maze 
For the plus-maze experiments, 119 singly housed rats and 106 group-housed rats were 
randomly allocated among the 5 drug groups (vehicle or nicotine 0.05,0.1,0.25 or 
0.45mg/kg s. c. ). On test days, the rats receiving each drug treatment were further sub- 
divided into three groups, and were tested either 5,30 or 60 minutes after their 
injection. Each rat was placed individually in the central square of the plus maze 
facing the closed arm, and its behaviour was scored for 5 min by an observer blind to 
the drug treatment. The number of entries onto the open and closed arms, and the time 
spent on the open arms, closed arms and in the central square was scored. Testing took 
place between 0900 and 1300 h in an order randomised for drug treatment. The arena 
was wiped with a damp tissue after each trial. After testing each rat was returned to its 
home cage. 
Statistics 
Data for the dose-response to nicotine in the social interaction test were analysed by a 
two-factor parametric analysis of variance (Factor 1, housing; Factor 2, drug 
treatment). A significant housing x drug interaction would show that the housing 
condition significantly influenced the drug effect. The data for the additional doses 
investigated only in the group-housed rats were analysed in a one-way analysis of 
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variance. The plus-maze data were analysed by a three-factor analysis of variance 
(Factor 1, housing; Factor 2, drug treatment; Factor 3, pre-treatment time). After the 
analyses of variance, comparisons between individual groups were made with Fisher's 
post-hoc tests and it is the significances of these that are shown in the figures and 
tables. A subsidiary analysis was conducted in order to determine whether the order of 
removal from the group influenced the scores in the two tests. The scores of the first 
and last rats to be removed from each cage were compared in all the groups in which 
nicotine had no effect. Thus, in the social interaction test the comparison included all 
groups, except for 0.025 mg/kg nicotine, and in the plus-maze the comparison included 
all the groups tested at the 60 min time-point. 
4.3 Results 
Social Interaction 
Overall, the group-housed rats spent significantly less time in social interaction than 
did those that were singly housed [F(1,78)=188.6, p<0.00001]. There were dose- 
dependent effects of nicotine, but these varied significantly in the two housing 
conditions [housing x drug interaction, F(5,78)=18.7, p<0.00001]. In the singly- 
housed rats, nicotine (0.05,0.1,0.25 mg/kg) significantly increased social interaction, 
whereas 0.45 mg/kg significantly decreased it, see Figure 4.1. In comparison, in the 
group-housed rats, only 0.025 mg/kg nicotine significantly increased social interaction, 
see Figure 4.1. In the group-housed rats, the lowest dose of nicotine (0.01 mg/kg) non- 
significantly increased, and the highest dose (1 mg/kg) significantly decreased, social 
interaction (see Table 4.1). 
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Table 4.1 Mean (± sem) time (s) spent in social interaction (s) and locomotor activity 
(beam breaks) of rats housed in social groups of 5 for 7 days and then tested 30 
min after injections of vehicle or (-) nicotine (0.01 or 1mg/kg s. c. ). * p< 0.05, 
* *p<0.001 compared with vehicle control group. 
Drug Treatment Social Interaction (s) Locomotor Activity 
(mg/kg) 
Vehicle 31.9 ± 5.8 243 ± 23.9 
0.01 45.3 ± 5.7 206 ± 16.7 
1 13.2 ± 1.5* 99 ± 17.5** 
Overall, the group-housed rats had lower locomotor activity than the singly housed rats 
[F(1,78) = 7.5, p<0.01). Nicotine produced a dose-related decrease in locomotor 
activity [F(5,78) = 2.8, p< 0.05), that reached significance in both housing conditions at 
the 0.45 mg/kg dose and in the singly housed rats also at the 0.25 mg/kg dose (Table 
4.2). There was no significant housing x nicotine interaction on locomotor activity 
[F<1.0]. 
108 











Figure 4.1 Mean (± sem) time (s) spent in social interaction by rats housed singly 
(clear bars) or in social groups of 5 (black bars) for 7 days and then 
tested 30 min after injection with vehicle or (-) nicotine (0.025- 
0.45mg/kg s. c. ). **p<0.01 compared with appropriate vehicle control 
group. ++p<0.01 comparing vehicle-injected singly and group housed 
animals. 
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Table 4.2 Mean (± sem) locomotor activity (beam breaks) of rats housed singly or in 
social groups of 5 for 7 days and then tested 30 min after injection with vehicle 
or (-) nicotine (0.025-0.45mg/kg s. c. ). *p<0.05 compared with vehicle control 
group 
Drug Treatment Locomotor Activity 
(mg/kg) 
Single Housing Group Housing 
Vehicle 302 ± 19.6 266 ± 24.3 
0.025 255±14.6 241 t6.7 
0.05 251±21.1 203±11.4 
0.1 258±21.1 219±12.5 
0.25 226 ± 18.7* 193 f 40.0* 
0.45 223±31.2* 204±21.9 
Elevated Plus-maze 
In the elevated plus-maze there was no overall effect of the housing conditions on any 
of the measures [F<1.4 in all cases]. However, the effects of nicotine on the measures 
of anxiety depended on both the housing conditions and the pre-treatment time [drug x 
housing x pre-treatment time, F(8,195) = 2.4, p<0.05 for % time on open arms and 
F(8,195) = 2.6, p<0.01 for % open arm entries). It can be seen from Figure 4.2 and 
Table 4.3 that in both singly and group-housed rats the doses 0.1- 0.45 mg/kg nicotine 
significantly decreased the percentage of time spent on the open arms and the 
percentage of open arm entries. However, these anxiogenic effects of nicotine were 
time-related and in the group housed animals were more evident at the 5 and 30 min 
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times of testing, whereas in the singly housed animals they were significant at 30 and 
60 min. Neither nicotine nor the housing conditions significantly affected the number 
of closed arm entries (see Table 4.3) and therefore nicotine had a specific anxiogenic 
effect in this test. 
Effect of order of removal from the group 
It can be seen from Table 4.4 that there was no difference in the time spent in social 
interaction or in the locomotor scores between the rats removed first from each cage 
and those removed last. However, in the elevated plus-maze the rats removed first 
showed an anxiogenic effect, indicated by decreased % of open arm entries 
[F(1,13)=9.8, p<0.01] and % time in the open arms [F(1,13)= 5.5, p<0.05] , see Table 
4.4. There was no effect on the number of closed arm entries. 
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Figure 4.2 Mean (± sem) % time spent on the open arms of the elevated plus maze 
by rats housed singly or in social groups of 5 for 7 days and then tested 
5,30 or 60 min after injection with vehicle or (-) nicotine (0.05- 
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Table 4.3 Mean (± sem) % entries onto open arms and number of closed arm entries on 
the elevated plus maze in rats housed singly or in social groups of 5 for 7 days 
and then tested 5,30 or 60 min after injection with vehicle or (-) nicotine 
(0.05-0.45mg/kg, s. c. ). *p<0.05 and **p<0.001 compared with appropriate 
vehicle control group. 
% Open arm entries Closed arm entries 
Single Housing Group Housing Single Housing Group Housing 
5 min 
Vehicle 29.1 ± 1.8 33.9 ± 4.8 13.0 ± 2.8 11.2 ± 0.8 
0.05 22.2±2.8 34.2±2.4 12.3 ± 1.2 11.7±0.9 
0.1 33.6 ±5.8 23.6 ± 5.2 13.0 ± 0.9 12.5 ± 1.7 
0.25 23.6±6.4 11.7±7.0** 10.1±1.7 8.8±2.6 
0.45 30.6±8.9 13.9±5.4* 5.3±1.1** 12.0±5.7 
30 min 
Vehicle 32.0±2.3 36.7±3.1 12.0±0.5 10.0±0.9 
0.05 33.1 ± 3.5 21.5f6.1* 9.5±1.1 10.8 ± 0.7 
0.1 17.6±2.2** 25.7±2.7 11.4±0.5 10.8±0.8 
0.25 22.0±2.9* 16.5±4.8** 9.6±0.8 10.7±1.0 
0.45 9.9±2.7** 10.2±4.1** 9.5±0.5 11.0±0.4 
60 min 
Vehicle 33.5 ± 5.3 26.2 ± 5.2 10.0 ± 1.0 12.8 ± 0.8 
0.05 28.5±2.0 26.4±4.4 ' 10.6±0.5 12.7±0.4 
0.1 19.8±3.2* 25.2±4.4 12.5±0.7 13.7±0.4 
0.25 22.9±3.5 20.8±5.0 13.8±1.2** 12.8±1.1 
0.45 12.9±4.2** 25.2±3.8 10.8 ±0.6 12.1 ±0.6 
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Table 4.4 Mean (± sem) time spent in social interaction (s), locomotor activity (beam 
breaks) % open arm entries, % time in the open arms and closed arm entries 
by rats removed first or 5th from the group cages. ** p<O. 01, *p <0.05. 
Order of removal 1st 5th 
Social Interaction (s) 50.0 ± 5.9 40.9 ± 6.5 
Locomotor Activity 209.3 f 21.6 223.3 f 22.6 
% open arm entries 17.0 ± 3.1 ** 29.3 ± 2.2 
% time on open arms 15.5f3.1* 29.7±5.4 
Closed arm entries 13.6 f 0.5 12.0 ± 0.8 
4.4 Discussion 
The increased social interaction in the singly housed rats confirmed earlier findings on 
the effects of social isolation in adulthood (Varlinskaya et al, 1999; Niesink & Van 
Ree, 1982; File & Pope, 1974a) and since weaning (Wongwitdecha & Marsden, 1996). 
This increased interaction is the main reason for routinely using singly housed rats in 
this test. However, this test has been used in group-housed rats (Costall et al, 1993; 
Dunn et al, 1991; Jones et al, 1988) and it is possible to detect anxiolytic effects of 
benzodiazepines in both housing conditions (Dunn et al, 1991; Gardner & Guy, 1984; 
File, 1980; File & Hyde, 1978). The present study showed that an anxiolytic effect of 
nicotine can be detected in both group and singly-housed rats, but it was manifested at 
a much wider dose-range in the singly-housed rats. This is perhaps surprising, since in 
general it is easier to detect increases in behaviour when baseline scores are low (e. g. 
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Crawley & Davis, 1982). Rate-dependent effects of nicotine have been detected in a 
wide range of behaviour, including its reinforcing effects (Perkins, 1999). Thus, it 
would seem to be the stress, or some other effect, of social isolation, rather than the 
baseline scores per se, that was enhancing the anxiolytic effects of nicotine in this test. 
Interestingly, the anxiogenic effects of nicotine were also enhanced in the isolated rats, 
which perhaps argues against an interpretation simply in terms of social isolation 
acting as a stressor. 
The results also showed that short-term social isolation in adult rats enhanced 
locomotor activity, as has been shown previously for rats reared in social isolation 
(Hall et al, 1998; Smith et al, 1997). This raises the possibility that the increased 
activity is a response to the current housing conditions and not necessarily a 
consequence of the long-term effects of isolation rearing. However, the current 
housing conditions did not modify nicotine's effects on locomotor activity, whereas 
isolation since weaning did enhance the locomotor stimulant effects of amphetamine 
and ethanol (Hall et al, 1998; Smith et al, 1997). 
In contrast to 'the social interaction test, the housing conditions did not modify 
behaviour in the elevated plus-maze, as has been previously found in mice (Rodgers & 
Cole, 1993). These results are also in general agreement with previous studies in 
which other test condition manipulations, such as extra-maze cues and lighting, were 
found not to influence baseline scores (Rodgers et al, 1997; Becker & Grecksh, 1996; 
Falter et al, 1992; Baldwin & File, 1986; Pellow et al, 1985). It is therefore even more 
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striking that the order of removal from the group did seem to affect behaviour, with the 
rats that were removed first having scores in the plus-maze that indicated increased 
anxiety. No such effects were found in a study on the effects of cohort removal in 
mice, but the mice were sequentially removed and not replaced in the group cage after 
testing (Rodgers et al, 1994). It is possible that the effects observed in this study were 
caused, not by cohort removal, but by the initial disturbance to the cage, to which the 
rats habituated after several disturbances. Further studies are clearly needed in this 
area. Another contrast between the two tests of anxiety was that the housing conditions 
did not influence the dose-response to nicotine in the plus-maze and only anxiogenic 
effects were detected in this test. The housing conditions did, however, alter the time 
at which nicotine's effects were detected, with the effects being delayed in the singly 
housed rats. Previously, rats reared in isolation have shown an altered time course of 
amphetamine-induced locomotor activity (Jones et al, 1992b). The shift in the time 
course in the present study does not appear to be dependent on baseline differences 
between singly and group housed rats. There is convincing evidence that the 
anxiogenic effects of nicotine in the elevated plus-maze are primarily mediated by 5- 
HT1A receptors in the lateral septum (Cheeta et al, 2000b). The present results therefore 
indicate possible alteration of serotonergic dependent function of the lateral septum 
following isolation housing of rats. However, it is also possible that isolation housing 
altered the pharmacokinetic effects of nicotine, and that the later onset of nicotine's 
anxiogenic effect was due to changes in nicotine absorption and metabolism, although 
as yet this still has to be determined. 
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Several factor analysis studies have provided evidence that different animal tests of 
anxiety are reflecting different underlying factors, and hence may be modelling 
different anxiety disorders (Flaherty et al, 1998; Ramos et al, 1997; Belzung & Le 
Pape, 1994; File, 1992). Inbred rat lines have showed different effects in different tests 
of anxiety (Chaouloff et al, 1994) and further differences between these tests have been 
shown in the effects of brain lesions and central drug administration (Menard & Treit, 
1999). Differential effects have also been found following systemically administered 
drugs (Fernandez-Guasti et al, 1999; Treit et al, 1993) and after the stress of 
inescapable shock (Steenbergen et al, 1990). 
The differences found between the social interaction test and the elevated plus-maze in 
the effects of nicotine. Thus, in Lister hooded rats and in the test conditions used, 
although low doses of nicotine were anxiolytic in the social interaction test, only 
anxiogenic effects have been found in the plus-maze (this experiment and Ouagazzal et 
al, 1999a; File et al, 1998). It is perhaps most striking that, in singly housed rats, 
nicotine (0.1 mg/kg 30 min after injection) had an anxiolytic action in the social 
interaction test, yet an anxiogenic effect in the plus-maze (Kenny et al, 2000b; 
Ouagazzal et al, 1999a). There was no dose of nicotine that had an anxiolytic effect in 
the plus-maze after acute administration. The lowest dose investigated in the present 
study was 0.025 mg/kg, but Ouagazzal et al (1999a) also found no effects with doses as 
low as 0.01 mg/kg. A further difference seems to lie in the brain regions mediating 
nicotine's anxiogenic effects in the two tests, which implies that different brain regions 
may be activated by the two tests. Thus, while both the dorsal hippocampus and the 
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lateral septum mediate the anxiogenic effects of nicotine in the social interaction test, 
only the latter structure mediates effects in the plus-maze (Cheeta et al, 2000b; Kenny 
et al, 2000b; Ouagazzal et al., 1999a, b). In all cases the anxiogenic effects were 
antagonised by co-administration of the 5HT1A antagonist, WAY 100,635 (Cheeta et 
al., 2000b; Kenny et al., 2000b). Since the group-housed rats did not show any 
anxiogenic effects to nicotine in the social interaction test, this implies that the housing 
conditions might have modified the nicotinic cholinergic and/or serotonergic systems 
in these brain regions. 
In conclusion, the results showed that even a few days of social isolation in adulthood 
can profoundly affect baseline responses in tests of anxiety and responses to nicotine. 
Singly housed rats have also shown greater physiological reactions to stress than did 
group-housed rats (Ruis et al, 1999; Baldwin et al, 1995). However, an increased 
stress response to the behavioural tests is an insufficient explanation for the pattern of 
results found with nicotine in this study. 
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CHAPTER 5 
Nicotine self-administration and withdrawal: modulation of 
anxiety in the social interaction test in rats 
5.1 Introduction 
Nicotine is known to produce a wider rangy of behavioural effects (for review see 
Stolerman et al., 1995) but one of the most striking behavioural properties is its 
reinforcing effects which results in tobacco addiction in smokers. Nicotine is one of 
the most widely abused substances in the world and in Great Britain it is estimated that 
28% of men and 25% of women smoke (Royal College of Physicians, 2000). Drug 
self-administration studies represent the most established paradigm available to 
investigate the reinforcing properties of abused substances in animals. Corrigall and 
Coen (1989) developed reliable schedules of intravenous nicotine self-administration in 
rats that has been replicated by other groups (Donny et al., 1995; Tessari et al., 1995). 
There is considerable evidence that the behavioural effects of nicotine change after 
repeated injections. In the social interaction test in rats, after 7 daily injections, 
tolerance developed to both the anxiolytic and anxiogenic effects of nicotine (0.1 
mg/kg) and there was an anxiogenic response 72 h after withdrawal from 7 and 14 days 
of treatment (Chapter 2). In order to examine the possible role of anxiety in nicotine 
self-administration the purpose of the present experiment was to determine the changes 
in anxiety that occur when rats are self-administering nicotine and when they are 
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withdrawn from nicotine after 4 weeks of self-administration. Intravenous self- 
administration of nicotine in rats is considered a useful model of nicotine dependence 
(Corrigall, 1999; Rose & Corrigall, 1997). In this study, rats that had been self- 
administering nicotine for 4 weeks were tested in the social interaction test of anxiety 
after their normal daily nicotine session and again after 24 and 72 h of withdrawal. In 
testing the effects of withdrawal from nicotine the animals were tested under extinction 
conditions, i. e. no nicotine reinforcements were delivered. In order to assess the 
importance of nicotine-associated cues, the conditioned stimuli were still presented 
during the extinction sessions and the performance of animals exposed to these cues 
was compared with a group that was tested immediately after removal from the home 
cage. 
5.2 Materials and Methods 
Animals 
Male Wistar rats (Charles River, Germany) were individually housed in a temperature- 
controlled environment with lights (<50 scotopic lux) on from 0600-1800 h. During 
the experiments, water was continuously available and animals were maintained at a 
constant body weight of 240-260g (85% of their ad libitum body weight). 
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Apparatus 
Operant Chamber 
The self-administration sessions were conducted in sixteen operant chambers 
(Coulbourn Instruments, Lehigh Valley, USA) encased in sound-insulated cubicles, 
equipped with ventilation fans (Ugo Basile, Comerio, Italy). Each chamber was 
equipped with two levers, symmetrically centred on the front panel, located 12.5 cm 
apart, 2 cm above the grid floor. The food magazine was situated in an opening in the 
panel between the two levers, 1 cm above the floor. A2W white house light was 
located 26 cm above the food magazine and activated throughout the entire session. 
Presses on the right lever ("active lever pressing"), corresponding to the Fixed Ratio 
values required by the schedules of reinforcement, produced delivery of 45 mg food 
pellets (Bioserv, Frenchtown NJ, USA) or the activation of the infusion pump, except 
during withdrawal conditions. Delivery of reinforcement was signalled by the 1s 
illumination of a4W white stimulus light located in the same hole of the food 
magazine and by the 1s sounding of a Sonalert device (2.9 Hz, 60 dB). Drug or 
vehicle solutions were administered via the infusion pump (Model A-99Z, Razel 
Scientific Instruments inc., Connecticut, U. S. A. ) at a volume of 0.022 ml during a1s 
period. Presses on the left lever did not have any consequence. Lever presses, food 
pellet and infusion deliveries were recorded. Data acquisition and schedule parameters 
were controlled by a Med-PC software (Med Associated, Georgia VT, USA) running 
on two Compaq microcomputers interfaced with the chambers via interface modules 
(Med Associated, Georgia VT, USA). 
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Social Interaction Test Arena 
See Chapter 2 for description. 
Training to lever-press for food reinforcement 
Following a 24 h deprivation period, rats were trained to press the right lever for food 
as a reinforcer. They were trained to a final Fixed-Ratio =2 (FR 2) schedule with a 
Time-out of 60 s (TO 60s). Each session lasted until the rat had received 100 pellets of 
food or was terminated after a maximum of 2 h. Once they reached this criterion, the 
rats underwent surgery. 
Surgery 
The surgical procedure described by Lane et al., (1992) was used with minor 
modifications. Rats were anaesthetised with a mixture of chlordiazepoxide (9 mg/kg; 
F. I. S., Alte Ceccato, Italy) and ketamine (50 mg/kg; Ketavet®100, Farmaceutici 
Gellini S. p. A, Aprilia, Italy), lml/kg IP (5 min pretreatment with atropine sulphate 1 
mg/kg IP; Sigma, St. Louis MO). They were then were implanted with a Silastic 
catheter (inner diameter 0.012 in, outer diameter 0.025 in; Dow Corning, Michigan, 
USA) in the right jugular vein. The free end of the catheter was connected to a 
connector consisting of a modified C313G cannula assembly (Plastic One, Roanoke 
VA, USA) and the resulting unit was mounted to the skull with dental acrylic cement 
and fixed via three stainless steel screws. Animals were injected IV with 0.1 ml of a 
solution containing 1 1U/ml heparin (Liquemin®, Roche S. p. A., Milano, Italy) and 65 
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mg/ml ticarcillin plus clavulanate (SmithKline Beecham, Milano, Italy), This 
treatment was repeated every 12h for 7 days after surgery (period of recovery). 
Nicotine Self-administration Training 
After the period of recovery, thirty-two rats were randomly allocated to self-administer 
either saline (n=15) or nicotine (n=17; 0.03 mg/kg/infusion; Sigma, St. Louis MO, 
USA). Nicotine self-administration was initiated on an FR 1 schedule of reinforcement 
with a TO 60 s after each infusion. During the time-out period, responses were 
recorded but did not lead to drug delivery. For the FR1 schedule of reinforcement, 
each session lasted until the rat had received 25 infusions of nicotine or was terminated 
after a maximum of 3h. If the animals met the criterion of 25 infusions within the end 
of the daily session, the FR value was increased to FR 2 the following day. For the 
FR2 schedule of reinforcement, each session lasted until the rat had received 15 
infusions of nicotine or was terminated after a maximum of 2 h. After about two 
weeks of training all rats were receiving 15 infusions of nicotine, and this was the case 
on the first social interaction test day, which took place after 4 weeks of self- 
administration. The control rats that were receiving saline infusions had their first 
session on the FR1 schedule of reinforcement but, were placed on an FR2 schedule for 
the subsequent training sessions. These rats had the same number of training sessions 
as the rats self-administering nicotine. Each control rat was paired with a rat self- 
administering nicotine, and the amount of time the control rat spent in the operant 
chamber was determined by the time that its partner took to receive its 15 infusions of 
nicotine. 
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Drugs 
All drugs were dissolved in heparinized saline (0.09% NaCl + 0.5 UI/ml heparin) and 
the pH was adjusted to 7.4 with NaOH. Nicotine doses are expressed as mg of free 
base/kg of body weight per infusion. 
Social Interaction Test Procedure 
The day before their first social interaction test, the rats received their usual daily self- 
administration session in the morning and in the afternoon they were familiarised with 
the test arena. Each rat was placed singly in the brightly lit arena, for a 10 min 
familiarisation trial. On each test day, each experimental rat was placed in the social 
interaction test with an unoperated partner and tested for 4.5 min. At the end of the 
test, the rats and any faecal boluses were removed and the arena wiped with a damp 
cloth. All animals were tested in an order randomised for drug treatment, between 
0900 and 1400 h. 
On the first social interaction test day, each rat received its usual daily self- 
administration session and 5 min after it had received its 15th infusion of nicotine it was 
placed in the social interaction test arena. Rats that were receiving saline were taken 
out of the operant chamber at a time corresponding to a nicotine animal. All the 
animals were then tested again 24 and 72 h later, without receiving any further nicotine 
or saline infusions. At both these time-points, the animals were either taken directly 
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from their home cages (saline, n=7; nicotine, n=9) or were tested 5 min after a 30 min 
extinction session in the operant chamber (saline, n=8; nicotine, n=8). During the 30 
min extinction session, responding on the `active lever' lever caused the presentation of 
the conditioned stimuli (FR1), but no delivery of nicotine or saline. 
Statistics 
The scores of the chronically treated rats were compared by one-way ANOVA. The 
scores from the tests in withdrawal conditions were analysed by two-way ANOVAs 
with chronic drug treatment (vehicle or nicotine) as one factor and experience prior to 
test (directly from the home cage or exposure to the operant chamber) as the other 
factor. Differences between individual groups were then assessed by Fisher's post-hoc 
tests, and it is these that are presented in Figure 5.1 and Table 5.11. Pearson's product- 
moment correlation coefficient was calculated for the social interaction score and the 
time taken to receive 15 nicotine infusions on the test day. 
5.3 Results 
The rats that had been self-administering nicotine spent significantly less time in social 
interaction than the group that had been self-administering vehicle, [F(1,3 1)=21.6, 
p<0.01; Figure 5.1]. The chronic nicotine self-administration did not result in any 
decreases of locomotor activity, see Table 5.1. Thus, this pattern of results indicates a 
specific anxiogenic effect of the chronically self-administered nicotine. For the 
nicotine self-administration group there was no correlation between the time taken to 
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receive 15 nicotine infusions on the test day and the social interaction score (r=-O. 18). 
Thus, the anxiogenic effect was not dependent on the rate at which the nicotine dose 
was received. 
The rats that were withdrawn for 24 and 72 h from chronic nicotine administration, did 
not differ from their saline control group in the time they spent in social interaction 
(see Figure 5.1) or in their locomotor activity (see Table 5.1). Thus, there was no 
evidence from these measures of a withdrawal response in the animals that had been 
self-administering nicotine for 4 weeks. However, there were significant effects that 
resulted simply from exposure to the operant chamber immediately prior to the social 
interaction test, regardless of drug treatment. The rats exposed to the chamber on the 
first extinction day spent significantly less time in social interaction than did those that 
were tested directly from their home-cages [F(1,28)=11.9, p<0.005]. This can be seen 
in Figure 5.1 by comparing the 24 h nicotine group tested straight from the home cage 
with the nicotine 24 h group that had prior exposure to the operant chamber, and by 
comparing the two saline 24 h groups. The rats exposed to the operant chamber on the 
second extinction day (72 h groups in Figure 5.1) also spent less time in social 
interaction than did those tested directly from the home-cage, but this no longer 
reached significance [F(1,28)=2.5]. There were no changes in locomotor activity as a 
result of exposure to the operant chamber, at either of the time intervals tested (see 
Table 5.1). 
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Figure 5.1 Mean (± sem) time spent in social interaction by rats tested 5min (0h), 
24h and 72 h after saline (V) or 4 weeks of nicotine (0.45 
mg/kg/session; Nic). The upper panel shows the scores for rats tested 5- 
min after a session in the operant chamber; the lower panels shows 
scores for rats tested directly after removal from the home-cage. All 
tests were conducted in the high light familiar (HF) test condition. 
**p<0.01 compared with appropriate vehicle control, +p<0.01 compared 
with corresponding group tested directly from the home cage. 
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Table 5.1 Mean (± sem) locomotor activity (number of line crossings) made by rats 
tested 5min (0h), 24 and 72 h after saline (V) or 4 weeks of nicotine (0.45 
mg/kg/session; Nic). On the first test day (0h), the animals were tested after 
their normal daily session in the operant chamber. For the 2 withdrawal time- 
points the animals were either taken directly from the home cage (Home Cage) 
or were tested 5 min after a 30 min session in the operant chamber (Operant 








Operant Chamber 114.7 163.2 129.6 115.7 126.9 137.0 
±9.0 ±9.3 ± 12.7 ± 17.0 ± 11.9 ± 16.5 
Home Cage -- 116.3 139.2 141.1 t 147.0 
± 14.6 ± 7.7 17.3 ± 14.5 
5.4 Discussion 
Rats that had been self-administering nicotine for 4 weeks showed a decrease in the 
time spent in social interaction when tested straight after their self-administration 
session. This can be interpreted as an anxiogenic effect, since it was not accompanied 
by any reduction in locomotor activity. The results therefore show that chronic self- 
administration of nicotine can be accompanied by an anxiogenic effect, as detected in 
the social interaction test. This suggests that either this dose of nicotine is sufficiently 
rewarding to overcome the adverse consequences of increased anxiety, or that the 
relatively mild increase in anxiety contributes to the rewarding effects. At present it is 
impossible to distinguish between these two alternatives. 
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The anxiogenic effect of chronic nicotine that we found in this study is at variance with 
the widely held belief that nicotine is anxiolytic in smokers. There is considerable 
evidence that smoking alleviates the increased anxiety resulting from abstinence, but 
little evidence that it has an anxiolytic effect in non-deprived smokers (Parrott, 1999). 
Indeed, there is evidence that smokers experience higher levels of stress and anxiety 
than non-smokers (Jones & Parrott, 1997; West, 1992; Warburton et al, 1991). 
Adolescent smokers also report significantly higher levels of nervousness, stress and 
anxiety than age-matched non-smokers (Lloyd & Lucas, 1997; Wills, 1986; Mitic et al, 
1985; Hirschman et al, 1984). It has generally been assumed that these increased 
anxiety levels are due to the periods of heightened anxiety during abstinence. The 
results of this study raise the possibility that chronic nicotine, even when self- 
administered, may itself have an anxiogenic effect. This may be related to the dose of 
nicotine and certainly after acute administration, high doses have anxiogenic effects in 
the social interaction test, whereas low doses have anxiolytic effects (File et al., 1998). 
At the two time-points tested, there was no evidence of an anxiogenic effect resulting 
simply from nicotine withdrawal, whether or not the animals were exposed to the 
extinction conditions of the operant chamber. This is surprising, since following 7 and 
14 days of sub-cutaneous administration of nicotine a significant decrease in social 
interaction was detected after 72 h of drug withdrawal (Chapter 2). However, there are 
several possible explanations for this result. One is that the wrong time-points had 
been chosen to detect such an effect following this particular dose-regime. The second 
is that withdrawal changes in anxiety were not detected because tolerance had not 
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developed to the anxiogenic effect of nicotine. The third is that these rats were 
accustomed to a 72 h period of abstinence every weekend, and that this may in some 
way have modified the withdrawal response. 
An interesting side finding of this experiment was that exposure to the operant chamber 
produced an anxiogenic effect in all of the animals, regardless of their drug group. 
This effect was not therefore the result simply of removal of nicotine delivery and 
suggests that confinement to the test chamber generates a level of anxiety. The 
anxiogenic effect was observed in those tested at the 24 h time-point and since it was 
equal in both the nicotine and control groups it is clear that exposure to nicotine- 
associated cues was not generating the anxiety. At the 72 h time-point there was no 
longer a significant effect of exposure to the operant chamber on social interaction. 
In conclusion, a main finding of this study is that increased anxiety when animals are 
withdrawn for 24 or 72 h from 4 weeks of nicotine self-administration is not 
contributing to self-administration in our test conditions. Furthermore, self- 
administration is maintained, not because of an anxiolytic effect of the self- 
administered nicotine, but despite (or because of) its anxiogenic effect. These results 
suggest that the increased anxiety and stress in smokers might be partially caused by 
persisting anxiogenic effects of nicotine and not solely due to those relating to 
withdrawal effects. 
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CHAPTER 6 
Different treatment regimens and the development of 
tolerance to nicotine's anxiogenic effects 
6.1 Introduction 
The treatment regimen by which a drug is administered can be an important factor that 
influences behavioural effects, and is one that is often overlooked. It has been shown 
that chronic treatment with drugs such as the benzodiazepines, amphetamine and 
cocaine has differing effects on behaviour depending on the route by which it is 
administered (Fernandes et al., 1999 Koff et al., 1994; King et al., 1992; Ellison and 
Morrison, 1981). Tolerance to the behavioural effects of nicotine has been seen after 
daily subcutaneous, intraperitoneal or intravenous injections, constant infusion or 
intake in drinking water (Chapters 2 and 3; Sparks and Pauly, 1999; Marks et al., 1987, 
1983; Clarke and Kumar, 1983 a, b; Stolerman et al., 1974,1973), but at present there 
is little in the literature investigating the differential effects between these treatment 
regimens. A study by Morgan and Ellison (1987) showed opposing effects on body 
weight in female rats when the same dose of nicotine (11.2 mg/kg/day) was 
administered chronically by subcutaneous injection or pellet infusion. Marks et al. 
(1987) found that mice exposed to chronic nicotine (4 mg/kg/day over a lh period) by 
discrete pulses (1-4 pulses/h) developed tolerance faster to the acute effects of nicotine 
on Y-maze activity than those receiving the same dose of nicotine by continuous 
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infusion. However, the up-regulation in [3H]-nicotine binding was the same in the two 
treatment regimens. 
Following 7 days of treatment with this low (0.1 mg/kg; s. c. ) dose of nicotine, 
tolerance developed to both the anxiogenic and anxiolytic effects, and 72h after 
withdrawal from the nicotine treatment an anxiogenic effect was observed in the social 
interaction test (Chapter 2). However, in the previous chapter an anxiogenic effect was 
observed in the social interaction test in animals that had been self-administering 
nicotine (0.45 mg/kg/day, 5 days/week) for 4 weeks and were tested 5 min after their 
daily self-administration session. In these animals, there was no evidence of an 
anxiogenic withdrawal response either 24 or 72h after the last self-administration 
session (Chapter 5). Since the two studies differed in both the dose and treatment 
regimen, it is not possible to say whether tolerance did not develop because the animals 
were self-administering nicotine or because a higher dose was used. 
Thus, the purpose of this study was to examine the effects on the development of 
tolerance to the anxiogenic effect of a high dose of nicotine using different treatment 
regimens. In all cases, rats received the same daily dose (0.45 mg/kg/day). One group 
of rats was passively administered i. v. doses of nicotine in the same pattern as that used 
for self-administration (15 infusions of 0.03 mg/kg, totalling 0.45 mg/kg/day, 5 
days/week). Two groups received s. c. injections of 0.45 mg/kg/day, but one received 5 
injections/week and the other received daily injections (7 injections/week). The final 
group received the same daily dose, but infused at a constant rate by an osmotic 
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minipump. The animals were tested in the social interaction 5 min after their normal 
daily nicotine injection or straight from the home cage (for the minipump group), and 
after 24 and 72h withdrawal. 
In order to determine whether there was any evidence for the development of 
pharmacokinetic tolerance, plasma nicotine concentrations were determined by gas 
chromatography (Feryerabend & Russell, 1990). 
6.2 Materials and Methods 
Animals 
Male Sprague-Dawley rats (Harlan Olac, Bicester, UK) were individually housed in the 
same room, maintained at 22°C, with lights (<50 lux) on from 0700 to 1900h. Food 
and water were freely available. At testing, the animals weighed between 300-375g. 
Nicotine Treatment 
Intravenous administration: The surgical procedure described by Lane et al., (1992) 
was used with minor modifications. Rats were anaesthetised by inhalation of 3% 
isoflurane (May and Baker, Dagenham, Essex, UK) in oxygen and were then were 
implanted with a silastic catheter (inner diameter 0.012 in, outer diameter 0.025 in; Bio 
Pure Technology Ltd, Hampshire, UK) in the right jugular vein. The free end of the 
catheter was connected to a connector consisting of a modified C313G cannula 
assembly (Plastic Products, UK) and the resulting unit was mounted to the skull with 
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dental acrylic cement and fixed via three stainless steel screws. Animals were injected 
i. v. with 0.1 ml of a solution containing 1 IU/ml heparin (Monoparin®, CP 
Pharmaceuticals Ltd, Wrexham, UK). This treatment was repeated every 12h for 7 
days after surgery (period of recovery). After the period of recovery, the animals 
received infusions of either vehicle or nicotine (0.03 mg/kg/infusion) every min for 15 
min, so that the nicotine animals received a total of 0.45 mg/kg/day. The drug 
solutions were administered at a volume of 0.025m1 during a3s period. 
Subcutaneous injections: Animals received daily morning injections (5 or 7 days/week) 
of either nicotine (0.45 mg/kg) or vehicle. All injections were in a volume of 1 ml/kg. 
Subcutaneous infusion: Rats were anaesthetised by inhalation of 3% isoflurane (May 
and Baker, Dagenham, Essex, UK) in oxygen and osmotic minipumps (Alzet, USA) 
delivering 0.45 mg/kg/day nicotine were subcutaneously implanted in the dorsal 
thoracic area. Animals were monitored daily and the osmotic minipumps manipulated 
by hand within the subcutaneous pouch to reduce the amount of connective tissue 
growing around the pump that could impair infusion rate. 
Apparatus 
The social interaction test, see Chapter 2 for description. 
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Drug 
For the i. v. injections, (-)-nicotine hydrogen tartrate (Sigma, Poole, UK) was dissolved 
in heparinized saline (0.09% NaCl + 0.5 UI/ml heparin) and for the s. c. injections and 
the minipumps it was dissolved in distilled water. Nicotine doses are expressed as mg 
of free base/kg of body weight. 
Procedure 
In order to familiarise rats with the social interaction test arena, each rat was placed 
singly in the test arena under high light for a 10 min familiarisation trial on the day 
prior to testing. For each experiment, animals were allocated to test partners on the 
basis of weight, such that members of a pair did not differ by more than 10g. On the 
test day, each experimental rat was placed together with its unoperated/uninjected 
partner in the test arena, 5 min after its daily injection or straight from the home cage 
(for the minipump groups). Social interaction was scored only for interaction that was 
initiated by the nicotine-treated animal, and was scored for 4.5 min by an observer 
blind to the drug treatment. All animals were tested in an order randomised for drug 
treatment, between 0900 and 1230h. At the end of each trial, any faecal boluses were 
removed from the test arena, which was cleaned with a damp cloth. 
Experiment 1: L v. administration of nicotine 
Rats were randomly allocated to vehicle or nicotine (0.45 mg/kg) groups and within 
these they were allocated to be tested after an acute injection (vehicle, n=5; nicotine, 
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n=11), after 4 days of injections (vehicle, n=7; nicotine, n=8) or 4 weeks (vehicle, n=4; 
nicotine, n=4). Animals that had been treated for 4 weeks were then retested 
undrugged 24 and 72h later. The small group sizes in the 4 week treatment groups are 
due to blockade of indwelling catheters over this period. 
Experiment 2a: s. c. injections 
Rats were randomly allocated to the following groups: vehicle (n=10) and nicotine 
(0.45 mg/kg) treatment for 4 days (n=10) or 4 weeks (n=20). Half of each of these 
groups received either 5 (Monday - Friday) or 7 (every day) injections per week. 
Immediately after test, four animals from the 4 day nicotine group and four from each 
of the 4 week nicotine treated groups (5 and 7 days/week) were taken for determination 
of plasma nicotine levels. The remaining animals in the chronic nicotine treatment 
group were retested undrugged 24 and 72h later with their vehicle controls. 
Experiment 2b: s. c. minipump 
Rats were randomly allocated to the following osmotic minipump groups: vehicle 
(n=7) and 4 days (n=10) or 4 weeks (n=10) of nicotine (0.45 mg/kg/day). 
Immediately after test, four of the animals from each of the nicotine treated groups 
were taken for determination of plasma nicotine levels. The remaining animals in the 4 
week treatment groups had their osmotic minipumps removed under anaesthesia and 
were then retested undrugged 24 and 72h later. 
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Experiment 2c: Determination of Plasma Nicotine Levels 
To compare the plasma nicotine levels of the animals that had been treated for 4 days 
or 4 weeks with nicotine, animals were taken straight from testing, killed by 
decapitation and trunk blood was taken. The blood was centrifuged for determination 
of plasma levels of nicotine by gas chromatography, using nitrogen phosphorus 
detection with detection limit of 100 pg/ml using 100 µl of plasma (Feyerabend & 
Russell, 1990). Three of the blood samples became contaminated and were therefore 
excluded from statistical analysis. 
Statistics 
For each experiment, the scores were analysed by one-way ANOVA and comparisons 
between individual groups were then made with the Fisher's post-hoc tests. Because 
of the low numbers of animals that were tested after 4 weeks of i. v. nicotine, the scores 
were compared using Mann-Whitney U-tests (although for ease of comparison all the 
scores in Figure 1 are presented as means ± sem). The plasma concentrations of 
nicotine were also assessed by Mann-Whitney U-tests due to the low number of 
animals used. 
6.3 Results 
Tolerance and withdrawal after 4 weeks of i. v. nicotine 
It can be seen from Figure 6.1 that an acute dose of nicotine significantly decreased the 
time spent in social interaction [F(1,14)=56.3, p<0.00001], indicating an anxiogenic 
139 
Treatment regimens and nicotine tolerance 
effect. There were still significant anxiogenic effects after 4 days [F(1,13)=, 19.6 
p<0.001] and 4 weeks (U=O, p<0.05) of nicotine treatment. Thus, although some 
tolerance appeared to have occurred it was not complete. There were no significant 
changes in locomotor activity [F(1,14)=0.5, F(1,13)ß. 7 and U=4, respectively], see 
Figure 6.1. 
The animals that were withdrawn for 24 and 72h from 4 weeks of nicotine 
administration did not differ from their saline control group in the time they spent in 
social interaction (U=8 and U=5, respectively), see Figure 6.1. However, the animals 
tested 24h after withdrawal from nicotine showed a significant increase in locomotor 
activity compared with saline controls (U=O, p<0.05), but this had disappeared by 72h 
(U=4), see Figure 6.1. 
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AC 4D 4W 24h WD 72h WD 
(5) 
Figure 6.1 %lean (Y sem) time (s) spent in social interaction (top panel) and 
locomotor activity (no of beam breaks, bottom panel) made by rats 
tested 5 min after acute (AC), 4 days (4D)or 4 weeks (4W, 5 
injections/week) of intravenous vehicle or nicotine (0.45 mg/kg/day), 
and 24 and 72h after 4 weeks of nicotine treatment. Rats were tested in 
the high light familiar (HF) test condition. * p<0.05 and ** p<0.01 
compared with the vehicle control. 
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Tolerance and withdrawal after 4 weeks of sa nicotine injections 
In animals tested 5 min after a s. c. injection of nicotine (0.45 mg/kg) there was a 
significant effect of nicotine on the time spent in social interaction [F(3,36)=15.3, 
p<0.00001], and post-hoc analysis showed that this was due to the scores from both the 
4 day and 4 week (5 and 7 days/week) nicotine groups being significantly lower than 
those of vehicle controls (p<0.01 for both groups; see Figure 6.2). However, the 
animals that had been chronically treated with nicotine for 5 or 7 days/week had 
significantly higher scores than those that had received nicotine for 4 days (p<0.01 for 
both groups), suggesting that partial tolerance had developed. There were no 
significant effects of nicotine on locomotor activity [F(3,36)=2.2], see Table 6.1. 
The animals that were withdrawn for 24 and 72h from 4 weeks of nicotine 
administration did not differ from their saline control group in the time they spent in 
social interaction [F(2,19)=0.4 and F(2,19)=0.9, respectively; see Figure 6.2] or in their 
locomotor activity [F(2,19)=1.1 and F(2,19)=1.3, respectively], see Table 6.1. 
Tolerance and withdrawal after 4 weeks of s c. minipump nicotine i, sion 
Animals receiving treatment via osmotic minipumps showed a significant effect of 
nicotine on the time spent in social interaction [F(2,24)=13.76, p<0.0001], and post- 
hoc analysis showed that the scores from the animals treated for 4 days (p<0.01) and 4 
weeks (p<0.05) with nicotine were significantly decreased compared with the vehicle 
controls, see Figure 6.2. However, the animals that had been treated for 4 weeks had 
significantly higher scores than those that had received nicotine for 4 days (p<0.01), 
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suggesting that again partial tolerance had developed. There were no significant 
effects of nicotine on locomotor activity [F(2,24)=0.21], see Table 6.1. 
The animals that were withdrawn for 24 and 72h from 4 weeks of nicotine 
administration did not differ from their saline control group in the time they spent in 
social interaction [F(1,11)ß. 7 and F(1,11)=0.1, respectively; see Figure 6.2]. 
However, the animals tested 24h after withdrawal from nicotine showed a significant 
increase in locomotor activity compared with saline controls [F(1,11)=5.2, p<0.05), but 
this had disappeared by 72h [F(1,11)=2.0], see Table 6.1. 
Plasma Nicotine Levels 
There was no significant difference in the plasma concentration of nicotine between 
rats treated for 4 days or 4 weeks with nicotine in either of the s. c. injection groups (5 
and 7 timestweek) or in the minipump infusion group, see Table 6.2. Thus, there was 
no evidence for any development of pharmacokinetic tolerance. Table 6.2 also shows 
that the plasma nicotine concentration at testing was significantly higher in both the s. c. 
injection groups than in the minipump group (U=O, p<0.05 in both cases). This 
confirms the higher peak concentrations produced by intermittent injections. 
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Figure 62 Mean (± sem) time (s) spent in social interaction made by rats after 
vehicle (V) or 4 days (4D) and 4 weeks (4W, 5 or 7 injections/week) of 
nicotine (0.45 mg/kg/day) administration, either by s. c. injection or 
minipump infusion (top panel), and 24 and 72h after 4 weeks of nicotine 
treatment (bottom panel). * p<0.05 and p<0.01, compared with the 
vehicle control, and ** p<0.01, compared with the 4 day group. 
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Table 6.1 Mean (± sem) locomotor activity (no of beam breaks) made by rats after 
vehicle (V), 4 days (4D) or 4 weeks (4W, 5 or 7 injectionshveek) of nicotine 
(0.45 mg/kg/day) administration, either by s. c. injection or minipump infusion, 
and 24 and 72h after withdrawal from 4 weeks of nicotine. * p<0.05 compared 
with the vehicle control. 
Locomotor Activity 
S. C. Minipump 
Tolerance 
V 491.4±19.1 455.1±19.0 
4D 412.3±30.7 455.7±31.0 
4W (5) 468.1 ± 24.1 - 
4W (7) 490.6 ± 25.5 476.7 ± 23.8 
24 h Withdrawal 
V 454±30.2 411.1 ±36.0 
4W (5) 425.8 ± 27.0 - 
4W (7) 490.2 ± 28.0 516.5 f 26.4 
72 h Withdrawal 
V 423.6±24.4 395.9±33.7 
4W (5) 509.7 ± 33.6 - 
4W (7) 444.5 ± 60.3 455.7 ± 23.2 
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Table 6.2 Median plasma nicotine levels following 4 days (4D) or 4 weeks (4W, 5 or 7 
injections/week) of nicotine administered by either, s. c. injections or constant 
infusion. ** p<0.01 compared to the same treatment in the animals that 
received constant infusion of nicotine. 
Treatment Group Plasma Nicotine Levels (ng/ml) n 
s. c. injections 
4D 123.1 ** 4 
4W (5) 105.9 3 
4W (7) 134.3 ** 4 
s. c infusions 
4D 5.7 3 
4W (7) 9.6 3 
6.4 Discussion 
The results of this study have clearly shown that after four days of nicotine treatment 
(0.45 mg/kg/day) there were decreases in social interaction, without changes in 
locomotor activity, suggesting specific anxiogenic effects. These effects were very 
similar, regardless of whether nicotine was given by intravenous injection, 
subcutaneous injection or infused by minipump. The plasma nicotine concentrations 
seen in this study after subcutaneous injections are similar to those reported by Shoaib 
& Stolerman (1999) after intravenous self-administration of nicotine, but these levels 
were very different from the plasma concentrations in the minipump group. The 
plasma concentrations in our minipump group are similar to those found by Rowell & 
Li (1997) following minipump infusions of 0.6 mg/kg/day. These results therefore 
suggest that, at least after 4 days of treatment, the anxiogenic effects were not related to 
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the plasma nicotine concentration and perhaps it is simply necessary to reach a certain 
threshold concentration to see an anxiogenic effect. After an acute dose of nicotine and 
after 10 days of treatment brain concentrations of nicotine are threefold higher than in 
plasma (Rowell and Li, 1997; Mansner and Mattila, 1975). It is possible that this 
difference is further enhanced after 4 weeks of treatment and perhaps to a greater 
extent in the continuous infusion group, although this was not the case after 10 days of 
treatment (Rowell and Li, 1997). 
The results of the present study strongly suggest that it takes more than 4 weeks for 
complete tolerance to develop to the anxiogenic effect of this relatively high dose of 
nicotine, but that the route and manner of nicotine administration is relatively 
unimportant to the rate of tolerance development. This is in contrast to the rapid rate of 
development of tolerance to the low dose of nicotine (0.1 mg/kg). The anxiogenic 
effects of high doses are mediated by stimulation of postsynaptic 5-HTIA receptors in 
the dorsal hippocampus (Kenny et al, 2000b) and the lateral septal nucleus (Cheeta et 
al., 2000b). It is therefore possible that different mechanisms and/or rates of tolerance 
operate in the different brain regions. The brain region mediating the anxiogenic effect 
of 0.1 mg/kg, that is observed 5 min after injection, is unknown at present. 
The results showing persistent anxiogenic effects following 4 weeks of nicotine 
treatment (0.45 mg/kg/day) support our previous findings that animals that had been 
self-administering nicotine (0.45 mg/kg/day) for 4 weeks had an anxiogenic response 
in the social interaction test when they were tested 5 min after their usual self- 
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administration session. This is important because it shows that a dose of nicotine can 
cause anxiety and be rewarding. Corrigall and Coen (1989) had suggested that higher 
doses of nicotine are not self-administered because of their aversive properties. Whilst 
this is likely in the proconvulsant range and possibly with an extreme level of anxiety, 
our results raise the possibility that a milder anxiogenic effect is actually rewarding. A 
very similar argument for the rewarding effects of cocaine has been proposed by 
Goeders (2001), who has shown that the release of the stress hormones CRH and 
corticosterone are necessary for cocaine self-administration. The dose of amphetamine 
that is self-administered is also one that has anxiogenic effects (Lin et al., 1999; Carroll 
and Lac, 1997; File and Hyde, 1979). 
After four weeks of treatment, the anxiogenic effects persisted, but there was 
development of partial tolerance. This is unlikely to be due to the development of 
pharmacokinetic tolerance, since there was no significant reduction in nicotine 
concentrations after four weeks of treatment. Several pharmacodynamic mechanisms 
are possible. An oppositional mechanism of tolerance is one that involves the 
progressive recruitment of processes that oppose the acute effect of the drug. Thus, 
following withdrawal of the drug these processes work unopposed and a behavioural 
response is seen in the opposite direction of the acute drug effect (Young & Goudie, 
1995). There was no evidence for an oppositional mechanism, since no anxiolytic 
withdrawal responses were observed at either 24 or 72h after the end of nicotine 
treatment. However, it is possible that the absence of a withdrawal response was 
because tolerance had not fully developed. An alternative mechanism of tolerance is a 
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decremental one, in which the behavioural impact of a drug is reduced, but which is 
without behavioural consequence in the absence of the drug (Young & Goudie, 1995). 
The pattern of results in this study would fit with a decremental process, such as 
receptor desensitisation, which has been observed in vitro with very low nicotine 
concentrations (IIencherif et al., 1995; Grady et al., 1994; Rowell and Hillebrand, 
1994; Marks et al., 1993a, b). However, in an in vivo study receptor desensitisation 
was only found with plasma nicotine concentrations of 24-87 ng/ml, and not with a 
concentration of 9 ng/ml (Benwell et al., 1995). Since our minipump group had a 
concentration of 9.6 ng/ml our results suggest that receptor desensitisation might occur 
at this concentration in at least some brain regions. 
There are also clear differences in the responses that can be seen on withdrawal from 
chronic treatment with the low and high doses of nicotine. Following 7 days of 
treatment with the low dose, an anxiogenic effect was seen 72h after the last dose 
(Chapter 2). Following the 4 weeks of treatment with the high dose, there were no 
changes in social interaction at either 24 or 72h in the present study or when rats were 
self-administering nicotine (Chapter 5). It had been speculated that the lack of a 
withdrawal response in the rats that had been self-administering nicotine was due to 
their having had previous experience of 72h withdrawal periods each weekend. 
However, this does not seem to be the crucial factor since there was no change in social 
interaction following withdrawal in the rats with daily injections or with constant 
infusions of nicotine. The results suggest that kindling of an anxiogenic response does 
not occur after repeated nicotine withdrawals. This has also been found following 
149 
Treatment regimens and nicotine tolerance 
repeated benzodiazepine withdrawals, although kindling of convulsions does occur 
(Ward and Stephens, 1998). Furthermore, whilst repeated administration of the 
benzodiazepine partial inverse agonist FG 7142 kindles seizures, it does not kindle 
anxiety (Taylor et al., 1988). The separation of anxiety and seizures was discussed by 
Pellow (1985). The only changes that we found when testing during withdrawal from 
the 4 weeks of nicotine treatment was that in two of the groups (i. v. injections 5 
times/week and continuous minipump infusion) there was a significant increase in 
locomotor activity. However, it would not seem correct to interpret the increased 
locomotor activity as a true withdrawal response, since locomotor activity was not 
decreased by either acute or 4 days of nicotine treatment. Furthermore, sensitisation to 
a locomotor stimulant effect, as measured in photocell activity cages, has been found 
(Zubaran et al., 2000) after 3 weeks of nicotine treatment (0.4 mg/kg/day). Whilst this 
was not detected in the conditions of the social interaction test, there was a trend 
towards increased locomotor activity in the 4 week intravenous nicotine group. The 
lack of locomotor sensitisation could be because two animals are present in the social 
interaction test and this could modify nicotine's effects on locomotor activity, as has 
been found for chlorpromazine (File and Pope, 1974b). Locomotor depressant effects 
have been found in the social interaction test following an injection of 0.5 mg/kg 
nicotine, but this was in the hooded Lister strain of rat. It is possible that there is a 
strain difference in sensitivity to these effects. 
In conclusion, the results of the present study show,. somewhat surprisingly, that the 
treatment regimen did not affect the rate of development of tolerance to the anxiogenic 
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effects of a high dose of nicotine, despite strikingly different levels of peak plasma 
concentration, and despite differences in the patterning of nicotine treatment. 
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CHAPTER 7 
The dorsal raphe nucleus is a crucial structure mediating 
nicotine's anxiolytic effects and is involved in the 
development of tolerance and withdrawal responses 
7.1 Introduction 
The dorsal hippocampus and the lateral septum have been identified as important 
neuroanatomical substrates mediating nicotine's anxiogenic effects (Ouagazzal et al, 
1999b; File et al, 1998). Furthermore, the anxiogenic effects of nicotine were 
antagonised by co-administration of the specific 5-HT1A receptor antagonist WAY 
100,635 (Cheeta et al, 2000b; Kenny et al, 2000b), suggesting an important role for 5- 
HT1A receptors in these brain areas in mediating nicotine's anxiogenic effects. An 
interaction between nicotinic and 5-HT1A receptors have been implicated in a number 
of nicotine's other behavioural effects (Rasmussen et al, 1997; Damaj et al, 1994; 
Riekkinen et al, 1994), and may therefore also exist for nicotine's anxiolytic actions. 
The 5-HT projections to the lateral septum arise from the DRN (Vertes, 1991; 
Andersen et al, 1983), and earlier research has demonstrated that direct administration 
of the specific 5-HTIA receptor agonist 8-OH-DPAT into the DRN induces an 
anxiolytic effect in the social interaction test (File et al, 1996a; Hogg et al, 1994; 
Higgins et al, 1988). This suggested that the DRN might be a good substrate for 
mediating the anxiolytic effects of nicotine. Therefore, this study investigated the 
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effects of direct administration of nicotine into the DRN in the social interaction test. 
To investigate whether there is a link between somatodendritic 5-HTIA receptors and 
nicotine's anxiolytic actions, the ability of WAY 100,635 to reverse the anxiolytic 
action of intra-DRN nicotine was investigated. 
In the social interaction test, tolerance to both the acute anxiogenic and anxiolytic 
effects of nicotine have been reported (Chapter 2). To date a neuroanatomical site 
mediating tolerance to the anxiolytic effects of nicotine has not yet been reported, and 
therefore this study explored the role of the DRN. 
In the social interaction test, an anxiogenic response is seen 72h following the 
termination of 7 days of nicotine administration (Chapter 2). The DRN has been 
implicated in the increased anxiety seen during nicotine withdrawal. Administration of 
ondansetron into the DRN antagonised the anxiogenic withdrawal response measured 
in the black/white crossing test (Costall et al, 1990c). Rasmussen & Czachura (1997) 
have also shown that on withdrawal from chronic nicotine, sensitivity to the 5-HT1A 
agonist, 8-OH-DPAT in the DRN is increased. Thus, this study also investigated the 
role of the DRN in mediating the increased anxiety detected in the social interaction 
test on withdrawal from chronic nicotine. 
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7.2 Materials and Methods 
Animals 
Male hooded Lister rats (Charles River, Margate, Kent, UK) weighing between 220- 
250g were used in all experiments. For Experiment 1, rats were housed singly 
following surgery and allowed to recover for 7 days prior to behavioural testing. For 
Experiment 2, following surgery rats were singly housed, and allowed to recover for 4 
days prior to the start of chronic injections. The unoperated rats used in each 
experiment were housed singly for the same length of time as their operated test 
partners. Food and water were freely available for all animals. The room in which 
animals were housed was lit with dim light and maintained at 22°C. Lights were on 
from 0700-1900h. 
Apparatus 
The social interaction test, see Chapter 2 for description. 
Surgery 
Surgery was conducted as described an in Chapter 3 with the exception that in 
Experiment 1 a, for unilateral cannulation of the DRN, 12 mm long steel guide cannulae 
(23 gauge) were positioned at 7.4mm posterior to bregma, ± 2.2 lateral and vertical - 
4.7 mm at an angle of 19°, thus siting them 2 mm above the target area (according to 
the atlas of Paxinos & Watson, 1986). For Experiments 1b and 2, the dorsal ventral co- 
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ordinate was changed to -4.5mm, but all other co-ordinates were those used in 
Experiment Ia. In all experiments, cannulae were kept patent using 12 mm long 
stainless steel stylets (30 gauge). 
Drugs and chemicals 
For the chronic sub-cutaneous injections, (-)-nicotine hydrogen tartrate (Sigma, Poole, 
UK) was dissolved in distilled water, in a volume of 1 ml/kg body weight and a dose of 
0.1 mg/kg was used; control animals received equal volume injections of distilled 
water. For the central injections, (-)-nicotine hydrogen tartrate and WAY 100,635 
(Sigma, Poole, UK) were dissolved in aCSF (composition as stated in Chapter 3). In 
order to perform antagonism studies, agonist and antagonist compounds were co- 
administered together in a single injection. All injection volumes were 0.5 µl. and 
injections were made over a period of 30 s using a CMA/102 microdialysis pump and 
the needles were left in position for a further 30 s to allow drug diffusion; control 
animals received 0.5 µl infusions of aCSF. All doses are given as free base. 
Behavioural Testing 
Social Interaction Test 
In order to familiarise rats to the social interaction test arena, each rat was placed 
individually in the test arena, under high light conditions of illuminance (300 lux) for a 
5 min familiarisation trial on each of the 2 days prior to social 
interaction testing. In all 
experiments, rats were allocated to pairs, such that members of a pair 
did not differ in 
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weight by more than 10 g. In experiments in which behaviour was assessed after a s. c. 
injection, the treated rat was injected with vehicle or nicotine and tested 30 min later, 
with an untreated rat, and behaviour initiated by the treated rat was scored. Within 
each experiment involving rats with cannulation of the DRN, three minutes after 
central injection, the operated rat was placed together with its unoperated partner in 
the test arena and social interaction initiated by the treated rat was scored. In all 
experiments, social interaction was scored for 4.5 min by an observer blind to the drug 
treatment. Rats were tested between 0830-1300h in an order randomised for drug 
treatment, and the test arena was cleaned with a paper towel after each trial. 
Allocation to drug groups 
In each experiment, the rats were randomly allocated to the treatment groups as 
specified below. The initial dose-response data following intra-DRN nicotine were 
collected from separate experimental test days. Since there were no differences in the 
baseline scores of social interaction in the aCSF treated animals between the different 
days, these control data were pooled. The numbers in parentheses indicate the numbers 
of rats in each group with verified cannulae placements. 
Experiment 1 
(a) Effects of intra-DRN injections of nicotine 
aCSF (n=16); nicotine: 5ng (n=9); lOng (n=4); 100ng (n=5); 1 gg (n=5): 4 gg (n=5). 
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(b) Reversal of the anxiolytic effect of nicotine by WAY 100,635 
aCSF (n=11); nicotine 5ng (n=10); nicotine 5ng + WAY 100,635 200ng (n=9); Way 
10063 5 200ng (n=9) 
Experiment 2 
(a) Effects of DRY injections of nicotine in animals chronically treated with sub- 
cutaneous nicotine 
Animals were randomly allocated to treatment with either vehicle or nicotine (0.1 
mg/kg, s. c. ) for 6 days. On the 7th day, no s. c. injections were given, and the animals 
were challenged with an intra-DRN injection. Animals chronically treated with vehicle 
were randomly allocated to the following DRN injections: aCSF (n=11), nicotine 2.5ng 
(n=8), 5ng (n=10), or 7.5ng (n=7). Animals that were treated with nicotine 0.1mg/kg 
s. c. daily were also tested on the 7th day following a DRN injection of either aCSF 
(n=9), nicotine 2.5ng (n=4), 5ng (n=7), or 7.5ng (n=8). 
(b) Reversal of the anxiogenic response observed following withdrawal from chronic 
nicotine 
Animals were randomly allocated to treatment with either vehicle or nicotine 
(0.1mg/kg, s. c. ) for 7 days. Animals that were chronically treated with vehicle (n=9), 
received an injection of aCSF into the DRN 72h after their last s. c. injection. Animals 
that had received chronic nicotine were split into two groups and received an intra- 
DRN injection of aCSF (n=13), or nicotine 5ng (n=6) 72h following the termination of 
chronic treatment. A final group of animals that had also received 7 days of 0.1 mg/kg 
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nicotine were tested following a s. c. injection of nicotine 0.1mg/kg s. c. (n=6) following 
72h withdrawal from chronic nicotine. 
Histology 
At the end of behavioural testing all animals were sacrificed, the brains removed and 
the injection sites verified histologically (according to the atlas of Paxinos & Watson, 
1986) by a person blind to drug treatment. Cannulae placements that were located 
within the DRN were found to be within the anterior planes of -7.30 to -7.80mm to 
bregma. Figure 7.1 depicting coronal slices through the DRN shows the target sites as 
shaded, and the tips of the injection needles for animals that were excluded (not in the 
target area) by the filled squares. Subjects in which the injection site was located 
outside the DRN were discarded from statistical analysis. 
Statistics 
Data were analysed by one or two-way ANOVA, as appropriate. A comparison 
between individual groups was then made with Fisher's least squared difference (LSD) 
test. When there were significant differences in both measures of anxiety and motor 
activity, ANCOVA were conducted in order to determine the independence of the 
changes. The data and significance levels shown in the tables and figures are those that 
remain after ANCOVA. 
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Figure 7.1 Coronal sections of rat brain showing the target areas (shaded) of the 
dorsal raphe nucleus. Placements falling outside the target area are 
shown by filled squares marking the tip of the injection needle. Values 
give the distance in mm anterior to posterior to bregma, according to the 
atlas of Paxinos & Watson (1986). 
160 
The dorsal raphe nucleus and nicotine tolerance 
7.3 Results 
Experiment 1 
(a) Effects of intra-DRN injections of nicotine 
Infusion of nicotine into the DRN showed dose dependent effects on the time spent in 
social interaction, [F(5,38)=17.04, p<0.0001], and post hoc tests showed that nicotine 
(5 and IOng) significantly increased social interaction, see Figure 7.2. At these same 
doses nicotine had no significant effects on locomotor activity (see Table 7.1), and thus 
seemed to be having a specific anxiolytic effect. However, at the higher dose of 4 µg, 
nicotine significantly decreased social interaction (see Figure 7.2), but this was also 
accompanied by a significant decrease in locomotor activity, see Table 7.1. In cases 
such as this, an analysis of covariance allows one to determine whether these are two 
independent effects or whether the other causes the decrease in one. Nicotine (4µg) 
still significantly decreased social interaction [F(1,18)=12.9, p<0.005] even when 
hypoactivity was accounted for, and thus seemed to be having a specific anxiogenic 
effect. Nicotine no longer had any effect on locomotor activity [F(1,18)=1.5] when the 
decrease in social interaction was accounted for, see Table 7.1. Thus, in this 
experiment the decrease in locomotor activity after nicotine administration was 
secondary to the increase in anxiety elicited by nicotine (4µg). 
(b) Reversal of the anxiolytic effect of nicotine by WAY 100,635 
Once again nicotine (5ng) significantly increased the time spent in social interaction 
[F(1,35)=10.13, p<0.005; Figure 7.3], and this effect was reversed by the specific 5- 
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HT1A antagonist WAY 100,635, which had no effect when administered alone 
[nicotine x WAY 100,635 interaction, F(1,35)=4.83, p<0.05; Figure 7.3]. Neither 
nicotine nor WAY 100,635 changed locomotor activity [F(1,35)<1.0 in both cases; 
Table 7.1]. 
Table 7.1 Mean (± sem) locomotor activity (beam breaks) of rats in Experiments la and 
lb, in the high light, familiar condition in the social interaction test following 
an injection into the dorsal raphe nucleus of (Experiment la) artificial 
cerebrospinal fluid (aCSF) or nicotine (5-4000ng), or (Experiment lb) nicotine 
(5ng) plus WAY 100,635 (200ng), or WAY 100,635 (200ng). n= number of 
rats in each group with verified cannulae placements. +difference compared 
with the appropriate aCSF control group that did not remain significant after 
ANCOVA. 
Drug Treatment Locomotor Activity n 
aCSF 307.06 ± 20.8 16 
Nicotine 5ng 345.11 ± 30.0 9 
Nicotine IOng 277.50 ± 58.8 4 
Nicotine 100ng 306.60 ± 48.5 5 
Nicotine 1000ng (1µg) 383.40 ± 24.6 5 
Nicotine 4000ng (4 µg) 208.95 ± 20.8F 5 
aCSF 333.54 f 23.5 11 
Nicotine 5ng 328.00 f 21.43 10 
Nicotine 5ng and WAY 200ng 315.11 ± 27.93 9 
WAY 200ng 355.66 ±29.5 9 
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Figure 7.2 Mean (± sem) time spent in social interaction by rats in the high light, 
familiar test condition following an injection into the dorsal raphe 
nucleus of artificial cerebrospinal fluid (aCSF) or nicotine (5-4000ng). 
*p<0.05 and **p<0.01 compared with the aCSF control group. 
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Figure 7.3 Mean (± sem) time spent in social interaction by rats in the high light, 
familiar test condition following an injection into the dorsal raphe 
nucleus of artificial cerebrospinal fluid (aCSF), nicotine (5ng) (NIC 
5ng), nicotine (5ng) & WAY 100,635 (200ng) (NIC 5ng + WAY 
200ng), and WAY 100635 (200ng) (WAY 200ng). **p<0.01 compared 
with aCSF control group, ++p<0.01 compared with NIC + WAY group. 
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Experiment 2 
(a) Effect of DRN injections of nicotine in animals chronically treated with sub- 
cutaneous nicotine 
Acute administration of nicotine (2.5 and 5ng) into the DRN significantly increased 
social interaction, but tolerance to these effects was seen in the group pre-treated for 6 
days with nicotine (0.1mg/kg/day s. c. ) [chronic x acute interaction: F(3,56)=3.34, 
p<0.05; see Figure 7.4]. There was no significant effect of either chronic treatment or 
the acute drug treatment on locomotor activity [F(3,56)=1.6; see Table 7.2]. 
(b) Reversal of the anxiogenic response observed following withdrawal from chronic 
nicotine 
As can be seen from Figure 7.5, there was a significant anxiogenic response in the rats 
withdrawn for 72h from 7 days of nicotine treatment (0.1 mg/kg/day). There was no 
significant decrease in locomotor activity in the nicotine withdrawal group (see Table 
7.3), therefore there seems to be a specific anxiogenic effect in these animals. The 
anxiogenic withdrawal response was reversed with nicotine either s. c. or into the DRN 
[F(3,30)=8.07, p<0.0001]. In the latter case, this was accompanied by an increase in 
locomotor activity (Table 7.3). 
Placement Errors 
The scores from animals with placements falling outside the DRN but receiving doses 
of 5-lOng nicotine were low (x = 49.0; range 7-127s). In comparison, the same doses 
in the DRN produced much higher scores (x = 163; range 98-260s). These values 
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Figure 7.4 Mean (± sem) time spent in social interaction by rats in the high light, 
familiar test condition that had been treated for 6 days (chronic 
treatment) with vehicle (VEH) or nicotine (0.1 mg/kg, s. c.; NIC) and 
then tested (test drug) following an injection into the dorsal raphe 
nucleus with artificial cerebrospinal fluid (aCSF) or nicotine (2.5- 
7.5ng). *p<0.05, **p<0.01 compared with rats treated with vehicle for 6 
days and then tested with aCSF in the dorsal raphe nucleus. ++p<0.01 
compared with rats treated with nicotine for 6 days and then tested 
following administration of 5ng of nicotine into the dorsal raphe 
nucleus. 
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Test Drug aCSF aCSF NIC NIC 
(5ng) (s. c. ) 
Figure 7.5 Mean (± sem) time spent in social interaction by rats that were in 72h 
withdrawal following treatment for 7 days (drug withdrawal) with 
vehicle (VEH) or nicotine (0.1 mg/kg, s. c.; NIC) and then challenged 
(test drug) with an injection into the dorsal raphe nucleus of artificial 
cerebrospinal fluid (aCSF), nicotine (5ng) (NIC 5ng), or a s. c. injection 
of nicotine (0.1mg/kg) (NIC s. c. ). Rats were tested in the high light, 
familiar test condition. **p<0.01 compared with animal treated for 7 
days with vehicle and tested following 72h withdrawal with aCSF; 
++p<0.01 compared with rats treated with nicotine for 7 days and then 
tested following 72h withdrawal with administration of either 5ng of 
nicotine into the dorsal raphe nucleus or a s. c. injection of 0.1mg/kg 
nicotine. 
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Table 7.2 Mean (± sem) locomotor activity (beam breaks) of rats that had been treated 
for 6 days with vehicle or nicotine (0.1 mg/kg/day, s. c. ) and then challenged 
with an injection into the dorsal raphe nucleus of artificial cerebrospinal fluid 
(aCSF) or nicotine (2.5-7.5ng). Rats were tested in the high light familiar test 
condition. n= number of rats in each group with verified cannulae placements. 
Drug Treatment Locomotor Activity n 
Pre-treatment: Vehicle 
aCSF 333.54 ± 23.5 11 
Nicotine 2.5ng 329.62 ± 16.2 8 
Nicotine 5ng 328.71 ± 21.4 10 
Nicotine 7.5ng 349.71 ± 4.5 7 
Pre-treatment: Nicotine (0.1 mg/kg s. c) 
aCSF 390.55 t 25.0 9 
Nicotine 2.5ng 311.50 ± 31.3 4 
Nicotine 7.5ng 383.00 t 18.5 7 
Nicotine 7.5ng 349.62 ± 35.6 8 
Table 7.3 Mean (± sem) locomotor activity (beam breaks) of rats withdrawn for 72h 
following treatment for 7 days with vehicle or nicotine (0.1 mg/kg/day, s. c. ). 
On the test day animals received an injection into the dorsal raphe nucleus of 
artificial cerebrospinal fluid (aCSF) or nicotine (5ng) or nicotine (0.1mg/kg, 
s. c. ). n= number of rats in each group with verified cannula placement where 
applicable. *p<0.05 compared with the chronic nicotine group tested following 
intra-DRN aCSF. 
Chronic treatment Treatment at test Locomotor Activity n 
Vehicle aCSF 282 ± 31.0 9 
Nicotine aCSF 240 ± 14.5 13 
Nicotine Nicotine 5ng 343 f 42.9* 6 
Nicotine Nicotine 0.1mg/kg s. c. 261 f 25.1 6 
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7.4 Discussion 
The present study demonstrated that in the social interaction test, administration of low 
doses of nicotine into the DRN induced anxiolytic effects, which were not 
accompanied by changes in locomotor activity, suggesting that nicotine was acting 
specifically to reduce anxiety. This effect was completely reversed by co- 
administration of a behaviourally inactive dose of the 5-HT1A receptor antagonist, 
WAY 100,635. Previously it has been demonstrated that the anxiogenic effects of 
nicotine seen in the social interaction test and elevated plus maze following intra- 
hippocampal or intra-septal administration are also reversed by co-administration of 
WAY 100,635 (Cheeta et al, 2000a; Kenny et al, 2000b). Therefore, these findings 
suggest that the link between the 5-HTIA receptors and nicotinic receptors in mediating 
the anxiogenic actions of nicotine, also extends to the DRN mediated anxiolytic action 
of nicotine. This finding adds to growing evidence that there may be a rather general 
5-HTlA-nicotinic receptor interaction in mediating certain behavioural effects of 
nicotine (Rasmussen et al, 1997; Damaj et al, 1994; Riekkinen et al, 1994; Hilleman et 
al, 1994,1992; West et al, 1991). 
Previously it has been demonstrated that DRN administration of the 5-HTIA receptor 
agonist, 8-OH-DPAT in the social interaction test induced an anxiolytic effect similar 
to that seen with nicotine (Hogg et at, 1994; Higgins et at, 1988). The mechanism that 
has been assumed to mediate the anxiolytic effects of 8-OH-DPAT is via stimulation of 
the 5-HT autoreceptors in the raphe nucleus leading to a reduction in 5-HT neuronal 
firing (Sprouse & Aghajanian, 1987), and a subsequent decrease in 5-HT release in 
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terminal regions of the limbic system. Nicotine stimulates the release of 5-HT in the 
DRN (Mihailescu et al, 1998), and the reversal of its anxiolytic effect by WAY 
100,635 suggest that this action is mediated by indirectly stimulating the 
somatodendritic 5-HT1A receptors. A recent study provides physiological evidence in 
support of this proposition, since it was demonstrated that i. v. nicotine administration 
reduced dorsal raphe firing in anaesthetised rats, an effect which could also be 
antagonised by WAY 100,635 (Engberg et al, 2000). However, they found no effect of 
nicotine on 5-HT firing when it was microiontophorised into the DRN. Nevertheless, 
with this technique, only very small amounts of nicotine are released, and this is 
unlikely to activate the receptors on the afferent 5-HT terminals on which nicotine 
induced 5-HT release occurs. The anxiogenic effect of the high dose of nicotine (4µg) 
into the DRN may result from an action at heteroreceptors leading to the release of 
other neurotransmitters such as noradrenaline. Alternatively, it could be the result of 
diffusion of nicotine outside the DRN and into surrounding structures. This diffusion 
could explain the lack of effect seen with intermediate doses of nicotine, since an 
anxiogenic effect mediated by these areas adjacent to the DRN could counteract the 
anxiolytic effect mediated within the DRN. The low scores from animals where the 
cannula placements fell outside the DRN would strengthen this possibility. A similar 
result was seen with the 5-HTIA agonist 8-OH-DPAT. This had an anxiolytic effect 
when administered in the DRN, but a marked anxiogenic effect when the placements 
fell outside (Gonzalez & File, 1997; File & Gonzalez, 1996). 
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In the present study, we have identified the DRN as a crucial neuroanatomical substrate 
involved in mediating the development of tolerance to nicotine's anxiolytic actions. 
Rapid tolerance was shown by a lack of response to intra-DRN nicotine (2.5 and 5ng) 
in chronically treated animals. Chronic nicotine treatment also did not change the 
response to a challenge with 7.5ng nicotine. However, Stolerman et al (1974) reported 
that one single previous systemic administration of nicotine (0.75 mg/kg i. p. ) could 
produce a shift to the right of the dose response curve for a second dose by a factor of 
about 2.4, which is similar to our results. In the study investigating tolerance to 
nicotine's anxiolytic actions, acutely administered 7.5ng nicotine was without effect, 
although an anxiolytic effect was reported following lOng nicotine in the initial dose 
response study. Therefore, there does seem to be a small difference in sensitivity to 
nicotine in these two experiments, although social interaction scores in the aCSF 
treated controls groups did not differ between these two experiments. However, an 
anxiolytic effect following 5ng nicotine was consistently observed in all experiments 
suggesting this to be an optimum dose within an approximate dose range. 
The anxiogenic response seen 72h after the end of chronic treatment seems to be a 
withdrawal response, because it could be reversed by either sub-cutaneous or intra- 
DRN nicotine. The existence of a withdrawal response is evidence of an oppositional 
mechanism of tolerance. A down-regulation or desensitisation of nicotinic or 5-HT1A 
receptors could account for the development of tolerance, but would not result in 
anxiogenic response when the drug was withdrawn. Alternatively, tolerance could be 
mediated by a compensatory change such as increased firing of the raphe neurones, 
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which would lead to increased release when the nicotine was withdrawn. This 
increased release in projection areas, such as the lateral septum, would lead to an 
anxiogenic response (Cheeta et al, 2000b). A similar mechanism in the median raphe 
nucleus has been shown to mediate the anxiogenic response that occurs on withdrawal 
from chronic benzodiazepine treatment (Andrews et al, 1997). In this case, it was 
shown that during benzodiazepine withdrawal there was enhanced sensitivity to 8-OH- 
DPAT in the median raphe. Rasmussen & Czachura (1997) have shown that during 
nicotine withdrawal there is enhanced sensitivity to the inhibitory effects of 8-OH- 
DPAT on DRN firing, suggesting that withdrawal from nicotine results in increased 
DRN firing and subsequent 5-HT release. 
In summary, the results from the present series of experiments, suggest that the 
anxiolytic effects of nicotine in the social interaction test are mediated by the 5-HT1A 
receptors in the DRN. Changes in this structure also mediate the development of 
tolerance to the effects of nicotine and the anxiogenic response that is detected during 
nicotine withdrawal. Evidence from other experiments suggests that this withdrawal 
response might also be mediated by 5-HT1A receptors. Therefore, further studies are 
needed to investigate the role of the 5-HTIA receptors in the development of tolerance 
and the expression of nicotine withdrawal responses. If the above hypothesis is correct for 
the anxiogenic effect seen after termination of nicotine treatment it would be interesting to 
investigate if the effect could be reversed by administration of WAY 100,635 into the dorsal 
hippocampus or lateral septum. 
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CHAPTER 8 
The role of the dorsal hippocampus in the development of 
tolerance to nicotine's anxiogenic effect 
in the social interaction test 
8.1 Introduction 
The dorsal hippocampus was found to be one brain region mediating the anxiogenic 
effect of nicotine in the social interaction test (File et al., 1998). The 5-HT1A receptors 
were implicated in this action, because co-administration into the dorsal hippocampus 
of the 5-HT1A receptor antagonist, WAY 100,635, reversed the anxiogenic effect of 
nicotine (Kenny et al., 2000a). Furthermore, it has been shown that nicotine increases 
5-HT release in the dorsal hippocampus (Kenny et al., 2000b) and that glycine 
significantly enhances this action of nicotine (File et al., 2000b). 
In the social interaction test, anxiogenic effects have been found 30 min after systemic 
administration of high (0.5 &1 mg/kg) doses of nicotine (File et al., 1998). 
Interestingly, an anxiogenic effect was also found 5 min after a low (0.1 mg/kg) dose 
of nicotine (Chapter 2), a dose that has an anxiolytic effect 30 min after systemic 
injection. After 7 days of nicotine treatment (0.1 mg/kg/day), tolerance developed to 
the anxiogenic and anxiolytic effects of subcutaneous administration of this dose 
(Chapter 2), and to the anxiolytic effects of administration of nicotine into the DRN 
(Chapter 7). The purpose of the present experiment was to explore whether this same 
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pre-treatment regimen resulted in tolerance to the anxiogenic effect of nicotine 
administered into the dorsal hippocampus. Animals were therefore treated for 6 days 
with nicotine (0.1 mg/kg, s. c. ) or vehicle and then tested in the social interaction test 
after a dorsal hippocampal injection with nicotine. The dose selected for hippocampal 
administration was 1µg, which has been shown in previous studies to be a dose that 
elicits an anxiogenic effect (Kenny et al., 2000a; File et al., 1998). In order to 
investigate a possible mechanism underlying the development of tolerance to the 
anxiogenic effect of nicotine in the dorsal hippocampus, [3H]-5-HT release was 
measured in superfused dorsal hippocampal slices taken from rats treated for 6 days 
with nicotine (0.1 mg/kg, s. c. ), in order to determine whether tolerance developed to 
the effects of nicotine on [3H]-5-HT release in this area. 
8.2 Materials and Methods 
Animals 
Male hooded Lister rats (Charles River, Margate, Kent, UK) weighing between 220- 
250g were housed singly. Rats that had undergone surgery were allowed to recover 
for 4 days prior to the start of chronic injections. Food and water were freely available, 
and the room in which they were housed was lit with dim light and maintained at 22°C. 
Lights were on from 0700-1900h. 
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Apparatus 
The social interaction test, see Chapter 2 for description. 
Surgery 
Surgery was conducted as described in Chapter 3. 
Drugs and chemicals 
For the chronic subcutaneous injections, (-)-nicotine hydrogen tartrate (Sigma, Poole, 
UK) was dissolved in distilled water, in a volume of 1 ml/kg body weight and a dose of 
0.1 mg/kg was used; control animals received equal volume injections of distilled 
water. For the central injections, (-)-nicotine hydrogen tartrate was dissolved in aCSF. 
Injections were O. 5µ1, and were made over a period of 30s using a CMA/102 
microdialysis pump (Biotech Instruments Ltd, Stockholm, Sweden) and the needles 
were left in position a further 30s to allow drug diffusion; control animals received 
O. 511 infusions of aCSF. All doses are given as free base. 
[3H]-5-HT creatine sulphate was obtained from Amersham International (Amersham, 
Buckinghamshire, UK). Krebs bicarbonate buffer of the following composition was 
used (mM): NaCl 118, KC14.8, CaC12 2.5, MgSO4 1.2, NaHCO3 25, KH2P04 1.2 and 
glucose 9.5. The medium was gassed continuously with 95% 02 / 5% CO2 and 
contained (µM) pargyline 50, ascorbic acid 100 and EDTA 35. 
176 
The dorsal hippocampus and nicotine tolerance 
Behavioural Testing 
Effect of a dorsal hippocampal injection of nicotine after chronic nicotine treatment 
Animals were randomly allocated to treatment with either vehicle or nicotine (0.1 
mg/kg, s. c. ) for 6 days. Within each of the two chronic treatment groups, animals were 
randomly allocated to the following hippocampal injection groups: aCSF or (-)nicotine 
(1µg). The numbers in each group ranged from 7-9 after verification of the cannula 
placements. On the 7th day, no s. c. injections were given but rats were tested with an 
unoperated, uninjected partner in the social interaction test 3 min after a bilateral 
injection into the hippocampus. Only interactions initiated by the operated rats were 
scored. 
Histology 
At the end of behavioural testing all animals were sacrificed, the brains removed and 
the injection sites verified histologically (according to the atlas of Paxinos & Watson, 
1986) by a person blind to drug treatment. Figure 8.1, depicting coronal slices through 
the dorsal hippocampus, shows the target site and the positions of the tips of the 
injection needles for the rats excluded from statistical analysis because of placement 
errors. 
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Figure 8.1 Diagrammatic representation of coronal sections (3.14 to 3.6 mm 
posterior to bregma) through the rat brain showing the area of 
placements accepted as falling within the dorsal hippocampus (shaded). 
Placements falling outside the target area are shown by filled circles 
marking the tip of the injection needle (data from these rats were 
excluded from analysis). 
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Measurement of release 
Twelve animals were randomly allocated to two groups (n = 6/group): vehicle or 
nicotine (0.1 mg/kg, s. c. ). Animals were given daily injections of vehicle or nicotine 
for 6 days and on the 7th day were killed and the effect of nicotine (50,100 and 
200µM) on the release of [3H]-5-HT from superfused slices of dorsal hippocampus was 
examined. 
Tissue Preparation 
Rats were stunned and killed by cervical dislocation. The brain was rapidly removed 
and the hippocampus dissected. Slices (0.2 mm) of the dorsal hippocampus were cut 
using a Macllwain tissue chopper (Mickle Lab. Engineering Co., Gomshall, Surrey, 
UK) and the tissues (five slices equating to approximately 10-15 mg wet weight) 
incubated separately in 5 ml Krebs bicarbonate medium at 37°C for 10 min. [3H]-5-HT 
was then added to the medium to give a final concentration of 90nM and the incubation 
was continued for another 30 min. Following incubation the slices were recovered and 
transferred to a superfusion chamber. 
Superfusion and Release 
The hippocampal slices were placed between two filter disks (GFB) in chambers (0.25 
ml volume) of a Brandel SF-06 superfusion system and superfused with oxygenated 
(95% 02 / 5% C02) bicarbonate medium at a rate of 0.5 ml/min for 30 min to obtain a 
consistent resting rate of fractional release. Following this washout period, samples of 
the superfusate were collected every 2 min. The effect of nicotine on the release of 
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[3 H]-5-HT was measured by exposing the tissue slices to the drug for 2 min. At the 
end of the experiment, the tissue slices were dissolved in 1 ml soluene (Packard) 
followed by addition of 200µM, glacial acetic acid (Sigma) and 3 ml scintillation fluid 
(Ultima Gold-XR; Packard). The radioactivity in each fraction was measured by liquid 
scintillation counting (LKB Wallac, 1214 Rackbeta). The efflux of radioactivity was 
expressed as the fractional rate coefficient (FRC = radioactivity released during a 
particular fraction, expressed as a percentage of the total amount of radioactivity 
present in the slices at that time). Basal resting release was taken as the mean FRCs of 
the two fractions prior to drug superfusion (Si), while nicotine-evoked release was 
defined as the maximum FRC after drug superfusion (S2). Nicotine-evoked increases 
in basal release was determined by statistically analysing the magnitude of S2 values 
compared to Si values. In Figure 8.3 all nicotine-evoked increases in release are 
expressed as percentage increases above baseline, calculated by determining the % 
increase in S2 values above Si values. 
Statistics 
The scores from the behavioural tolerance study were analysed with two-way ANOVA 
with chronic treatment and acute hippocampal injection as the two factors. 
Comparisons with individual groups were then made with Fisher's post-hoc tests, and 
it is the significances of these that are shown in the figures and the tables. 
For the measurement of release, the increase from the baseline of the nicotine-evoked 
release was analysed by single factor repeated measures for each dose of nicotine. The 
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difference between the chronic vehicle and nicotine groups was analysed by two-way 
ANOVA with chronic treatment and dose of nicotine as the two factors. Comparisons 
between the individual groups were then made with Fisher's post-hoc tests. 
8.3 Results 
Effect of a dorsal hippocampal injection of nicotine after chronic nicotine treatment 
Figure 8.2 shows that chronic nicotine treatment significantly modified the response to 
nicotine when directly administered into the dorsal hippocampus in the social 
interaction test [chronic x acute interaction: F(1,28)=4.0, p=0.05]. Thus, acute 
administration of nicotine (1µg) into the dorsal hippocampus significantly decreased 
the time spent in social interaction, and tolerance was seen to this effect following pre- 
treatment for 6 days with nicotine (0.1 mg/kg; s. c. ). Although there was some 
reduction in locomotor activity with acute nicotine administration in the vehicle pre- 
treated rats, there was no overall significant effect of either acute or chronic nicotine 
treatment after dorsal hippocampal administration on locomotor activity [F(1,28)=2.4, 
F(1,28)=1.0, respectively] or rears [F(1,28)=0.6, F(1,28)=0.5, respectively], see Table 
8.1. 
Effect of nicotine on rat dorsal hippocampal (HJ-5-HT release after chronic nicotine 
treatment 
Nicotine stimulated a significant dose-related increase in [3H]-5-HT release from 
dorsal hippocampal slices, but this effect was significantly lower in slices taken from 
rats that had been chronically treated with nicotine [F(1,31)=20.6, p<0.01], indicating 
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the development of tolerance to the effects of nicotine on 5-HT release, see Figure 8.3. 
There were no significant differences between the baseline levels of [3H]-5-HT release 
for all the animals, which ranged from 0.89-0.96 frc. 
Table 8.1 Mean (± sem) locomotor activity (beam breaks) of rats pre-treated for 6 days 
with vehicle or nicotine (0.1 mg/kg, s. c. ) and then on the 7`h day challenged 
with bilateral injection into the dorsal hippocampus with aCSF or nicotine 
(1µg). Rats were tested in the high light familiar (HF) test condition, 3 min 
after central injection. 
Locomotor Activity 
Pre-treatment: Vehicle 
aCSF (n=9) 298.3 ± 20.5 
1 µg (n=7) 233.9 ± 25.6 
Pre-treatment: Nicotine (0.1 mg/kg, s. c. ) 
aCSF (n=9) 301.4 ± 26.9 
1 µg (n=7) 313.1 ± 31.9 
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Figure 8.2 Mean (± sem) time (s) spent in social interaction by rats that had been 
treated for 6 days with vehicle or nicotine (0.1 mg/kg, s. c. ) and then 
challenged with bilateral injection into the dorsal hippocampus with 
either aCSF or nicotine (1µg). Rats were tested in the high light familiar 
(HF) test condition, 3 min after hippocampal injection. ** p<0.01 
compared with all other groups. 
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Figure 8.3 Mean (± sem) % increase in basal [3H]-5-HT release evoked by nicotine 
(50,100 and 200µM) from rat dorsal hippocampal slices from rats that 
had been treated for 6 days with vehicle (A) or nicotine (0.1 mg/kg, s. c.; 
B). * p<0.05 and ** p<0.01 compared with the baseline release, and 
p<0.05 and ++ p<0.01 compared with both the baseline release and the 
nicotine evoked release in vehicle treated animals. 
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8.4 Discussion 
Previous studies established the importance of the dorsal hippocampus as one area 
mediating the anxiogenic effect of nicotine in the social interaction test (File et al., 
1998). In this study, a decrease in social interaction was observed after a dorsal 
hippocampal injection of nicotine without any change in locomotor activity, indicating 
that nicotine was having a specific anxiogenic effect, as seen previously. After 6 days 
of subcutaneous nicotine injections, tolerance occurred to this anxiogenic effect and 
again no significant change in locomotor activity emerged. The animals that had been 
chronically treated with nicotine but that were tested after aCSF injections into the 
hippocampus were in 24h withdrawal from nicotine. These animals showed no change 
in social interaction or locomotor activity, and thus there was no indication of a 
withdrawal responses at this time-point. However, an increase in anxiety has been 
found in the social interaction test 72h after 7 or 14 days of nicotine (0.1 mg/kg; s. c. ) 
treatment (Chapter 2). Thus, the results of the present study demonstrate that tolerance 
can be observed in the social interaction test at a time-point at which no withdrawal 
responses are found. An oppositional mechanism of tolerance is one that involves the 
progressive recruitment of processes that oppose the acute effect of the drug. Thus, 
following withdrawal of the drug these processes work unopposed and a behavioural 
response is seen in the opposite direction of the acute drug effect (Young and Goudie, 
1995). As no withdrawal response was observed it suggests that the underlying 
mechanism is unlikely to be an oppositional one. 
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The present results demonstrate that the dorsal hippocampus is an area crucially 
concerned with mediating the development of tolerance to the anxiogenic effect of 
nicotine. Nicotinic acetylcholine receptors (nAChRs) are situated predominantly on 
presynaptic terminals in the brain where they modulate the release of many 
neurotransmitters, including 5-HT (Vizi and Kiss, 1998; Wonacott, 1997). Previously 
it has been suggested that the anxiogenic effect of nicotine in the dorsal hippocampus 
is mediated by nicotine's action at heteroreceptors on the 5-HT terminals, causing an 
increase in 5-HT release (File et al., 2000b) and an activation of post-synaptic 5-HT1A 
receptors, because the 5-HT1A receptor antagonist WAY 100,635 can reverse the 
anxiogenic effect of nicotine (Kenny et al., 2000b). After 6 days of nicotine pre- 
treatment there was a significant attenuation of the ability of nicotine to stimulate 5-HT 
release in the dorsal hippocampus, which could have arisen as a result of receptor 
desensitisation (Radcliffe et al., 1999). This decreased effect of nicotine on the release 
of 5-HT from the terminals could be sufficient to mediate tolerance to the anxiogenic 
effect observed after nicotine injection into the dorsal hippocampus, and could account 
for the development of tolerance without the incidence of a withdrawal response. 
Rather high concentrations of nicotine are needed to evoke 5-HT release from dorsal 
hippocampal slices and the nAChRs are more sensitive to the nicotinic agonists, 
dimethylphenylpiperazine and lobeline, than to nicotine (Lendvai et al., 1996). 
However, there are two factors that are likely to enhance this effect in vivo, especially 
in conditions that evoke anxiety. With an increase in anxiety, it has been shown that 
there is an increase in 5-HT and glycine release in the dorsal hippocampus (File et al., 
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1987b) and both these factors will enhance nicotine's effects on 5-HT release (File et 
al., 2000b). The effects of nicotine on 5-HT release are most likely to be seen in vivo 
following high systemic doses of nicotine (0.5 and 1.0 mg/kg) and by 1µg injected 
directly into the dorsal hippocampus, all of which have been shown to have anxiogenic 
effects (File et al., 1998). 
Previous studies have shown that a relatively short period of treatment with a low dose 
of nicotine is sufficient to lead to the development of tolerance to both the anxiogenic 
and anxiolytic effects of systemic nicotine (Chapter 2), and to the anxiolytic effects of 
central injections of nicotine (Chapter 7). The present study has shown that tolerance 
can also be seen to the anxiogenic effect of central injections of nicotine after the same 
chronic nicotine treatment regime. At present, it is not clear whether the mechanism 
and brain regions mediating the anxiogenic effects of high doses (0.5 and 1.0 mg/kg) 
are the same as those mediating the anxiogenic effect observed 5 min after the 0.1 
mg/kg dose. In order to determine this, further experiments are needed, in which 
antagonists are injected into specific brain regions, following systemic injections of 
nicotine. So far, both the dorsal hippocampus and the lateral septum have been 
identified as areas mediating anxiogenic effects (Cheeta et al., 2000a, b; Kenny et al., 
2000b; Ouagazzal et al., 1999a, b; File et al., 1998). 
In summary, the results from the present series of experiments suggest that changes in 
the dorsal hippocampus mediate the development of tolerance to the anxiogenic effects 
of nicotine. A possible mechanism for the tolerance that is seen is an attenuation of the 
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ability of nicotine to stimulate 5-HT release in the dorsal hippocampus after 6 days of 
nicotine treatment. 
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CHAPTER 9 
Tolerance to midazolam's anxiolytic effects in the social 
interaction test after short-term nicotine treatment 
9.1 Introduction 
Benzodiazepines are still widely used as anxiolytics, despite concerns about the 
development of dependence (Argyropoulos and Nutt, 1999). In a clinical situation it is 
difficult to determine whether tolerance develops to their anxiolytic effects, but in 
several animal tests of anxiety it has been shown to develop after about 3 weeks of 
treatment (Fernandes and File, 1999; Fernandes et al., 1999; Chopin et al., 1993; File et 
al., 1987a; Treit, 1985; Vellucci & File, 1979). Nicotine has been shown to have 
anxiolytic effects in non-smoking young women exposed to mild stress (File et al 
2000a; Netter et al 1998) and in several animal tests (Chapter 2; File et al., 1998; Cao 
et al., 1993; Brioni et al., 1993; Costall et al., 1989b; Vale and Green, 1986). However, 
in contrast to the benzodiazepines, tolerance develops much more quickly. After 6 days 
of treatment with nicotine (0.1 mg/kg/day; s. c. ) tolerance develops to the anxiolytic 
effects in the social interaction test after been probed on the 7th day with either a 
subcutaneous or central injection of nicotine (Chapters 2 and 7). 
It is possible that many smokers will be receiving benzodiazepine medication as there 
is an increased incidence of anxiety disorders among smokers (Breslau et al., 1991), 
and 64% of adolescent girls say smoking makes them feel calmer (McNeill et al., 
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. 1997). The purpose of the present study was therefore to 
determine whether a short 
period of nicotine pre-treatment modified the anxiolytic effects of benzodiazepines. 
We decided to probe the anxiolytic efficacy of the benzodiazepines after direct 
administration to the brain, since there is evidence of a possible pharmacokinetic 
interaction between chronic nicotine and benzodiazepines (Smith et al., 1983; Norman 
et al, 1981). The dorsal hippocampus and the DRN are two brain sites that mediate the 
anxiolytic effects of benzodiazepines (Nazar et al., 1999; Gonzalez et al., 1998; 
Gonzalez and File, 1997; Stefanski et al., 1993; Thiebot et al., 1982). The effects of 
nicotine on anxiety are somewhat different in these two regions. Low doses are 
anxiolytic in the DRN, but silent in the dorsal hippocampus, and high doses are 
anxiogenic in both regions (Chapter 7; Cheeta et al., 2000a; File et al., 1998). After 
one week of nicotine treatment there is tolerance to the anxiolytic effects in the DRN 
and to the anxiogenic effects in the dorsal hippocampus (Chapters 7 and 8). These two 
brain areas were selected to probe the efficacy of midazolam in the social interaction 
test of anxiety, after one week of nicotine pre-treatment. 
This study also investigated whether there were any changes in benzodiazepine 
receptor binding in these brain areas as a result of chronic nicotine treatment. The 
binding was conducted at two concentrations in order to obtain an estimate of whether 
any changes were in receptor affinity or density. 
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9.2 Materials and Methods 
Animals 
Male hooded Lister rats (Charles River, Margate, Kent, UK) weighing between 220- 
250g were housed singly. Rats that had undergone surgery were allowed to recover 
for 4 days prior to the start of chronic injections. Food and water were freely available, 
and the room in which they were housed was lit with dim light and maintained at 22°C. 
Lights were on from 0700-1900h. 
Apparatus 
The social interaction test, see Chapter 2 for description. 
Surgery 
Surgery was conducted as described in Chapters 3 and 7. 
Drugs and chemicals 
For the chronic sub-cutaneous injections, (-)-nicotine hydrogen tartrate was dissolved 
in distilled water, in a volume of 1 ml/kg body weight and a dose of 0,1 mg/kg was 
used; control animals received equal volume injections of distilled water. All doses are 
given as free base. For the intracerebral injections midazolam maleate (kindly donated 
by Roche products Ltd, Welwyn Garden City, UK) was dissolved in 0.9% sodium 
chloride (NaCl) solution. Injections were O. 5pl, and were made over a period of 30s 
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using a CMA/102 microdialysis pump and the needles were left in position a further 
30s to allow drug diffusion; control animals received 0.5µl infusions of 0.9% NaCl. 
[3H]Flunitrazepam (85 Ci/mmol; DuPont, NEN, Stevenage, UK) was diluted to the 
appropriate concentration using ice cold 50mM Tris HCI. Diazepam (Sigma, UK) was 
made up as a1 mg/ml stock solution by dissolving in ethanol and then diluted to the 
appropriate concentration using ethanol. 50mM ice cold buffer was made from Tris 
HCI and Tris base purchased from Sigma (Poole, Dorset, UK). 
Behavioural Testing 
Animals were randomly allocated to a6 day pre-treatment with either vehicle (n=52) or 
nicotine (0.1 mg/kg, s. c.; n=43) for 6 days. On the 7th day, no s. c. injections were 
given and within each of the two chronic treatment groups, animals were randomly 
allocated to the following dorsal hippocampal injection groups: 0.9% NaCl; midazolam 
(2µg, 4µg or 8µg), and to the following DRN injection groups: 0.9% NaCl; midazolam 
(4µg or 8µg). The numbers of rats in each group after verification of cannula 
placements are shown in Table 9.1. On the test day each operated animal was allocated 
to an unoperated/undrugged test partner that was matched in weight (± 10g). 
In order to familiarise the rats with the social interaction test arena, each rat was 
placed singly in the test arena, under high light conditions of illuminance (300 lux) 
arena, on the 2 days prior to testing, for a5 min familiarisation trial. In both 
experiments, the operated rat was placed together with its unoperated partner in the test 
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arena, three minutes after central injection, and only social interaction initiated by the 
operated animal was scored. Social interaction was scored for 4.5 min by an observer 
blind to the drug treatment. Rats were tested between 0900 and 1230h in an order 
randomised for drug treatment, and at the end of each trial the arena was wiped with a 
damp cloth and faecal pellets removed. 
Histology 
At the end of behavioural testing all animals were sacrificed, the brains removed and 
the injection sites verified histologically (according to the atlas of Paxinos & Watson, 
1986) by a person blind to drug treatment. Figures 9.1 and 9.2, depicting coronal slices 
through the DH and DRN, show the target site and the positions of the tips of the 
injection needles for the rats excluded from statistical analysis because of placement 
errors. 
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Figure 9.1 Diagrammatic representation of coronal sections (3.14 to 3.6 mm 
posterior to bregma) through the rat brain showing the area of 
placements accepted as falling within the DH (shaded). Placements 
falling outside the target area are shown by filled circles marking the tip 
of the injection needle (data from these rats were excluded from 
analysis). 
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Figure 9.2 Diagrammatic representation of coronal sections (7.3 to 7.8 mm 
posterior to bregma) through the rat brain showing the area of 
placements accepted as falling within the DRN (shaded). Placements 
falling outside the target area are shown by filled circles marking the tip 
of the injection needle (data from these rats were excluded from 
analysis). 
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Measurement of binding 
Animals were randomly allocated to treatment for 7 days with either vehicle or nicotine 
(0.1 mg/kg/day; s. c. ). Animals were sacrificed 30min after their last injection by 
decapitation and their brains removed, and the hippocampus (vehicle, n=6; nicotine, 
n=5) and mid-brain (vehicle, n=6; nicotine, n=7) dissected. These brain regions were 
frozen in an isopentane dry ice bath and stored in a -80°C freezer until needed. 
Membrane Homogenate Preparation 
Frozen brain tissue was defrosted, weighed and suspended in 15mis of ice cold distilled 
water. Each sample was then homogenised using a polytron homogeniser at maximum 
setting for IOs. The homogenate was then centrifuged at 3 8000g for 20 min at 4°C. The 
supernatant was discarded and the pellet was resuspended in 15 mis of 50mM Tris HCl 
and homogenised. The homogenate was then centrifuged at 38000g for 30 min at 4°C. 
This step was repeated a further three times. The final sample was then suspended in 
10mis of 50mM Tris HCl and frozen. When needed, the sample was defrosted and the 
volume made up to 15mis and re-spun at 38000g for 30 min at 4°C. 
[3HJFlunitrazepam Binding Assay 
Aliquots (75µg protein/ml final concentration) of membrane suspension were 
incubated with either 2 or 10 nM [3H]flunitrazepam, corresponding to the KD and BMAX 
concentrations respectively, in a final volume of 0.5m1 for lh on ice. Non-specific 
binding was determined in the presence of 3µM diazepam. Specific and non-specific 
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binding were both performed in triplicate. Following incubation, the samples were 
filtered by vacuum filtration through Whatman GF/B glass fibre filters using a Brandel 
cell harvester (Semat, Hertfordshire, UK) and washed 3 times with 4mls ice cold 
50mM Tris HCl in order to separate bound from free ligand. The filter paper was pre- 
soaked in 0.05% polyethylenimine to inhibit non-specific binding. The filters were 
then put into scintillation vials with 4mls of Packard Emulsifier safe scintillation fluid 
and mixed. The radioactivity of the samples was measured using liquid scintillation 
counting (LKB Wallac, 1214 Rackbeta) and the amount of specific binding of ligand 
determined (as fmol/mg protein) from this. 
Protein Assay 
Protein concentrations were assessed in duplicate using Comassie Plus protein assay 
reagent (Pierce) and measuring absorbance at 595nm. Bovine serum albumin was used 
as the protein standard. 
Statistics 
The behavioural scores were analysed with two-way analyses of variance (ANOVA) 
with chronic treatment and acute DRN or DH injections as the two factors. 
Comparisons with individual groups were then made with least significance difference 
(LSD) post-hoc tests, and it is the significances of these that are shown in the figures 
and the tables. The specific binding (fmol/mg protein) was analysed by one-way 
ANOVAs and it is the significances of these that are shown in the figures. 
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9.3 Results 
Effects of midazolam in the DH and DRN 
It can be seen from Figures 9.3 and 9.4 that microinjection of midazolam into the DH 
and DRN significantly (p<0.01) increased social interaction in the vehicle-pre-treated 
rats. There were no changes in locomotor activity (see Table 9.1) and thus midazolam 
had clear anxiolytic effects in both brain regions. The nicotine pre-treatment 
significantly modified these anxiolytic effects (p<0.01 in both cases) and only 4µg 
midazolam in the DRN retained any anxiolytic efficacy. 
Effects on [3HJFlunitrazepam binding 
Nicotine treatment significantly decreased [3H]flunitrazepam binding in the DH at both 
2 and 10 nM (p<0.05, in both cases), see Figure 9.5. The ratio of binding seen at both 
2 and 10 nM in nicotine pre-treated animals was not significantly different (p>0.05) to 
that seen in vehicle pre-treated animals, suggesting it is most likely that the decreased 
binding is due to a decrease in receptor density. Nicotine treatment did not change 
[3H]flunitrazepam binding in the midbrain at either concentration, see Figure 9.5. 
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Figure 9.3 Mean (± sem) time (s) spent in social interaction by rats that had been 
treated for 6 days with vehicle or nicotine (0.1 mg/kg, s. c. ) and then 
challenged with bilateral injection into the DH with either 0.9% NaCl or 
midazolam (2µg, 4µg and 8µg). Rats were tested in the high light 
familiar (HF) test condition, 3 min after hippocampal injection. ** 
p<0.01 compared with the vehicle control, ++ p<0.01 compared with 
animals treated chronically with vehicle for 6 days and then challenged 
with 2µg, 4µg and 8µg midazolam in the DH on the 7th day. 
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Test Drug aCSF NUD (4µg) MID (8 tg) 
Figure 9.4 Mean (± sem) time (s) spent in social interaction by rats that had been 
treated for 6 days with vehicle or nicotine (0.1 mg/kg, s. c. ) and then 
challenged with unilateral injection into the DRN with either 0.9% NaCl 
or midazolam (4µg and 8µg). Rats were tested in the high light familiar 
(HF) test condition, 3 min after DRN injection. ** p<0.01 compared 
with the vehicle control, ++ p<0.01 compared with animals treated 
chronically with vehicle for 6 days and then challenged with 4µg and 
8µg midazolam in the dorsal hippocampus on the 7t' day. 
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Table 9.1 Mean (± sem) locomotor activity (beam breaks) made by rats that had been 
treated for 6 days with vehicle or nicotine (0.1 mg/kg, s. c. ) and then challenged 
with bilateral injection into the DH with either 0.9% NaCI or midazolam (2µg, 
4µg and 8µg), or unilateral injection into the DRN with either 0.9% NaCI or 
midazolam (4µg and 8µg). Rats were tested in the high light familiar (HF) test 
condition, 3 min after injection. The numbers in parentheses are the number of 




0.9% NaCl 190.9 ± 25.0 (7) 280.6 ± 20.9 (14) 
2µg 254.4 ± 16.9 (5) nd 
4µg 209.9 ± 28.2 (6) 259.7 ± 20.1 (6) 
8µg 216.2 ± 23.5 (5) 260.1 ± 9.1 (9) 
Pre-treatment: Nicotine (0.1 mg/kg, s. c. ) 
0.9% NaCl 191.6 ± 18.0 (5) 285.6 ± 24.7 (8) 
2µg 196.5 ± 12.5 (6) nd 
4µg 251.0 ± 33.4 (6) 294.4 t 17.5 (7) 
8µg 297.0 ± 28.3 (6) 247.8 f 19.6 (5) 
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Figure 9.5 Mean (± sem) specific binding (fmol/mg protein) of [3H]-Flunitrazepam 
binding to dorsal hippocampal and midbrain membranes of rats that had 
been- treated for 7 days with vehicle or nicotine (0.1 mg/kg, s. c. ). 
*p<0.05 compared with vehicle control. 
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9.4 Discussion 
The present study demonstrated that, in the social interaction test, administration of 
midazolam to the DH and DRN had significant anxiolytic effects in vehicle pre-treated 
animals. These anxiolytic effects were not dose-dependent, but this was probably due 
to the supra-maximal doses of midazolam that were used. These high doses were used 
in order to investigate if there was a shift in the anxiolytic effects of midazolam after 6 
days of nicotine treatment. However, after 6 days of nicotine (0.1 mg/kg/day; s. c. ) 
treatment tolerance developed to these anxiolytic effects of midazolam in both the DH 
and DRN. This rate of cross-tolerance development is much more rapid than the 
tolerance that develops after chronic benzodiazepine treatment, which usually takes 
around 3 weeks to develop (Fernandes and File, 1999; Fernandes et al., 1999; Chopin 
et al., 1993; File et al., 1987a; Treit, 1985; Vellucci & File, 1979). There is 
considerable evidence of cross-tolerance between nicotine and ethanol (Luo et al, 
1994; de Fiebre et al, 1993; Collins et al, 1988) and thus the cross-tolerance seen in this 
study is not surprising given the similarity in the pharmacological profile of 
benzodiazepines and ethanol. 
Since central administration of benzodiazepines was used a pharmacokinetic 
explanation of the results was able to be excluded. O'Neill and Brioni (1994) have 
shown that the acute anxiolytic effect of nicotine can be blocked by the benzodiazepine 
receptor antagonist, flumazenil, which suggests some interaction between nicotine and 
benzodiazepine receptors in modulating anxiety. Certainly, the reduction in 
benzodiazepine binding found in the hippocampus would be sufficient to explain the 
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behavioural tolerance seen after microinjections of midazolam into this region. No 
decrease in binding in the midbrain was found, but this may be due to the relatively 
gross dissection of this region, of which the dorsal raphe nucleus forms only a small 
part. 
The mechanism by which nicotine administration changes benzodiazepine binding is at 
present unknown, but one possibility is via a nicotine-induced increase in GABA 
release. Nicotine increases GABA release in the hippocampus (Lu et al., 1998; 
Alkondon et al., 1997). A decrease in benzodiazepine receptor binding could be an 
adaptive change to the increased GABA release following repeated nicotine injections. 
Lu et al (1998) also found that nicotine increased GABA release in synaptosomes from 
the midbrain, but this effect was less marked than that seen in synaptosomes from the 
hippocampus. It is therefore possible that a different explanation must be sought for 
the tolerance found to the effects of midazolam injected into the DRN. 
Nicotine increases 5-HT release in the DRN (Mihailescu et al., 1998) and its anxiolytic 
effect in the DRN can be reversed by the 5-HT1A receptor antagonist, WAY 100,635 
(Chapter 7). This suggests that the anxiolytic action of nicotine is mediated by 
stimulation of the 5-HTIA autoreceptors. A stimulation of the autoreceptors would lead 
to a reduction in raphe firing rate and, indeed, intravenous nicotine has been shown to 
reduce raphe firing, an effect that was blocked by WAY 100,635 (Engberg et al., 
2000). After chronic treatment, nicotine administration may no longer change the 
raphe firing, compared with the control level. The anxiolytic effect of benzodiazepines 
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is also thought to be mediated by a reduction in raphe firing rate and hence in 5-HT 
release in the terminal areas (Kahn et al., 1988; Balfour, 1980). Hence the 
administration of midazolam into the DRN would simply have substituted for the daily 
dose of nicotine. In the present experiment we tested the rats 24h after their last 
nicotine injection, a time at which a withdrawal response has not previously been 
observed in the social interaction test (Chapters 2 and 7) and was not observed in the 
present experiment. An increase in anxiety in this test is found 72h after nicotine 
withdrawal (Chapter 2) and during nicotine withdrawal there is enhanced sensitivity to 
the inhibitory effect of 8-OH-DPAT on DRN firing (Rasmussen & Czachura, 1997). 
This suggests the increased anxiety during nicotine withdrawal results from increased 
DRN firing and subsequent 5-HT release in limbic areas. Thus, we would expect that 
benzodiazepines would be as effective as nicotine at reversing this nicotine withdrawal 
response, although one clinical study has shown this not to be case (Hao et al., 1988). 
However, in this study a number a measures were looked at and thus any effect on 
anxiety may have been obscured. 
Whilst further studies are needed into the roles of benzodiazepine receptors, GABA- 
benzodiazepine receptor coupling and the 5-HT system in mediating cross-tolerance 
between the benzodiazepines and nicotine, there are clear clinical implications of these 
results. The results of this study suggest that the clinical efficacy of benzodiazepines 
may be reduced in smokers. This is particularly pertinent since patients dependent on 
benzodiazepines are significantly more likely to smoke than people who are not (Lekka 
et al., 1997). 
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10.1 Differences Between the Tests of Anxiety 
There is increasing evidence that suggests animal tests of anxiety measure different types 
of anxiety. Several factor analysis studies have provided evidence that different animal 
tests of anxiety are reflecting different underlying factors and hence may be modelling 
different anxiety disorders (Flaherty et al., 1998; Ramos et al., 1997; Belzung and Pape, 
1994; File, 1992). Furthermore, accumulating evidence from lesion and central drug 
administration has shown that different brain regions and neurotransmitters control 
behaviour in the different animal tests of anxiety (Menard and Treit, 1999). Differential 
effects have also been found following systemically administered drugs (Trefft et al, 1993; 
Fernandez-Guasti et al, 1999) and after the stress of inescapable shock (Steenbergen et 
al, 1990). The social interaction test has been extensively validated as a model of GAD 
(File 1997,1980), whereas it has been suggested that the elevated plus-maze may model 
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some aspects of panic disorder (Graeff et al., 1993). It can be seen from Table 10.1 that 
the pattern of nicotine's effects on anxiety after acute and chronic nicotine 
administration, and after withdrawal from chronic nicotine differs in the social interaction 
and elevated plus-maze tests, thus providing further evidence for the difference in 
anxiety generated between the two tests, and suggesting that nicotine may have 
differential effects in different anxiety disorders. 
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Table 10.1 The effects of nicotine (0.1 mg/kg; s. c. ) in the social interaction and plus-maze 
tests after acute and chronic (7 days) treatment, and withdrawal from chronic 
treatment. 1, indicates a significant anxiogenic effect; T, indicates a significant 
anxiolytic effect; =, indicates no effect on anxiety. 
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In animal tests of anxiety, nicotine has been shown to have both anxiogenic and 
anxiolytic effects in rats and mice (Ouagazzal et al., 1999a; File et al., 1998; Vale and 
Green, 1996; Brioni et al., 1994,1993; Cao et al., 1993; Costall et al., 1989b). Table 
10.1 shows a summary of the results found in Chapters 2-4, and it can be seen that both 
anxiolytic and anxiogenic effects are seen in the social interaction test, whilst only 
anxiogenic effects were seen in the elevated plus-maze after acute nicotine 
administration. These results are in concordance with other studies done in the 
laboratory (Ouagazzal et al., 1999a; File et al., 1998). One of the most striking findings 
is that nicotine (0.1 mg/kg) has an anxiolytic effect 30 min after injection in the social 
interaction test (Chapter 2) but an anxiogenic effect in the elevated plus-maze at this 
time-point (Chapters 3 and 4). This suggests that a different neurotransmitter or 
neuroanatomical site is activated in the two tests. Both the anxiolytic and anxiogenic 
effects of nicotine are known to be mediated through the 5-HT system as both effects 
have been reversed with the 5-HT1A receptor antagonist WAY 100,635. Therefore, the 
likely cause for the difference in responses is due to different neuroanatomical substrates 
being activated. 
The hippocampus and septal nuclei are two regions of the limbic system that have long 
been implicated in the control of anxiety (Gray, 1982), but they are not equally important 
in all animal tests of anxiety. Both these structures play an important role in mediating 
the anxiogenic effects of nicotine in the social interaction test (Cheeta et al., 2000b; 
Ouagazzal et al., 1999b; File et al., 1998), whilst the anxiolytic effect is mediated by the 
DRN (Chapter 7). In general, the dorsal hippocampus does not seem to play an 
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important role in controlling behaviour on Trial 1 of the elevated plus-maze (Cheeta et 
al., 2000a; Ouagazzal et al., 1999a; Gonzalez et al., 1998) and indeed administration of a 
wide range of nicotine doses administered into this area has no effect in the elevated 
plus-maze (Ouagazzal et al., 1990a), although there is evidence of this region becoming 
activated in stressful situations (Netto and Guimaraes, 1996; McBlane and Handley, 
1994; Titze-de-Almeida et al., 1994). In contrast to the dorsal hippocampus, the lateral 
septum plays an important role in mediating behaviour in plus-maze naive rats (Cheeta et 
al., 2000b; Pesold and Treit, 1996). Direct injection of nicotine into this area produces 
anxiogenic effects (Cheeta et al., 2000b; (Ouagazzal et al., 1990a), although in the social 
interaction test 30 min after a dose of 0.1 mg/kg nicotine it seems that an anxiolytic site 
is the most predominant, i. e. the DRN, whereas in the elevated plus-maze it is an 
anxiogenic site, i. e. the lateral septum. Interestingly, a higher dose of nicotine (0.45 
mg/kg) has an anxiogenic effect in both tests 30 min after injection. Thus, with this dose 
an anxiogenic site is the most predominant in both tests due to a possible alteration in 
serotonergic dependent function in the anxiolytic and anxiogenic brain structures. 
In the elevated plus-maze only anxiogenic effects are seen after acute nicotine 
administration, see Table 10.1. This is in contrast to the results of Brioni and colleagues 
(1994,1993) that have shown anxiolytic effects in this test in both mice and Wistar rats. 
There are a number of explanations that could clarify these contrasting results. In both 
of Brioni's studies an 
increase in total arm entries was observed suggesting that the 
anxiolytic effect could 
be due to an increase in locomotor activity and not actually a 
change in anxiety. Costall et al. 
(1989b) also showed anxiolytic effects in the light-dark 
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exploration test after nicotine treatment but again in this test the measure of anxiety is 
highly contaminated by changes in locomotor activity. Another possible explanation for 
the differences could be the differences in strain and species of animals. A review of 
results from many laboratories using the elevated plus-maze has shown that Wistar rats 
are much more responsive to anxiolytic drugs, whilst the Lister hooded animals show a 
greater response to anxiogenic drugs (Hogg, 1996). There is evidence to suggest that 
responses to drugs can vary depending on the housing conditions of the animals (Ahmed 
et al., 1995; Thielen et al., 1993; Gardner and Guy, 1984). However, the results in 
Chapter 4 show that the anxiogenic response to nicotine is seen irrespective of housing 
conditions since anxiogenic effects are seen in both the singly and group housed animals. 
Furthermore, there was no change in baseline scores between singly and group housed 
animals, and they were similar to those found in previous experiments with nicotine 
which also found an anxiogenic effect in singly housed animals (Ouagazzal et al., 1999a). 
However, the baseline scores of both the rats and mice in Brioni's studies were 
approximately half those seen in the singly and group housed animals in Chapters 3 and 
4. Previous studies have shown that when the baseline scores are low (e. g. 10% open 
arm entries) a 5-HT1A receptor agonist administered to the dorsal hippocampus has an 
anxiolytic effect (Menard and Treit, 1998), whereas with higher 
baseline scores (30%) 
neither benzodiazepines nor a 5-HT1A receptor agonist 
have any action (Gonzalez et al., 
1998; File et at., 1996b). In contrast, when baseline scores are high an anxiogenic effect 
can be seen after administration of a 5-HTIA receptor agonist to the 
lateral septum 
(Cheeta et at., 2000a), whereas it is without effect if baseline scores are low (Menard and 
Treit, 1998). Thus, the differences seen in the response to nicotine in the elevated plus- 
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maze between Chapters 3 and 4 and Brioni's studies could be due to different brain 
structures being activated. The low baseline scores in the Brioni studies could indicate 
that their rats are more stressed than ours are and so the dorsal hippocampus is 
activated. Further evidence for this is that in animals that were exhibiting an anxiogenic 
effect after withdrawal from nicotine an injection of nicotine into the hippocampus 
reversed this effect (Chapter 3), suggesting that the dorsal hippocampus was involved. It 
would be interesting to investigate whether the response to nicotine changed in animals 
that were stressed prior to nicotine treatment. If the above hypothesis is correct it would 
be expected that in stressed animals an anxiolytic effect of nicotine would be seen after 
systemic and intra-hippocampal injections of nicotine but no effect would be seen after 
septal administration. 
An anxiolytic effect was observed in the elevated plus-maze test in animals that were 
tested 5 min after the last of 7 days of nicotine treatment. This is in concordance with 
Pandey et al. (2001) and Ericson et al. (2000) who saw an anxiolytic effect in the plus- 
maze after 10-14 days of treatment with a higher dose of nicotine. After 7 days of 
nicotine treatment, tolerance is seen to the anxiogenic effect induced by nicotine (0.1 
mg/kg) at 30 min. This would suggest that tolerance has to be seen to the anxiogenic 
effect of nicotine in this test before the anxiolytic effect emerges. The DRN 
is a site that 
is known to mediate the anxiolytic effects in the social interaction test and thus it is 
possible that it takes a short treatment of nicotine for this 
brain structure to become 
activated in this test. This could 
be investigated by treating the animals for 6 days with 
systemic nicotine and then on the seventh 
day, giving an intra-DRN injection of nicotine. 
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A further difference in these two tests that stands out from the results in Table 10.1 is the 
time-point at which an anxiogenic withdrawal response is observed after termination of 
nicotine treatment. In the social interaction test an anxiogenic response is observed at 72 
h after nicotine withdrawal whereas in the elevated plus-maze it is seen at 24h. A 
number of other studies have shown that termination of nicotine causes an anxiogenic 
withdrawal response (Pandey et al., 2001; Rasmussen et al., 1997; Costall et al., 1989b). 
In concordance with the result seen in Chapter 3, Pandey et al. (2001) observed an 
anxiogenic withdrawal response 18h after termination of nicotine treatment. Costall et 
al. (1989b) observed an anxiogenic response 8-96h after withdrawal from chronic 
nicotine (0.1 mg/kg/day) in the light-dark exploration test whilst the acoustic startle 
response was shown to be enhanced on day 1 of withdrawal, peaking on day 4 and back 
to baseline by day 7 (Rasmussen et al., 1997). Thus, showing that the withdrawal 
response has a different time course depending on the test of anxiety that is used and 
therefore suggesting that different types of anxiety are involved at different times after 
withdrawal from nicotine. 
10.2 Time Course of Nicotine's Effects on Anxiety 
There is considerable evidence that nicotine can modulate anxiety, but unlike 
benzodiazepines it does not consistently reduce anxiety. Several factors are crucial in 
determining the direction of nicotine's effect on anxiety. File et al. (1998) have shown 
that in the social interaction test the effects of an acute nicotine 
injection are dose- 
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dependent, with low doses of nicotine having anxiolytic effects and high doses 
anxiogenic effects. In the elevated plus-maze, Ouagazzal et al (1999a) have found no 
effect of nicotine at low doses (0.001 - 0.1 mg/kg) of nicotine, but anxiogenic effects at 
high doses (0.1 and 0.5 mg/kg). However, other studies using similar doses have shown 
no effect (0.4 mg/kg) and an anxiolytic effect (0.3 mg/kg) in this test. The results in this 
thesis have shown that a low dose of nicotine (0.1 mg/kg) has differing effects on anxiety 
at different times after an acute injection in both the social interaction (Chapter 2) and 
elevated plus-maze (Chapters 3 and 4; for summary, see Table 10.1) tests. Thus, the 
effect on an acute dose of nicotine is both dose- and time-dependent. 
10.2.1 Effects on anxiety seen S minutes after acute nicotine (0.1 mg/kg) injection 
Five min after an acute injection of nicotine an anxiogenic effect is seen in the social 
interaction test (Chapter 2), whereas no effect is seen in the elevated plus-maze at this 
time point (Chapters 3 and 4). It is known that both the lateral septum and dorsal 
hippocampus mediate the anxiogenic effects of nicotine in the social interaction test (File 
et al., 1998; Ouagazzal et al., 1999b). In both cases this anxiogenic effect is reversed by 
co-administration of a behaviourally inactive dose of the 5-HT1A receptor antagonist 
WAY 100,635, suggesting involvement of post-synaptic 5-HTIA receptors in both these 
structures (Cheeta et al., 2000b; Kenny et al., 2000b). The dorsal hippocampus does not 
seem to play an important role in controlling behaviour on Trial 1 of the elevated plus- 
maze and administration of nicotine into this area is without effect on Trial 1 of the plus- 
maze (Ouagazzal et al., 1999a). However, in the elevated plus-maze nicotine is without 
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effect when administered into the dorsal hippocampus but a significant anxiogenic effect 
is seen after lateral septal administration (Cheeta et al., 2000b; Ouagazzal et al., 1999b). 
If the lateral septum were the region activated 5 min after nicotine injection one would 
expect that the anxiogenic effects would be detected in both the social interaction and 
elevated plus-maze tests. Thus, it is more likely that the dorsal hippocampus, or some 
other area not so far explored, such as the basolateral amygdala is the crucial structure 
involved in mediating this anxiogenic effect in the social interaction test. 
The brain regions crucially involved in mediating this short-term effect of nicotine could 
be investigated by administering mecamylamine, a non-competitive nicotinic antagonist, 
directly into particular brain regions after systemic nicotine. Once the brain site or sites 
mediating this anxiogenic effect has been elucidated it would be interesting to attempt to 
block the anxiogenic effect with nAChR antagonists that are selective for specific 
nAChR subtypes. The dorsal hippocampus is known to contain a number of nAChR 
subtypes, predominantly a4, a7, and 02 (Lena et al., 1999; Zarei et al., 1999), and 
therefore the non-competitive antagonists MLA and DHßE, that are selective for a7 and 
a402 respectively, could be used to attempt to block the effect. 
The anxiogenic effect in the dorsal hippocampus is due to nicotine causing an increase in 
5-HI which then acts on postsynaptic 5-HT1A receptors. Thus, future experiments could 
investigate the ability of the 5-HT1A receptor antagonist, WAY 100,635 when it is 
administered directly into the 
dorsal hippocampus, to reverse this anxiogenic effect 
caused by systemic nicotine. 
It is known that nicotine can increase other 
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neurotransmitters in the dorsal hippocampus, such as dopamine and noradrenaline (Shim 
et al., 2001; Kiss et a!., 1997; Sershen et al., 1997; Clarke and Reuben, 1996; Sacaan et 
al., 1996; Toth et al., 1992). Thus, if the effects were not mediated through the 5-HT 
system it would be interesting to investigate the role of these transmitters by 
administering antagonists for specific dopamine and noradrenergic receptors into specific 
brain areas. 
Due to the rapidity of the anxiogenic effect a possible mediator of the anxiogenic effect 
seen in the social interaction test could be corticotrophin-releasing factor (CRF). Central 
administration of CRF has been shown to have anxiogenic effects in many tests of 
anxiety, including the social interaction and elevated plus-maze tests (Britton et al., 
2000; Spina et al., 2000; Baldwin et al., 1991; Dunn and Berridge, 1990; Dunn and File, 
1987). Studies have shown that the effects of CRF are mediated via its binding to two 
types of receptors, CRF1 receptors (CRF1R) and CRF2 receptors (CRF2R; Chang et al., 
1993; Chen et al., 1993). CRF1R knockout mice have shown reduced anxiogenic-like 
behaviour in animal tests of anxiety compared to wild-type mice (Contarino et al., 1999; 
Timpl et al., 1998), whereas the knockdown of CRF2 receptors did not result in 
alterations of anxiety-like behaviours (Heinrichs et al., 1997). Limbic regions, such as 
the dorsal hippocampus, lateral septum and basolateral amygdala receive a large input of 
CRF-releasing afferents from the paraventricular nucleus (PVN) of the hypothalamus 
(Sakanaka et al., 1988a, b; Herman et al., 1996; Kiss et al., 1993). The dorsal 
hippocampus and basolateral amygdala both have high expression of CRF1Rs and 
CRF2R, where as the lateral septum has a high expression of CR21Rs (Chalmers et al., 
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1995). The effect is most likely through increases of CRF in the dorsal hippocampus as 
no effect is seen in the elevated plus maze at this time-point. Evidence to support this is 
that CRF administration into the dorsal hippocampus has shown to have no effect in the 
elevated plus-maze (Radulovic et al., 1999), whereas an anxiogenic effect is seen after 
amygdaloid administration (Shepard et al., 2000). The anxiogenic effect is unlikely to be 
due to an increase in CRF in the lateral septum as no effect is seen in the plus-maze and 
the receptors in this region are CRF2Rs. Radulovic et al (1999) have demonstrated that 
stimulation of lateral septal CRF receptors increases anxiety in plus-maze naive animals. 
However, the dose used in this study was very high and so may have activated the small 
amount of CRF1Rs that are in this area. 
Further experiments could investigate the ability of selective CRF antagonists, such as a- 
helical CRF941, to reverse this anxiogenic effect caused by systemic nicotine. 
Furthermore, stimulation of 5-HTIA receptors has been shown to increase the release of 
CRF (Pan and Gilbert, 1992; Kageyama et al., 1998). Therefore, it is possible that the 
anxiogenic effect of nicotine in the dorsal hippocampus arises because of an increase in 
the release of 5-HT, which then evokes CRF release by an action at 5-HT1A receptors. If 
this were the case it would be expected that CRF receptor antagonists would also be 
capable of reversing the anxiogenic effect. 
It is known that in humans acute systemic nicotine cause aversive effects such as 
gastrointestinal distress, dry mouth, nausea and vomiting 
(Royal College of Physicians, 
2000). Thus, a further possibility for this anxiogenic effect is that the nicotine is acting 
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peripherally to cause aversive effects that may induce anxiety. In order to determine if this 
anxiogenic effect is mediated through the CNS, animals could be administered N- 
methylnicotines that have been shown to poorly penetrate the blood brain barrier (Oldendorf 
et al., 1993; Aceto et al., 1983). Therefore, if the anxiogenic effect is mediated through the 
CNS the effect should not be present. Another alternative would be to administer the 
animals' hexamethonium, a nAChR antagonist that does not cross the blood brain barrier, or 
mecamylamine prior to nicotine administration. If hexamethonium does not block the 
anxiogenic effect and mecamylamine does it suggests that the effect is centrally mediated. 
10.2.2 Effects on anxiety seen 30 minutes after acute nicotine (0.1 mg/kg) injection 
Thirty min after an acute injection of nicotine the results are striking, an anxiolytic effect 
is seen in the social interaction test but an anxiogenic effect is seen in the elevated plus- 
maze. This suggests that at this time-point different brain structures are activated in the 
two tests. 
The DRN has been shown to be a neuroanatomical site mediating the anxiolytic effect of 
nicotine in the social interaction test (Chapter 7). Nicotine stimulates the release of 5- 
HT in the DRN (Mihailescu et al, 1998), and the reversal of its anxiolytic effect by WAY 
100,635 suggest that this action is mediated by indirectly stimulating the somatodendritic 
5-HT1A receptors (Chapter 7). Therefore, future experiments could investigate the ability 
of the 5-HTIA receptor antagonist, WAY 100,635, to reverse this anxiolytic effect when 
it is administered directly into the DRN after systemic nicotine. The DRN is known to 
contain nAChRs and therefore it would be interesting to attempt to 
block the anxiolytic 





DHf E. The a402 sub-type is the most likely candidate as double immunohistochemical 
labelling has shown the near complete overlap of expression of the serotonin marker 
tryptophan hydroxylase and the a4 nAChR subunit in the DRN (Bitner et al., 2000). 
Also, nicotine elicited currents could not be evoked from 5-HT neurones in the DRN in 
mice lacking both or either of the a4 and 02 sub-units (Cordero-Erausquin et al., 2000). 
In contrast to the anxiolytic effect seen in the social interaction test 30min after nicotine 
injection there is an anxiogenic effect seen in the elevated plus-maze at this time-point. 
The lateral septum is a site known to mediate the anxiogenic effect of nicotine in this test 
and therefore the anxiogenic effect seen at this time-point could be due to activation of 
nAChRs in this area. Therefore, future experiments could again investigate the ability of 
the 5-HTIA receptor antagonist, WAY 100,635, and nAChR antagonists that are 
selective for specific nAChR subtypes to reverse this anxiogenic effect. There is little in 
the literature on the nAChR subtypes that are in the lateral septum but as this site 
receives a huge input from the dorsal hippocampus it is likely that similar nAChR 
subtypes are present. Thus, administration of MLA and DHOE may be possible 
antagonists for blocking this effect. One study did find that there was a high amount of 
[3H]-cytisine binding in this area (Davila-Garcia et al., 1999). As cytisine has high 
affinity for the 04 subtype it would suggest that these are the present. At this point in 
time there is no receptor antagonist that is highly specific for this sub-unit. 
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10.2.3 Effects on anxiety seen 60 minutes after acute nicotine (0.1 mg/kg) injection 
Sixty min after an acute injection of nicotine an anxiogenic effect is observed in the social 
interaction test but no effect is seen in the elevated plus-maze. After systemic 
administration of nicotine maximal amounts of nicotine are seen in the brain 30-60 min 
later (Crooks and Dwoskin, 1997). Therefore, it may take until 60 min after nicotine 
administration when the nicotine concentration in the brain is at its highest for activation 
of a particular nAChR to occur. Thus, the anxiogenic effect could again be due to 
activation of nAChRs in the dorsal hippocampus or lateral septum increasing 5-HT 
release. If the dorsal hippocampus were mediating the initial anxiogenic effect seen at 5 
min it would be unlikely that it is also mediating the anxiogenic effect seen at 60 min. 
Thus, the lateral septum would appear to be the likely candidate. However, again at this 
time-point there is no effect seen in the plus-maze. In contrast, to the effects seen in the 
plus-maze 5 min after injection, higher doses (0.25-0.45 mg/kg) do induce an anxiogenic 
effect 60 min after injection. The anxiogenic effect seen after later septal administration 
appears to be greater in the social interaction test (81% after 4µg) than in the plus-maze 
(30% after 4µg) and thus, 0.1 mg/kg nicotine may be high enough to cause an 
anxiogenic effect in the social interaction test but not in the elevated plus-maze at this 
time-point. 
Therefore, the brain regions involved in mediating this late effect of nicotine could be 
investigated by administering mecamylamine directly into particular brain regions after 
systemic nicotine. Again, after finding the brain site mediating this effect attempts could 
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be made to block the anxiogenic effect with nAChR antagonists that are selective for 
specific nAChR subtypes. As the anxiogenic effect in the lateral septum is due to 
nicotine causing an increase in 5-HT, future experiments could investigate the ability of 
the 5-HT1A receptor antagonist, WAY 100,635, to reverse this anxiogenic effect caused 
by systemic nicotine. 
Another possibility is that the anxiogenic effect could be mediated by another 
neurotransmitter. A stimulant effect on locomotor activity is observed 60 min after an 
acute injection of 0.1 mg/kg nicotine (Clarke and Kumar, 1983 a, b) and this is thought to 
be due to dopamine. Furthermore, dopamine release has been shown to be increased in 
certain brain areas 60 min after injection (Shim et al., 2001). Therefore, further 
experiments could investigate whether administering antagonists for specific dopamine 
receptors into specific brain areas could reverse the anxiogenic effect seen 60 min after 
nicotine. 
For more details of the mechanisms that mediate the complex time course in social 
interaction see Appendix 1. 
10.3 Tolerance to Nicotine's Effects on Anxiety 
One of the main themes of this thesis has been investigating the development of tolerance 
to nicotine's effects on anxiety. Tolerance is a reduced sensitivity to the behavioural 
effects of a drug following repeated administration and is thought to involve multiple 
adaptive processes (Young and Goudie, 1995). There are thought to be two different 
types of tolerance, dispositional (pharmacokinetic) and functional (pharmacodynamic) 
tolerance. Dispositional tolerance results from changes in absorption, distribution or 
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metabolism of a drug, whereas functional tolerance is usually taken to be tolerance that is 
mediated by changes in the sensitivity of the neuronal, receptor or neurochemical system 
which may limit a drug's actions (Goudie, 1989). It has been suggested that functional 
tolerance may be made of two distinct processes, decremental and oppositional (Littleton 
and Little, 1989). A decremental adaptation is described as a response in a system 
resulting in a decreased effect on the drug system but as this adaptation would only be 
apparent in the presence of the drug, there would not necessarily be any functional 
indication ip the absence of the drug. Oppositional refers to an activation of an 
oppositional mechanism within a system to counteract the drug effect and in this case, 
withdrawal responses would be a manifestation of the functional disturbance created by 
an oppositional adaptation that is not counteracted by the presence of the drug. When 
considering the development of tolerance, it is important to remember that it is possible 
for multiple processes to be involved (Young and Goudie, 1995). 
10.3.1 Tolerance to the low dose of nicotine 
In the social interaction test, tolerance was found to occur to both the anxiogenic and 
anxiolytic effects that were observed 5 and 30 min after acute nicotine administration, 
respectively, after 7 days of nicotine treatment (Chapter 2). This 
is consistent with the 
time course of tolerance to other behavioural effects of nicotine, such as anti-nociception 
and milk intake (McCallum et al., 1999; Wewers et al., 1999). 
The DRN and dorsal 
hippocampus were found to be brain structures involved in mediating tolerance to these 
anxiolytic and anxiogenic effects, respectively 
(Chapters 7 and 8). Tolerance to the 
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anxiolytic effect is thought to be due to an oppositional mechanism as an anxiogenic 
withdrawal response is seen 72h after termination of nicotine treatment. The mechanism 
that mediates this tolerance is thought to be due to a compensatory change such as 
increased firing of the raphe neurones, which would lead to increased 5-HT release in 
limbic areas when the nicotine is withdrawn. A similar mechanism in the median raphe 
nucleus has been shown to mediate the anxiogenic response that occurs on withdrawal 
from chronic benzodiazepine treatment (Andrews et al, 1997). However, tolerance to 
the anxiogenic effect is thought to be due to a decremental mechanism as a significant 
attenuation of the ability of nicotine to stimulate 5-HT release in the dorsal hippocampus 
after chronic treatment is observed, which could have arisen as a result of receptor 
desensitisation (Radcliffe et al., 1999; Alkondon et al., 1997). Administration of nicotine 
into the lateral septum had an anxiogenic effect in the social interaction and elevated 
plus-maze tests. Thus, it would be interesting to investigate if tolerance is seen to the 
anxiogenic effect in these tests after 7 days of nicotine treatment. The anxiogenic effect 
seen in both the tests after lateral septal administration is blocked by the 5-HT1A receptor 
antagonist, WAY 100,635, suggesting that nicotine increases 5-HT release which then 
acts on postsynaptic 5-HT1A receptors. Thus, future experiments could investigate the 
of ect of nicotine on 5-HT release from this brain site in animals that were drug naive and 
had been chronically treated with nicotine. This could either be done using in vitro slice 
release or a better technique would be to use in vivo microdialysis. 
Interestingly, after 6 days of nicotine treatment tolerance is observed to the anxiolytic 
effects of midazolam in both the 
dorsal hippocampus and DRN (Chapter 9). This result 
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is very striking as the development of tolerance is much more rapid than the tolerance 
that develops after chronic benzodiazepine treatment, which usually takes approximately 
3 weeks to develop, thus , showing that nicotine treatment can modify 
it's own 
behavioural effects and those of the benzodiazepines. It would be interesting to do the 
reverse of this study and investigate if chronic benzodiazepine treatment altered 
nicotine's effects on anxiety. Chronic nicotine also decreased [3H]-flunitrazepam binding 
in the dorsal hippocampus and therefore, a further study would be to investigate if there 
was a change in nicotinic receptors after chronic benzodiazepine treatment. 
10.3.2 Why is tolerance so slow to the high dose of nicotine? 
After 4 weeks of treatment with a high dose of nicotine (0.45 mg/kg/day) complete 
tolerance does not develop to the anxiogenic effects and this is consistent between the 
different routes of administration that were used (Chapters 5 and 6). This is in contrast 
to the rapid rate of development of tolerance to the low dose effects of nicotine on 
anxiety and the tolerance to nicotine's effects on anti-nociception (0.35 mg/kg) and milk 
intake (0.66 mg/kg) after treatment with a high dose for 7 days (McCallum et al., 1999). 
It is also surprising that no tolerance was seen to the anxiogenic effects of this high dose 
of nicotine as tolerance normally develops faster when a higher dose 
is administered. 
Indeed, tolerance to the acute stimulatory effects of caffeine were seen faster with a 
higher dose than with a lower dose (Gasior et al., 2000). File et al. (1998) showed that 
there was no difference in the anxiogenic response after 0.5 and 1.0 mg/kg nicotine 
suggesting at a certain anxiogenic 
dose there is a floor effect of nicotine which cannot be 
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augmented by increasing the nicotine dose and thus nicotine may only be able to modify 
anxiety within certain limits, although pharmacologically it may be having a much greater 
effect. Therefore, the high dose of nicotine used in Chapters 5 and 6 may cause a 
paharmacological change, such as alteration in the homeostatic balance of the serotonergic 
and cholinergic systems, and tolerance has to be seen to this alteration before a change is 
observed in the behaviour. Therefore, it may be, and is likely, that longer treatment with this 
dose would have resulted in complete tolerance. This could be investigated further by 
treating the rats for a longer period of time and testing them for tolerance. 
It is also possible that different mechanisms of tolerance have to be recruited to see 
tolerance to the anxiogenic effects of this high dose. There is now considerable evidence 
for the role of learning as an adaptive process influencing the development of tolerance 
arising from an individual's experiences in the drugged state (Goudie and Griffiths, 1996; 
Young and Goudie, 1995). A process thought to be important in the mediation of drug 
tolerance is one in which an individual learns to deal with the effect of the drug, resulting 
in acquired behavioural skills for coping with the drug-induced effect. Although 
tolerance resulting from a learned coping ability could involve a non-specific strategy and 
be situation independent (Demellweek and Goudie, 1983), it could theoretically be 
augmented by "practising" in the presence of the drug stimulus and possibly by 
association with the environment in which the individual practices the coping strategy 
(King et al., 1987). However, it is unlikely that learned tolerance plays a role in 
tolerance to the anxiogenic effect of this high dose of nicotine as the same effects were 
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seen in the animals that received nicotine via minipumps where the drug is not paired to 
anything and has no clear onset of action. It is unlikely that metabolic tolerance is 
playing a part as there is no difference in plasma nicotine levels between the animals that 
were treated for 4 days or 4 weeks with nicotine by subcutaneous injections or 
continuous infusion by osmotic minipump. 
10.3.3 Why is there no withdrawal from the high dose of nicotine? 
Termination of nicotine treatment results in an anxiogenic withdrawal that has been 
observed in a number of animal tests of anxiety (Pandey et al., 2000; Rasmussen et al., 
1997; Costall et al., 1989b). Termination from one week of treatment with a low dose 
of nicotine results in an anxiogenic withdrawal response that is seen at 24h in the 
elevated plus-maze (Chapter 3) and 72h in the social interaction (Chapters 2 and 8) tests. 
However, in animals receiving a higher dose of nicotine (0.45 mg/kg/day) for 4 weeks no 
anxiogenic withdrawal response was observed at either the 24 or 72h time-point 
(Chapter 5 and 6). This was again irrespective of treatment regimen. This lack of 
withdrawal response at these two time-points is very surprising but there are possible 
reasons to explain it. The simplest reason is that the wrong time-points after termination 
of nicotine treatment were used to test the rats following this particular dose-regime. 
Results from other studies have shown that an anxiogenic withdrawal response can be 
seen at time-points ranging from 18h to approximately 4-5 days (Chapters 2,3 and 8; 
Pandey et al., 2000; Rasmussen et al., 1997; Costall et al., 1989b). In order, to 
investigate this possibility a more detailed study needs to be conducted in which an 
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increased number of time-points after termination of nicotine treatment are used. 
Another possible explanation is that because the animals had not developed complete 
tolerance to the anxiogenic effect of nicotine no significant withdrawal changes had yet 
developed. The withdrawal response observed in the social interaction test after a low 
dose of nicotine is thought to be due to an oppositional mechanism of tolerance to the 
anxiolytic effect. It was suggested that the delayed anxiolytic effect observed in the 
elevated plus-maze after 7 days of treatment was due to the need for tolerance to the 
anxiogenic effect to be seen before an anxiolytic effect emerged. Therefore, in the case 
of the higher dose of nicotine, tolerance may have to be seen to the anxiogenic effect of 
nicotine before the anxiolytic effect emerges which could then cause an oppositional 
mechanism that would result in a withdrawal response. 
10.4 Implications for Smoking 
Many smokers report cigarettes have an anxiety reducing influence and that mood 
control is a core reason for maintaining their smoking habit (Parrot, 1994). Most of the 
theories concerning the role of anxiety states in smoking behaviour have focussed on the 
putative anxiolytic effects. Indeed, smokers frequently report calming and anxiety 
reducing effects (Ikard et al., 1969). There is evidence that 
during episodes of stress and 
depression smoking increases (Breslau et al., 1991). Furthermore, a recent report 
demonstrated that high yield nicotine, but not low yield nicotine, cigarettes reduce 
subjective anxiety in smokers 
during stressful situations suggesting that nicotine has 
dose-dependent effects on humans (Kassel and Unrod, 2000). However, there is 
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evidence that not all smokers experience anxiolytic effects from smoking (Parrott and 
Garnham, 1998) and in general it seems that smoking has anxiolytic effects when 
smokers are exposed to moderate levels of stress/anxiety, but is ineffective when there is 
no stress (Gilbert and Wessler, 1989). Furthermore, it has been reported by Newhouse et 
al. (1990) that smokers with high neuroticism scores become more anxious and tense 
after smoking a cigarette. The results from this thesis showing that nicotine can have 
both acute anxiolytic and anxiogenic effects would lend further weight to a likely bi- 
directional effect of smoking on anxiety. It is unclear what the role of these acute effects 
of nicotine would have in the onset of smoking, as there are a number of different factors 
that could influence this, such as stress and peer pressure. However, it is likely that 
anxiety has an important role in the maintenance of smoking. Chapter 5 showed that an 
increase in anxiety was observed in rats chronically self-administering nicotine, compared 
with rats chronically self-administering saline. This suggests that a continuing anxiolytic 
effect is not necessary for the maintenance of nicotine self-administration and that the 
rats may actually self-administer nicotine precisely for its ability to produce an increase in 
anxiety, and a very similar argument has been proposed 
for the rewarding effects of 
cocaine (Goeders, 2001). This persisting anxiogenic effect was also observed 
in animals 
that received the same dose of nicotine by intravenous and subcutaneous injections or 
subcutaneous infusion (Chapter 6). This suggests that the route of administration of 
nicotine may be of less importance 
for the role that anxiety plays in maintaining smoking 
behaviour. 
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It is the general consensus that an increase in anxiety is seen in nicotine withdrawal in 
smokers (Shiffman and Jarvik, 1976; West and Russell, 1985) and those using nicotine 
gum (Hughes et al., 1990; Keenan et a1., 1989; Wesnes and Warburton, 1983). Nicotine 
withdrawal symptoms peak within the first week of abstinence and can last up to 4 
weeks (Jorenby et al., 1996; Hughes et al., 1990). Nicotine patches and tablets have 
been shown to reduce anxiety in smokers and this has been suggested to be due to a 
reversal of withdrawal anxiety (Netter et al., 1998; Warburton and Mancuso, 1998; 
Wesnes and Warburton, 1983). Indeed, it has been proposed that the anxiolytic effects 
of nicotine observed in smokers arises only because nicotine reverses the withdrawal- 
reduced anxiety (Parrott, 1999). The studies reported in this thesis also show an 
anxiogenic response accompanies nicotine withdrawal in rats and can be reversed by 
nicotine. This further suggests a role for anxiety in the maintenance of smoking and 
provides an animal model for investigating the neurobiological mechanism involved in 
smoking behaviour and relapse. 
Both in the human and animal literature there has been a lack of attention paid to the sex 
differences seen in nicotine's response to nicotine, but a recent review (Perkins et al., 
1999) highlights the potential importance of this. There is accumulating evidence to 
suggest that males and females may differ in factors that maintain tobacco smoking and 
nicotine self-administration. The effects of nicotine 
in non-smokers are particularly 
relevant to the issue of smoking 
initiation. In a recent study conducted on non-smoking 
20 year-olds the effects of sex differences in response to nicotine were examined (File et 
al., 2000a). After exposure to a moderately stressful situation, nicotine 
blocked the 
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increase in anxiety and discontent and reduced aggression in females, but not males. 
This provides important evidence that there are sex differences in the anxiolytic effects of 
nicotine. All the experiment conducted in this thesis have been conducted in adult male 
rats and therefore it would be interesting to investigate the effects of nicotine treatment 
in female rats in both the social interaction and elevated plus-maze tests of anxiety. 
Perhaps though a more appealing study would be to investigate the effects of nicotine in 
both adolescent male and female rats. To date, there is no existing data on the response 
to nicotine in behavioural tests using adolescent rats. This would be particularly 
pertinent as adolescent smokers report significantly higher levels of nervousness, stress 
and anxiety than do age-matched non-smokers (Lloyd and Lucas, 1997; Wills, 1986; 
Mitic et al., 1985; Hirschman et al., 1984) and 64% of adolescent female daily smokers 
report that they feel calmer after smoking (McNeill et al., 1997). 
10.5 Future Research 
Chapter 9 showed that after just 6 days of systemic nicotine treatment tolerance was seen to 
the anxiolytic effects of midazolam when it was injected directly into the dorsal hippocampus 
and the DRN. It would be interesting to investigate if cross-tolerance was seen between 
nicotine and other psychostimulants, such as cocaine and caffeine. Horger et al. (1992) 
showed that the acquisition of low-dose intravenous cocaine self-administration was more 
rapid in animals that had been prexposed to nicotine compared to controls, thus suggesting 
that cocaine may show cross-tolerance with nicotine. In contrast, a recent study showed that 
there was no cross-tolerance to caffeine in animals that were tolerant to the stimulant effects 
of nicotine (Domino et al., 2001). 
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10.6 Conclusion 
In conclusion, the studies in this thesis have high-lighted that the effects of nicotine on 
anxiety are dependent on a number of factors including the dose of nicotine, the chronicity of 
drug treatment and the animal test of anxiety used. Furthermore, different neuroanatomical 
substrates have been shown to play distinct roles. Taken together these studies highlight the 
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APPENDIX 1 
The time course of nicotine's effects on anxiety in the social 
interaction test 
The results of the experiments in Chapter 2 show that there is a complex pattern of change in 
social interaction induced by nicotine. Anxiogenic effects are seen 5 and 60 min after 
injection and an anxiolytic effect 30 min after injection. It is thought that these different 
effects are mediated by nicotine's action in different neuroanatomical sites. The initial 5 min 
effect may be due to nicotine acting at a7-type nAChRs in the dorsal hippocampus, a known 
anxiogenic site for nicotine (File et al., 1998). It is known that this receptor sub-type 
predominates in this area (Zarei et al., 1997). Activation of this nAChR is then thought to 
cause an increase in 5-HT release that acts on post-synaptic 5-HTIA receptors and elicits an 
anxiogenic effect in the social interaction test (File et al., 2000b; see Figure Al. 1). However, 
this receptor sub-type is known to undergo rapid desensitisation whereas the a4ß2 is known 
to desensitise at a slower rate (Gerzanich et al., 1994). It is possible that the anxiolytic effect 
seen 30 min after injection is due to nicotine's action at a4ß2-type nAChRs in the DRN, a 
known anxiolytic site for nicotine (Chapter 7). There is much evidence to suggest the DRN 
contains this receptor subtype in high abundance (Bitner et al., 2000; Cordero-Erausquin et 
al., 2000). This anxiolytic effect is thought to be 
due to nicotine causing an increase in 5-HT 
release in the DRN that acts on somatodendritic 
5-HTIA receptors leading to a reduction in 5- 
HT neuronal firing, and a subsequent decrease in 5-HT release in terminal regions of the 
limbic system (Chapter 7; see Figure A1.1). The anxiogenic effect seen 60 min after injection 
may be mediated by the action of nicotine in the 
lateral septum. Like the dorsal hippocampus 
the lateral septum is known to mediate the anxiogenic effects of nicotine in the social 
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interaction test by activating a presynaptic nAChR on a 5-HT neurone causing an increase in 
5-HT which then activates post-synaptic 5-HTIA receptors (Ouagazzal et al., 1999b). 
However, it is unknown which nAChR sub-types that are in the lateral septum. If it is this 
structure that mediates the anxiogenic effect seen Ih after nicotine injection then these pre- 
synaptic nAChRs must either have a low affinity for nicotine and only become activated when 
maximal amounts of nicotine are seen in the brain, or they must desensitise much slower than 
the two aforementioned nAChR sub-types. 
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Figure Al.! Proposed mechanisms for nicotine's effects on anxiety in the social interaction 
test. DRN, Dorsal Raphe Nucleus; MRN, Median Raphe Nucleus; LS, Lateral 
Septum; DH, Dorsal Hippocampus; a7, a4ß2-type nAChR; a4ß2, a4ß2-type 
nAChR; X, nAChR sub-type unknown; 5-HT, Serotonin; IA, 5-HTIA 
receptors. 
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APPENDIX 2 
Effects of chronic diazepam treatment on [3H]nicotine 
binding 
A2.1 Introduction 
Benzodiazepines and nicotine are drugs that are abused by many individuals and it is thought 
that there may be a link between the mechanisms involved in their dependence. There is 
evidence to suggest that people dependent on benzodiazepines are significantly more likely to 
smoke than people who are not (Lekka et al., 1997). Further evidence for cross tolerance 
between these two drugs is seen in Chapter 9 where after only 6 days of treatment with a low 
dose of nicotine tolerance is seen to the anxiolytic action or midazolam. The main action of 
the benzodiazepines appear mainly to involve the GABAergic system in the brain as they bind 
to a site on the GABAA receptor allosterically modulating it. However, there have been some 
indications in the literature that the cholinergic system may also be involved in the action of 
benzodiazepines (Skolnick and Paul, 1981). Benzodiazepines have been shown to increase 
the content of ACh in various brain areas of animals (Consolo et al., 1974; Bianchi et al., 
1975) and to decrease the turnover of ACh (Zsilla et al., 1976). It has been shown that in rats 
treated with diazepam for 3 weeks there are changes in both the number and affinity of the 
muscarinic receptors in the brain (Popova et al., 1988). There appears at present to be no 
literature examining whether chronic treatment with benzodiazepines has alters these changes 
in nicotinic receptors in the brain. 
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APPENDIX 2 
Effects of chronic diazepam treatment on [3H]nicotine 
binding 
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between these two drugs is seen in Chapter 9 where after only 6 days of treatment with a low 
dose of nicotine tolerance is seen to the anxiolytic action or midazolam. The main action of 
the benzodiazepines appear mainly to involve the GABAergic system in the brain as they bind 
to a site on the GABAA receptor allosterically modulating it. However, there have been some 
indications in the literature that the cholinergic system may also be involved in the action of 
benzodiazepines (Skolnick and Paul, 1981). Benzodiazepines have been shown to increase 
the content of ACh in various brain areas of animals (Consolo et al., 1974; Bianchi et al., 
1975) and to decrease the turnover of ACh (Zsilla et al., 1976). It has been shown that in rats 
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literature examining whether chronic treatment with benzodiazepines has alters these changes 
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To study whether there is a possible link between benzodiazepines and nicotinic receptors 
during benzodiazepine dependence, the aim of this work was to investigate the effect of 
chronic diazepam (15 mg/kg/day, s. c. ) exposure on the number of nicotinic receptors in the 
frontal cortex and cerebellum of rat. The first part of the study involved conducting a number 
of small experiments to optimise the conditions for the nicotinic acetylcholine binding site 
assay. Unfortunately, for the main part of the study only the cerebellar tissue was investigated 
due to the frontal cortex homogenates becoming contaminated with bacteria. 
A2.2 Materials and Methods 
Animals 
Brain tissue was obtained from the animals used in the previous chapter that were treated with 
daily sub-cutaneous injections of vehicle, acute diazepam or 7,14 or 28 days of diazepam (15 
mg/kg/day). Animals were sacrificed immediately after testing by decapitation, and the brains 
immediately removed, dissected, frozen in an ethanol dry ice bath and stored at -20°C until 
required. Brain tissue for optimising the assay conditions came from untreated animals that 
were killed the same way. 
Membrane Preparation 
Frozen brain tissue was thawed at room temperature and homogenised in ice-cold 0.32M 
sucrose using an Ultra-Turex homogeniser. The homogenate was centrifuged at 1000g (10 
min, 4°C) to remove myelin and cell debris. The pellet was discarded and the supernatant was 
then centrifuged at 15000g (20 min, 4°C). The pellet was resuspended in 10ml of 50mM Tris- 
HCI buffer containing 120mM NaCl and 5mM KCI, pH 7.4 (referred to as Tris-HC1 plus 
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salts) and centrifuged at 15000g (20 min, 4°C). The latter process was repeated a further two 
times increasing the volume of Tris-HC1 plus salts to 20 and 30mis, respectively. The final 
pellet was resuspended in a volume of Tris-HC1 plus salts to give a concentration of 60 mg 
wet weight tissue/ml. Samples of each membrane preparation were stored at -20°C for 
determination of protein content. 
Receptor Binding Assay 
Drugs and radioligand were prepared in 50mM Tris-HC1 plus salts, pH 7.4. Assays were 
performed in Macrowell 1.4m1 tubes (Helios Biotech). Aliquots of membrane preparation 
(475µl; approximately 75µg protein), 5µl [3H]nicotine (5nM) and 20µl of either Tris-HCI plus 
salts to define total binding or 100µM (final) nicotine to define non-specific binding (final 
volume 500pl) were incubated at room temperature for 30 min and then at 4°C for 1 h. Total 
and non-specific binding were both performed in triplicate. 
Termination of Incubation 
Bound and free ligand were separated by vacuum filtration with a cell harvester (Skatron AS) 
through Whatman GF/C glass fibre filters, previously treated with 0.01% polyethylenimine to 
inhibit non-specific binding. Filters were washed for 15 s with ice-cold 50mM Tris-11CI plus 
salts buffer, pH 7.4. 
Scintillation Counting 
The filters were placed in Pico Pro scintillation vials with 5mls Packard Emulsifier safe 
scintillation fluid and thoroughly mixed. The amount of radioactivity per tube was determined 
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using a Wallas WinSpectral (Model 1414) scintillation counter programmed to count for 5 
min per sample at an efficiency of 42-43%. Counts per minute (cpm) were converted to 
disintegrations per min (dpm) using external standardisation. 
Protein Assay 
Protein concentrations were assessed in triplicate using Comassie Plus protein assay reagent 
(Pierce) and measuring absorbance at 595nm. Bovine serum albumin was used as the protein 
standard. 
Chemicals 
L-[3H]nicotine (N-methyl-[3H]; 81.5 Ci/mmol) was purchased from DuPont, NEN 
(Stevenage, UK). (-)-nicotine hydrogen tartrate, sucrose, Tris HCI, Tris Base and KCI were 
purchased from Sigma (Poole, Dorset, UK). NaCl was purchased from BDH (Poole, Dorset, 
UK). 
Statistics 
The % specific binding was analysed by one-way analysis of variance and comparisons 
between individual groups were then made with the LSD (least significance difference) post. 
hoc test. 
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A2.3 Results 
Initially, a series of experiments was conducted to determine the optimal conditions for the 
nicotinic acetylcholine binding site assay. Membrane preparation and binding assays were 
carried out as described above, unless otherwise stated. 
Determination of the Optimal Protein Concentration in the Frontal Cortex 
The binding of [3H]nicotine to frontal cortical homogenates was investigated using protein 
concentrations of 125,100,75,50,37.5,25 and 12.5 µg/assay. The results are summarised in 
Table A2.1. 
Table A2.1 The effect of varying tissue concentration on [; H]nicotine binding to membranes 
prepared from frontal cortical homogenates. Results are expressed in % specific 
binding ± sem. 
Protein Concentration (µg/assay) % Specific Binding 
125 58.3±1.2 3 
100 36.0 2 
75 50.5 ± 3.8 6 
50 29.0 2 
37.5 28.2 ± 4.3 4 
25 20.5 2 
12.5 14.8 ± 8.6 4 
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A tissue concentration of 75µg/assay was chosen for further studies. Although 125 µg/assay 
showed the greatest percentage of specific binding this was not significantly different from 75 
µg/assay and so in order to minimise the amount of tissue used the above concentration was 
decided on. 
Determination of the Optimal Ligand Concentration and Incubation Method in the Frontal 
Cortex 
The binding of [3H]nicotine to frontal cortical homogenates was investigated using ligand 
concentrations of 5,7.5 and lOnM using a 2h incubation at 4°C (Method 1) or incubation at 
room temperature for 30 min and then placed at 4°C for lh (Method 2). The results are 
summarised in Table A2.2. 
Table A2.2 The effect of varying tissue concentration on [3H]nicotine binding to membranes 
prepared from frontal cortical homogenates. Results are expressed in % specific 
binding ± sem. 
% Specific Binding 
Ligand Concentration (nM) Method 1 Method 2 
10 43.5±5.5 36.5±3.5 
7.5 21.0±4.0 43.5±1.5 
5 25.0 ± 8.0 35.5±9.5 
A ligand concentration of 5nM was chosen in order to minimise the amount of ligand used 
and therefore the cost. There was no difference 
between the methods of incubation and so 
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method 2 was chosen as there seemed to be lower non-specific binding with this method than 
method 1 for each of the ligand concentrations used. 
Determination of the Optimal Protein and Ligand Concentration in Cerebellar Tissue 
The binding of [3H]nicotine to cerebellar homogenates using protein concentrations of 100, 
75,50, and 25µg/assay using 2 ligand concentrations, 5 and lOnM, were investigated. The 
results are summarised in Table A2.3. 
For the cerebellar homogenates 75pg/assay and 5nM were chosen as the respective protein 
and ligand concentration in order to minimise the amount of tissue and ligand needed. 
Table A2.3 The effect of varying tissue and ligand concentration on [3H]nicotine binding to 
membranes prepared from cerebellar homogenates. Results are expressed in % 
specific binding ± sem. 
Ligand Concentration (nM) 
Protein Concentration (pg/assay) 5 10 
100 52.0 ± 10.0 46.5 ± 9.5 
75 52.5 ± 1.5 37.0±19.0 
5043.5 ± 8.5 46.0±5.0 
25 37.0±4.0 48.0± 1.0 
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The Effect of Duration of Diazepam Treatment on [3HJnicotine Binding in Cerebellar 
Homogenates 
There was a significant effect of duration of diazepam treatment on [3H]nicotine binding in 
cerebellar tissue [F(4,12)=3.3, p<0.05); Figure A2.1]. Acute administration of diazepam was 
not significantly different from vehicle controls. Post-hoc tests showed that following 7 days 
treatment of diazepam there was a significant decrease in the % specific binding compared to 
the vehicle and acute diazepam groups (p<O. 05 for both groups). After 14 days of diazepam 
treatment there was still a significance decrease compared to the vehicle group (p<0.05) but 
there was no longer a difference from the acute group. After 28 days diazepam treatment there 
was no significant change from any of the groups. 
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Figure A2.1 Rats were treated with daily sub-cutaneous injections of vehicle (n 5), acute 
(n=2) diazepam or 7 (n-4), 14 (n=3) or 28 (n==3) days of diazepam (15 
mg/kg/day). The nAChR density in cerebellar homogenates was measured by 
[3[1 ]nicotine binding and results are expressed in % specific binding ± scm. 
*p<0.05 compared with vehicle control and acute group and 'p- 0.05 compared 
with vehicle control 
A2.4 Discussion 
The initial series of experiments showed that to obtain optimal binding a concentration of 75 
µg/assay of tissue should be incubated with 5nM [3N]nicotine for 30 min at room temperature 




Chronic diazepam treatment and [3H]-nicotine binding 
decrease in the number of nicotinic receptors following 7 and 14 days treatment with 
diazepam (15 mg/kg/day; s. c. ) measured with [3H]nicotine as the radioligand in the 
cerebellum. After 28 days treatment of this dose of diazepam there was no change in the 
number of nicotinic receptors compared to vehicle controls. This suggests that sub-chronic 
treatment with this high dose of diazepam causes a decrease in the number of nicotinic ACh 
receptors which with further treatment induces some kind of adaptive process that brings the 
nicotinic receptor number back to baseline levels. 
As mentioned before the benzodiazepines bind to the GABAA receptor and allosterically 
modulate. The GABAA receptor also has binding sites for other modulatory agents such as 
the barbiturates and ethanol. It has also been well documented that there is cross-dependence 
between these two drugs and the benzodiazepines (Woods et al., 1990). This suggests that 
information known about the actions of these two drugs on the cholinergic system might be 
useful in determining the mechanism of action of the benzodiazepines. As for the 
benzodiazepines it is known that both the barbiturates and ethanol increase endogenous 
acetylcholine in various brain areas and increases the number of muscarinic receptors. It is 
known that the barbiturates bind to both muscarinic and nicotinic receptors but to date this has 
not been observed for ethanol or benzodiazepines (Nordberg and Wahlström, 1992). 
Therefore, it is possible that diazepam may bind to a site on the nicotinic ACh receptor that is 
as yet unknown. It is well reported that chronic treatment with nicotine results in an increase 
in the number of nicotinic receptors in the brains of both humans (Benwell et al., 1988) and 
animals (Collins et al., 1994,1990,1988; Marks et al., 1985,1984,1983). This upregulation 
is thought to occur due to desensitisation or inactivation of the nicotinic receptors. Chronic 
treatment with diazepam could increase the release of ACh and/or bind directly to the 
nicotinic receptors causing an initial decrease in the number of nicotinic receptors. Over time 
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these two possible effects could begin to cause desensitisation or inactivation of theses 
receptors causing the numbers to increase. Thus, if the treatment with diazepam was 
continued for a further few weeks a possible increase in these receptors could be seen. 
In conclusion, this study has shown that chronic treatment with diazepam can produce 
decreases in the number of nicotinic receptors in the cerebellum, which after a longer period 
of time go through an adaptive process bringing them back to normal levels. Further work is 
warranted into the search to discover whether there is a link between the benzodiazepines and 
nicotine in dependence. It would also be interesting to look in areas of the brain that are 
believed to be involved in anxiety to try and elucidate whether there is a link between the 
tolerance mechanisms to anxiety for these two drugs. 
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